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 The solid-state form of a drug influences its physico-chemical and 
biopharmaceutical properties. Consequently, phase transformations induced during 
processing/storage affects drug performance. Understanding the transformation 
mechanisms is valuable for anticipating and controlling phase transformations. In this 
dissertation, the mechanisms of conversion of crystalline drugs to cocrystals and factors 
affecting cocrystal stability are reported. Specifically, the objectives are to: (i) identify 
the factors governing the formation of different stoichiometry cocrystals, (ii) examine 
coformer, excipients and cosolvents effects on cocrystal hydrate thermodynamic stability, 
(iii) investigate the propensity and mechanisms of cocrystallization in solid mixtures due 
to moisture sorption, and (iv) identify the mechanisms by which mechanical activation 
induces cocrystal formation in mixtures. Model compounds selected in this study include 
carbamazepine, theophylline and coformers that form cocrystals.  
 Coformer solution concentration governs the formation and stability of different 
stoichiometry cocrystals. Studies with 1:1 and 2:1 carbamazepine-4-aminobenzoic acid 
cocrystals indicate that the cocrystal richer in coformer is more stable at higher coformer 
concentration. Phase diagrams showing cocrystal solubility and stability domains are 
generated using mathematical models based on cocrystal and solution chemistry.
 xxi
 
 Coformer concentration also governs the formation and stability of cocrystal 
hydrates in aqueous solutions. Studies with theophylline-citric acid and carbamazepine-4-
aminobenzoic acid cocrystal hydrates indicate that coformers that modulate the water 
activity (aw) of aqueous solutions can induce cocrystal hydrate to anhydrous cocrystal 
conversion. Addition of excipients or cosolvents to aqueous solutions similarly affects 
cocrystal hydrate stability by decreasing aw. 
 Cocrystallization can also occur in solid mixtures of cocrystal reactants. 
Cocrystals of carbamazepine-nicotinamide, carbamazepine-saccharin, and caffeine or 
theophylline with various carboxylic acid coformers are formed due to moisture sorption 
and deliquescence in reactant mixtures. Transformation mechanism involves moisture 
uptake, reactant dissolution, cocrystal nucleation and growth. The rate and extent of 
cocrystal formation depends on RH, moisture uptake, deliquescent material, mixture 
composition, and reactant dissolution rates.  
In the solid-state, cogrinding carbamazepine with saccharin or nicotinamide forms 
cocrystals. Cocrystal formation is shown to be amorphous phase mediated, and depends 
on cogrinding temperature, presence of moisture, and reactant hydrated form. Higher 











An important decision to be made in the early stages of drug development is 
regarding the selection of an appropriate solid form for an active pharmaceutical 
ingredient (API). Polymorphs, salts, hydrates and solvates, and amorphous phases of 
APIs may be selected for development. The API solid form affects its physico-chemical 
properties such as solubility, dissolution rates, and hygroscopicity, physical and chemical 
stability, and mechanical properties. For instance, the chemical stability of 
carbamazepine and cinnamic acid is dependent on the solid-state form.1, 2   Polymorphs of 
chloramphenicol palmitate and carbamazepine exhibit different bioavailabilities due to 
different solubility and dissolution rates of the solid forms.3-5  Salts of poorly soluble 
drugs are sometimes used to enhance drug solubility and bioavailability.6 Amorphous 
phases of APIs also enable to achieve high drug concentrations.7  However, they are more 
prone to physical and chemical instability than the crystalline phases due to high 
reactivity.8-10 Hydrates and solvates of API similarly impact the biopharmaceutical 
properties. API hydrates have lower aqueous solubilities, while solvates have higher 
aqueous solubilities when compared to anhydrous crystalline phases.11-14  Consequently, 
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hydration or dehydration of APIs can impact the biopharmaceutical properties and 
manufacturability.15  Differences in the properties of different API solid forms are a 
consequence of differences in molecular interactions, structure and composition that 
result in different energetics.16  A classification of API solid forms based on structure and 




Figure 1.1: Classification of API solid form based on structure and composition. 
   
Cocrystals have recently gained attention as attractive alternate solid forms for 
drug development. A pharmaceutical cocrystal is a single crystalline homogenous phase 
consisting of a drug and excipient or another drug.16-23  The different components in the 
cocrystal are neutral in nature when compared to salts that have ionized components.17, 20, 
23-25  The components in a cocrystal exist in a definite stoichiometric ratio, and assemble 
via non-covalent interactions such as hydrogen bonds, ionic bonds, π-π or van der Waals 
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interactions. Cocrystals thus possess different composition and structure when compared 
to the crystals of parent components. Table 1.1 compares the crystallographic parameters 
of some carbamazepine (CBZ) cocrystals with anhydrous form III CBZ. Table 1.2 shows 
examples of some crystalline drugs for which pharmaceutical cocrystals have been 
discovered. 
 
Crystal engineering and design of cocrystals 
Cocrystal design is based on crystal engineering principles. The term ‘crystal 
engineering’ refers to engineering or construction of crystalline solids with desirable 
properties, and is based on a fundamental understanding of inter-molecular interactions 
that govern the assembly of molecules into a network superstructure.26, 27  The molecules 
in the network are held together by synthons that are basic structural units formed from 
non-covalent interactions such as van der Waals interactions, π − π interactions, and 
hydrogen bonds between the functional groups in the molecules.28-31  Figure 1.2 shows 
some examples of commonly occurring synthons in the crystal structures of single and 
multiple-component materials. 
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Table 1.1: Crystallographic properties of CBZ(III)32 and CBZ cocrystals19 
 CBZ (III)  CBZ-NCT CBZ-SAC CBZ-trimesic acid 
Stoichiometry      - 1:1 1:1 1:1 
Molecular weight 236.27 358.39 419.46 446.40 
Crystal system Monoclinic Monoclinic Triclinic Monoclinic 
Space group P21/n P21/n P-1 C2/c 
a (Å) 7.54 5.09 7.51 32.53 
b (Å) 11.16 17.59 10.45 5.27 
c (Å) 13.91 19.65 12.68 24.16 
α (degree) 90 90 83.64 90 
β (degree) 92.86 90.92 85.70 98.19 
γ (degree) 90 90 75.41 90 
Volume (Å3) 1168.30 1761.6 957.0 4099.3 
Density (g/cm-3) 1.34 1.35 1.46 1.45 
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Table 1.2: Examples of pharmaceutical cocrystals   
 




Carbamazepine Nicotinamide19  1:1 UNEZES 
 Saccharin19  1:1 UNEZAO 
 Benzoquinone19  1:1 UNEYOB 
 Trimesic acid19  1:1 UNIBAU 
 Terephthalaldehyde19 1:1 UNEYUH 
 Formamide19  1:1 UNIBOI 
 Adamantane-1,3,5,7-
tetracarboxylic acid19  
1:1 UNIBIC 




 Malonic acid34, 35  2:1  
 Succinic acid34 2:1  
 2,6-pyridinedicarboxylic  
acid33  
 XAQRIR 
 Aspirin36  TAZRAO 
    
Caffeine Oxalic acid21  2:1 GANXUP 
 Adipic acid37  1:1 CESKAN 
 Malonic acid21  2:1 GANYAW 




 Glutaric acid21 1:1 (Forms I, II) EXUQUJ 
 Citric acid38             1:1 KIGKER 
 Methyl gallate39 1:1 DIJVOH 
 4-hydroxybenzoic acid40 1:2 
2:1 
 
 d-tartaric acid41  1:1 NEXWUJ 
 1-hydroxy-2-napthoic acid42  1:1 KIGKIV 
 3-hydroxy-2-napthoic acid42 1:1 KIGKOB 




Itraconazole Fumaric acid45  2:1  
 Succinic acid45 2:1 IKEQEU 
 Malic acid45  2:1  
 Tartaric acid45 
 
2:1  
Piracetam Gentisic acid46  1:1 DAVPAS 





Table 1.2 (continued)  
 




Theophylline 5-fluorouracil monohydrate47 2:1 ZAYLOA 
 Phenobarbital48 2:1 THOPBA 
 Oxalic acid22 2:1 XEJWUF 
 Maleic acid22  1:1 XEJXEQ 
 Glutaric acid22  1:1 XEJXIU 
 Malonic acid22  1:1 XEJXAM 




 Saccharin35  1:1  
 Salicyclic acid25, 49 1:1 KIGLES 
 dl-Tartaric acid41 2:1 NEYCIE 
 Sorbic acid25  1:1 KIGLAO 
 5-chlorosalicylic acid25 1:1 CSATEO 
 4-hydroxybenzoic acid25 1:1 KIGLOC 
 Sulfathiazole50 1:1 SULTHE 
 1-hydroxy-2-naphthoic acid25 1:1 KIGLIW 
 2,4-dihydroxybenzoic acid25  1:1 DEYREF 
 Acetaminophen25  
 
1:1 KIGLUI 
Sulfadimidine Acetylsalicylic acid51 1:1 VUGMIT 
 4-aminosalicylic acid51 1:1 VUGMOZ 
 2-aminobenzoic acid51  1:1 SORWEB 
 4-aminobenzoic acid51 1:1 SORWIF 
    
Piroxicam Fumaric acid18  4:1 DIKDIL 
 Benzoic acid18  1:1 DIKDOR 
 Succinic acid18 2:1 DIKCIK 
 1-hydroxy-2-naphthoic acid18 1:1 DIKCOQ 
 4-hydroxybenzoic acid18  1:1 (form I) 
1:1 (form II) 
DIKDEH 
NIFKIX 
 Malonic acid18  1:1  








Due to their directionality, strength and frequency of occurrence, hydrogen bonds 
are extensively employed in cocrystal design.18, 19, 21, 22, 52-55   By studying the packing 
motifs and hydrogen bond patterns in the crystal structures of large number of organic 
compounds, Etter and Donohue have proposed the following three hydrogen bonds 
rules:52, 56, 57  
(i)   all acidic hydrogens in a molecule will be used for hydrogen bond formation  
(ii)  all good hydrogen bond acceptors will be used when there are available  
       hydrogen bond donors, and 
(iii) the best hydrogen bond donor and best acceptor will preferentially form  
       hydrogen bonds to one another.  
Using these rules, hydrogen bond and synthon formation between the functionalities of 
different molecules can be predicted and rank ordered,58-60 and strategies for cocrystal 
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design can be derived. This approach was used to design cocrystals of the anti-epileptic 
drug carbamazepine (CBZ) in 2003.19   
 The molecular structure of CBZ (figure 1.3) shows an azepine ring with a primary 
amide functional group that has two hydrogen bond donors and two acceptors. The 
crystal structures of form III CBZ exhibits the carboxamide homodimer (figure 1.4A) due 
to hydrogen bonding between the amide groups of two CBZ molecules.27, 61, 62   The anti-
NH in the amide group remains free due to steric hindrance from the azepine ring. 
However, in the crystal structure of carbamazepine dihydrate (CBZ(D)), the anti-NH 
forms N―H····O hydrogen bonds with water molecules (figure 1.4B). One of the 
strategies in the design of CBZ cocrystals, therefore, is to utilize the anti-NH of CBZ to 
form hydrogen bonds with other coformer molecules, such as NCT and SAC, while 




O NH2  
 
Figure 1.3: Molecular structure of carbamazepine 
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Figure 1.4: Hydrogen bonding patterns in (A) CBZ(III),32 (B) CBZ(D),63 (C) CBZ-NCT 
cocrystal,19 and (D) CBZ-SAC cocrystal19 
 
  
An alternative strategy for designing CBZ cocrystals is to replace the amide-
amide interactions in the carboxamide homodimer with stronger acid-amide interactions 
resulting in a heterodimer.19  CBZ cocrystals with trimesic acid, 5-nitroisophhalic acid, 
and CBZ-malonic acid have been designed in this manner19, 35 (figure 1.5). Using these 
strategies, as many as 40 cocrystals of carbamazepine have been discovered to date.19, 33, 
34, 64   Cocrystals thus enhance the diversity of CBZ solid forms. 
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Figure 1.5: Hydrogen bonding patterns in (A) CBZ-trimesic acid,19 (B) CBZ-5-
nitroisophthalic acid,19 and (C) CBZ-malonic acid35 
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 Strategies to design caffeine and theophylline cocrystals were similarly developed 
based on hydrogen bond rules and synthon formation. Caffeine and theophylline are 
characterized by basic nitrogen and carbonyl groups in the imidazole and pyrimidine ring 
that serve as hydrogen bond acceptors. Theophylline, in addition, has a hydrogen bond 
donor. The molecular structure of these two compounds is shown in figure 1.6. 
 Cocrystals of caffeine were designed using coformers such as dicarboxylic acids 
that donate hydrogen bonds.21, 42  The cocrystals are formed as a result of heteromeric 
O−H···N and C−H···O interactions that replace the homomeric interactions in the crystal 
structure of caffeine.21, 42  Figure 1.7 shows the hydrogen bonding patterns in some 
caffeine-dicarboxylic acid cocrystals. Cocrystals of theophylline with dicarboxylic acids 
were similarly designed using dicarboxylic acids that serve as both hydrogen bond donors 
and acceptors22 (figure 1.8). In this case, N−H···N interactions between theophylline 
molecules in anhydrous theophylline are replaced by stronger O−H···N interactions 
between the carboxylic acid and basic nitrogen of theophylline. The –NH donor in 
theophylline interacts with the carbonyl of adjacent theophylline via N−H···O interactions 
to form theophylline dimer.22  
 
                               






       
 
Figure 1.7: Molecular assemblies in caffeine cocrystals: (A) caffeine-oxalic acid,21 and 






Figure 1.8: Molecular assemblies in (A) anhydrous theophylline,65 (B) theophylline-





Examples in the preceding section show that cocrystallization alters the molecular 
interactions and composition of pharmaceutical materials. As such one can expect 
changes in physico-chemical properties such as chemical stability, hygroscopicity, 
dissolution rates and solubility due to cocrysallization of pharmaceutical materials. This 
has been demonstrated for a few API cocrystals. 
 
Chemical stability 
Cocrystallization can improve the chemical stability of an API. For instance, 
carbamazepine is reported to undergo chemical degradation to cyclobutyl dimer after 
forming a hydrate.2, 66  The degradation reaction requires that the distance between the 
azepine rings of adjacent CBZ molecules be less than or equal to 4.1Å.66 
Cocrystallization of CBZ with coformers such as saccharin (SAC) or nicotinamide (NCT) 
alters the molecular interactions and packing arrangement of CBZ molecules. Hence, 
these cocrystals exhibit greater stability against hydration and degradation.  
 
Melting point 
The melting point of cocrystals, in general, differs from those of the individual 
components due to changes in molecular interactions, composition and structure.  Table 
1.3 compares the melting points of some drugs, coformers, and the corresponding 
pharmaceutical cocrystals. Cocrystals with lower melting points can be advantageous 
during pharmaceutical processing; for example when a melted state of a thermally labile 
API is desired during some processes such as hot melt extrusion, a cocrystal with a 
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melting point lower than that of the pure crystalline API will allow for melting at lower 
temperatures to avoid chemical degradation. 
 
Table 1.3: Melting points of single components and their cocrystals19, 35, 67-72 
Drug/coformer M.P. (°C)  Cocrystal M.P. (°C) 
Carbamazepine (CBZ) 192  CBZ-NCT 160 
Caffeine (CAFF) 236  CBZ-SAC 177 
Theophylline (THP) 269  CBZ-GLA 125 
Sulfamerazine (SFZ) 237  CAFF-SAC 124 
Nicotinamide (NCT) 126-128  CAFF-GLA 96 
Saccharin (SAC) 229  THP-SAC 207 
Glutaric acid (GLA) 98  THP-GLA 118 
Salicylic acid (SAA) 158-162  SFZ-SAA 201 
 
 
Hygroscopicity and hydrate formation 
Pharmaceutical cocrystals can alter API hygroscopicity and prevent hydrate or 
solvate in APIs. Hydrate or solvate formation of APIs relies on interactions between the 
drug and the solvent in the crystal. Replacing these interactions with those between the 
API and cocrystal former can inhibit API hydrate or solvate formation. This has been 
shown for CBZ cocrystals with SAC and NCT.  Anhydrous carbamazepine transforms to 
CBZ(D) on exposure to high relative humidities. However, CBZ-NCT and CBZ-SAC 
cocrystals under similar conditions exhibit greater stability against CBZ(D) formation66 
(figure 1.9). Similar behavior is reported for cocrystals of caffeine and theophylline with 
























100%RH, 22°C,  3 weeks
  98%RH, 22°C, 10 weeks
 
 
Figure 1.9: Hygroscopicity of carbamazepine (CBZ), nicotinamide (NCT), saccharin 
(SAC), CBZ-NCT cocrystal, and CBZ-SAC cocrystal20 
 
 
Dissolution rates and solubility 
Cocrystals alter the solubility and dissolution rate of crystalline drugs. 
Itraconazole (ITZ), an antifungal agent, is an API with very low aqueous solubility. 2:1 
cocrystals of itraconazole were prepared using 4 dicarboxylic acids (l-tartaric acid, maleic 
acid, succinic acid, and fumaric acid).45 Dissolution rates of the cocrystals were 
compared with that of the pure crystalline and amorphous drug in 0.1N HCl at 25°C.45 
The cocrystals showed 4 – 20 fold faster dissolution relative to the crystalline drug. In the 
case of ITZ−l-tartaric acid and ITZ−l-malic acid cocrystals, the dissolution profiles were 
comparable with the amorphous form of the drug.  
Cocrystals of fluoxetine hydrochloride, an anti-depressant, were synthesized with 
benzoic acid, succinic acid and fumaric acid.73  Powder dissolution studies indicated 
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rapid dissolution of the cocrystals in water at 20°C.73  Intrinsic dissolution rate studies 
were therefore performed to compare the dissolution rates of cocrystals and the 
crystalline salt. The dissolution rate of 2:1 fumaric acid cocrystal was similar to the pure 
crystalline fluoxetine hydrochloride, but the dissolution rate for the benzoic acid 1:1 
cocrystal was half that of the API. Fluoxetine hydrochloride-succinic acid 2:1 cocrystal 
had approximately three times higher dissolution rate, but the dissolution was so fast that 
an accurate value was difficult to measure. Thus cocrystal synthesis with different ligands 
offers the opportunity to tailor the dissolution rates of drugs.  
Solubility studies with carbamazepine-nicotinamide (CBZ-NCT) cocrystal have 
shown that cocrystal solubility decreases with increasing ligand concentration (figure 
1.10).74 These studies further show that cocrystal solubility dependence on ligand 
concentration can be predicted using mathematical models based on cocrystal 
dissociation and complexation equilibria as shown below for a 1:1 cocrystal forming 1:1 
solution complex.74 
 
 Asoln + Bsoln
Ksp
ABsolid
              (1)       
Asoln + Bsoln ABsoln
K11
                  (2) 
Equilibrium constants for these reactions are the solubility product 
]B][A[=Ksp           (3)       







=K          (4) 






=]A[         (5) 




Figure 1.10: Solubility of 1:1 CBZ:NCT cocrystal at 25 °C as a function of total NCT 
concentration in ethanol, 2-propanol, and ethyl acetate.74 The solid lines represent the 
predicted solubility according to equation (5). Filled symbols are experimental cocrystal 
solubility values in (■) ethanol, (▲) 2-propanol, and (●) ethyl acetate.  
 
 
For cocrystals with ionizable drug and/or coformer, cocrystal solubility is also 
dependent on solution pH. This dependence can be predicted using mathematical models 
based on ionization and cocrystal dissociation equilibria. For a binary cocrystal RHA, 
where R is the drug and HA is the acidic ligand, the solubility (Scocrystal) dependence on 











1KS aspcocrystal         (6) 
Ksp is the solubility product of the cocrystal, and Ka is the ligand dissociation constant. 
Figure 1.11 shows the predicted solubility dependence on pH for a cocrystal with weak 
acidic ligand and neutral drug.20  Models predicting pH dependent solubility have also 
been developed for cocrystals with ionizable drug and coformer.75 
 
 
Figure 1.11: pH-solubility dependence for cocrystal with neutral drug and acidic ligand 
plotted using equation (6) with Ksp values of 0.001M2 (―) and 0.01M2 (- - -), and ligand 




 Due to differences in molecular interactions and crystal structure, cocrystals also 
exhibit different mechanical properties. For instance, 1:1 cocrystal of caffeine with 
methyl gallate shows improved tabletability over caffeine and methyl gallate at high 
compaction pressures (> 240 MPa).39  In contrast, tablets of caffeine showed lamination 
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at compaction pressures greater than 180 MPa, and a sharp reduction in tensile strength 
due to elastic deformation at pressures greater than 240 MPa. Methyl gallate tablets 
exhibited poor tensile strength and high elastic recovery at low compaction pressures. 
Improved tabletability of the cocrystal is attributed to the presence of slip planes that are 
absent in caffeine.39  Cocrystals of CBZ with SAC and NCT are similarly reported to 
have improved tableting characteristics when compared to CBZ(D) or CBZ(III). While 
high pressure (5000 psi) applied for 30 minutes were required to make tablets of CBZ(III) 
or CBZ(D) to avoid capping, tablets of cocrystals could be made at lower compaction 
pressures over shorter times.66  
 The preceding examples illustrate the potential offered by cocrystals for altering 
physico-chemical properties. Considerable effort and time have therefore been expended 
on cocrystal design and screening. 
 
Cocrystal screening 
 Screening for cocrystals is performed using solution or solid-state based methods. 
Cocrystal screening by solution based approaches is usually performed by slow 
evaporation of organic solvents containing the drug and coformer in stoichiometric molar 
ratios.19, 33, 64  While this approach has generally been successful for discovering 
cocrystals, it is nevertheless empirical, and suffers from the risk of crystallizing single 
components. A more effective approach for screening cocrystals is the reaction 
crystallization method where supersaturation with respect to cocrystal is selectively 
achieved by dissolving the least soluble component, usually the drug, in solutions of the 
highly soluble component, usually the coformer.76  Thus, the drug and coformer may be 
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in non-stoichiometric molar ratios in this method.  The effectiveness of this approach for 
cocrystal screening was demonstrated in a recent study with CBZ cocrystals. Twenty-
seven cocrystals of CBZ with several carboxylic acids were discovered using aqueous or 
organic solvents.34  
 Recent studies have also employed thermal methods for cocrystal screening where 
the drug and coformer are heated in DSC or hot stage.35, 77  Cocrystal formation in this 
case is preceded by the formation of eutectic melt. Cocrysals of carbamazepine, caffeine, 
sulfamerazine, theophylline and flurbiprofen with several coformers were identified using 
this approach.35, 77  
 In the solid-state, cocrystal screening is performed by cogrinding the reactants.51, 
52, 78-80  Small quantities of organic solvents or water added to the reactants during 
grinding have been shown to improve the success of discovering cocrystals.38, 41, 81, 82 
Cocrystals that could not be identified by slow evaporation of organic solvents or by dry 
grinding were identified by cogrinding reactants with small quantities of solvent, with the 
outcome being dependent on the nature of solvent.82-84    
 
Research objectives  
Much of the current emphasis in the field of pharmaceutical cocrystals has been 
on cocrystal design and screening. Only a few studies have investigated cocrystal 
properties. Several reports indicate the potential for cocrystals as alternate solid-state 
forms for drug development, however less is known about the factors affecting cocrystal 
formation and stability. Lack of such understanding can lead to unanticipated phase 
changes during processing or storage, and result in poor pharmaceutical product 
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performance. This has been shown for AMG-517, a class II Amgen compound. 
Transformation of the drug to cocrystal during development resulted in solubility limited 
absorption.85  The objective of the current study, therefore, is to understand the 
mechanisms of cocrystallization, and to identify the factors that affect cocrystal formation 
and stability using carbamazepine and theophylline cocrystals as model systems. The 
specific goals are to:  
(i) Identify the factors governing the formation and stability of cocrystals with 
different stoichiometry,  
(ii) Determine the mechanisms by which moisture induces cocrystal formation  
                             in reactant mixtures    
(iii) Examine the effect of hygroscopic additives, such as sucrose and fructose, and  
            reactant properties on the formation and stability of cocrystals 
(iv) Identify the factors governing the formation and thermodynamic stability of 
anhydrous and hydrated cocrystals  
(v) Determine cocrystal formation mechanisms during cogrinding and            
storage.  
 
Subsequent chapters in this thesis will address the above goals. The remaining 
portion of the current chapter will present model APIs and cocrystals used in this 
research. Chapter 2 examines the factors affecting the formation and stability of 
cocrystals with different stoichiometry. Key parameters to identify cocrystal stability 
domains are presented. Mathematical models based on heterogenous and homogenous 
equilibria to (i) predict cocrystal and drug solubilities, and (ii) generate phase solubility 
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and triangular phase diagrams are presented. The utility of models for estimating 
cocrystal solubility in pure solvents, and for predicting cocrystal solubilities with 
minimum number of experiments is demonstrated. Chapter 3 presents the mechanism of 
cocrystal formation due to moisture sorption and deliquescence in reactant mixtures. The 
effects of hygroscopic additives and the factors affecting cocrystal formation and stability 
are addressed. Chapter 4 discusses the role of coformer, excipient and cosolvent aqueous 
concentrations on the formation and thermodynamic stability of anhydrous and hydrated 
cocrystals. Phase diagrams showing the solubility and stability dependence of anhydrous 
and hydrated cocrystals on coformer concentration are presented.   Chapter 5 focuses on 
the mechanism of cocrystal formation during cogrinding. The effects of grinding time, 
temperature, and solid-state form of reactants on cocrystal formation during cogrinding 
are presented. Results showing transformations during storage, and the effect of storage 
conditions on cocrystal formation rates are presented. 
 
Model Compounds and cocrystals 
Carbamazepine and theophylline were chosen as the models drugs in this study. 
Carbamazepine is a BCS class II compounds and has low solubility and high 
permeability. In contrast, theophylline is a class I compound with high solubility and 
permeability. Cocrystals of both drugs have been identified with several pharmaceutically 
relevant coformers using the crystal engineering principles and strategies outlined in a 





Carbamazepine, an anti-convulsant drug, exists in four polymorphic forms.61, 62 
The crystal structures of all four polymorphic forms of carbamazepine exhibit similar 
molecular conformations and hydrogen bonding patterns resulting in a carboxamide 
homodimer.27  The primary difference between the different forms is in the packing 
arrangements that results in different crystallographic properties as illustrated in table 1.4. 
Of the four polymorphic forms, monoclinic form III is the thermodynamically stable 
form at room temperature.67  
 In addition to the four polymorphic forms, carbamazepine also forms a dihydrate 
and solvates.19, 86, 87  The crystal structure of carbamazepine dihydrate exhibits the 
carboxamide dimer motifs similar to those observed in the carbamazepine polymorphs. 
However, the anti-NH of carbamazepine amide forms hydrogen bonds with water 
molecules that results in the formation of water channels along the b-axis in 
carbamazepine dihydrate. Due to these differences in the hydrogen bond patterns and 
packing arrangements, carbamazepine dihydrate exhibits different crystallographic and 
physico-chemical properties. Thermal analysis of CBZ(D) shows an endotherm at 50-
80°C and a 13% weight loss corresponding to the loss of water from the crystal. CBZ(D) 
is the thermodynamically stable form at high relative humidities (RH > 70%), and has the 
lowest solubility in water when compared to the anhydrous forms. Consequently, the 





Table 1.4: Crystallographic properties of CBZ polymorphs  
 CBZ (I)62  CBZ (II)88  CBZ(III)32  CBZ(IV)61  CBZ(D)63  
Crystal system Triclinic Trigonal Monoclinic Monoclinic Monoclinic 
Space group P-1 R-3 P21/n C2/c P21/c 
a (Å) 5.17 35.45 7.54 26.61 10.07 
b (Å) 20.57 35.45 11.16 6.93 28.72 
c (Å) 22.25 5.25 13.91 13.96 4.83 
α (degree) 84.12 90 90 90 90 
β (degree) 88.01 90 92.86 109.70 103.45 
γ (degree) 85.19 120 90 90 90 
Volume (cm3) 2344.8 5718.3 1168.3 2421.9 1358.3 




 Approximately 40 cocrystals of carbamazepine (CBZ) have been reported to 
date,19, 33, 34, 64 and table 1.2 lists some examples of CBZ cocrystals. Cocrystals of 
carbamazepine with nicotinamide (NCT), saccharin (SAC) and 4-aminobenzoic acid 
(4ABA) were selected as model systems in the current study since the crystallographic  
and physico-chemical properties of these cocrystals are reported.19, 33  
Both CBZ-NCT and CBZ-SAC cocrystals exhibit polymorphism. Form I CBZ-
NCT and CBZ-SAC were first identified in 2003 by slow evaporation of organic solvents 
containing the reactants in stoichiometric molar ratio.19 The crystal structures of both 
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cocrystals and hydrogen bonding patterns have been presented in an earlier section 
(figure 1.4). Polymorphic form II CBZ-NCT cocrystal was identified by melt-quenching 
form I cocrystal and reheating the resulting amorphous phase,89 as well as by polymer 
mediated nucleation and growth from solutions.90  Form I is thermodynamically stable 
phase at room temperature, and is monotropically related to form II cocrystal. Form II 
exhibits an exothermic transformation to form I at 83-90°C.89  Upon dissolution in water, 
form I CBZ-NCT transforms to CBZ(D) due to higher aqueous solubility of the cocrystal.  
Form II CBZ-SAC cocrystal polymorph was identified by polymer mediated 
nucleation.90  Unlike the form I CBZ-SAC cocrystal, form II CBZ-SAC cocrystal does 
not retain the CBZ amide homodimer. Instead, the CBZ amide forms heterosynthon by 
hydrogen bonding with the SAC amide90 as shown in figure 1.12. Based on thermal 
analysis and stability study of form II CBZ-SAC cocrystal in suspensions, form I is 
reported to be the thermodynamically stable phase at room temperature.90  However, 
form I CBZ-SAC transforms to CBZ(D) upon dissolution in water due to higher aqueous 





Figure 1.12: Hydrogen bonding in form II CBZ-SAC cocrystal90 
 
Carbamazepine-4-aminobenzoic acid (CBZ-4ABA) cocrystal is reported to exist 
in the anhydrous and hydrated form.33  The crystal structures of the two cocrystals are 
shown in figure 1.13. The 2:1 anhydrous structure shows the expected acid−amide 
heterosynthon as well as an unexpected amide-amide homosynthon. Two acid-amide 
heterosynthons are connected through N−Hanti⋅⋅⋅O hydrogen bonds to from a tetrameric 
unit. These tetramers are hydrogen bonded to CBZ homodimers on each side via amino 
N−H⋅⋅⋅O hydrogen bond (figure 1.13A).33 In the 2:1 hydrated structure, water molecule 
interrupts the expected acid−amide heterosynthon. A second CBZ molecule interacts with 
the water interrupted dimer via O−H⋅⋅⋅O and N−H⋅⋅⋅O hydrogen bonds to form a tetramer. 
These tetramers are in turn connected by amino N−H⋅⋅⋅O hydrogen bond to form a eight 
molecule discrete unit (figure 1.13B).33  
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Both the anhydrous and hydrated cocrystals were discovered by slow evaporation 
of organic solvents containing CBZ and 4ABA in 1:1 mol ratio.33  However, the relative 
thermodynamic stabilities of the two cocrystalline phases are not known. Identifying the 
factors governing the formation and thermodynamic stability of the two cocrystalline 
phases will enable anticipation of phase transformation, and is therefore a subject matter 
of interest in the current study. 
CBZ-NCT, CBZ-SAC and CBZ-4ABA cocrystals were also selected in the 
current study as the coformers (NCT, SAC and 4ABA) in these cocrystals exhibit 
different properties such as solubility, hygroscopicity and melting points. Nicotinamide 
exists in four polymorphic forms and has a melting point of 126-128°C.69  It has high 
aqueous solubility, and is known to self-associate in aqueous solutions.91  Further, NCT 
has been shown to enhance the solubility of several drugs significantly by forming 
complexes in solution.92, 93  During storage at high relative humidity, NCT sorbs more 
than 50% water and deliquesces.66   In contrast, 4-aminobenzoic acid and saccharin are 
non-hygroscopic and have low aqueous solubility.94, 95  Both ligands are ionizable. SAC 
is a weak acid with a pKa of 1.8,96 while 4ABA is amphoteric with pKas of 2.45 and 
4.85.97  The melting point of 4ABA and SAC are higher when compared to NCT. 4ABA 










Figure 1.13: Molecular assemblies in CBZ-4ABA cocrystals33 (A) 2:1 anhydrous 




 Theophylline (THP), a bronchodialator, exists in 3 polymorphic forms (forms I, 
I*, I'),15, 98 and as a hydrate.99  The molecular structure of theophylline is shown in figure 
1.6.  Of the three polymorphs, form I is the stable phase at room temperature, while forms 
I' and I* are meta-stable. Form I* was identified by heating theophylline hydrate,15 and 
form I' was identified by heating form I at 260-280°C for 1 hour.98 Form I' is 
enantiotropically related to form I, while form I* is monotropically related.  All three 
anhydrous forms transform to theophylline hydrate in water since theophylline hydrate is 
the least soluble phase in water.15, 98  
Theophylline has two hydrogen bond acceptors and one hydrogen bond donor 
(figure 1.6). Hence, it can form cocrystals with coformers capable of donating and 
accepting hydrogen bonds. Table 1.2 shows examples of theophyline cocrystals with 
several coformers. While most theophylline cocrystals are anhydrous, the cocrystal with 
citric acid (CTA) is reported to exist in the anhydrous and hydrated form.38 The 
cocrystals were identified by cogrinding reactants.38   Anhydrous cocrystal was formed 
by cogrinding anhydrous THP and CTA. Cocrystal hydrate was formed by cogrinding the 
hydrated reactants or by cogrinding the anhydrous reactants with small quantities of 
water. Both THP-CTA cocrystals were also identified by slow evaporation of organic 
solvent containing the reactants in stoichiometric ratios.38  
Water activity is well known to affect the formation and stability of 
pharmaceutical hydrates.100, 101   The water activity can be varied by altering the solution 
composition.102  Citric acid is highly water soluble, and increasing citric acid aqueous 
concentration is known to decrease the water activity.103  Since cocrystal stability has 
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been shown to depend on coformer concentration, THP-CTA cocrystals were selected as 
model systems to examine the effect of coformer concentration on the formation and 
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THE ROLE OF COCRYSTAL AND SOLUTION CHEMISTRY ON THE 





 Achieving the desired bioavailability is the ultimate goal and a major challenge in 
drug development. One of the significant ways to achieve this is by generating different 
crystalline or amorphous forms of an API with a range of physicochemical and 
pharmaceutical properties.1-8 Screening for API cocrystals, salts, polymorphs, solvates, 
hydrates, and amorphous phases with desirable properties is therefore an active and 
routine procedure in drug discovery and development.9-14 Cocrystal design based on 
crystal engineering principles and strategies enables modulation of API properties such as 
solubility, dissolution rates, physical and chemical stability, and mechanical properties.15-
21 
 The number of API cocrystals continues to increase and for some drugs as many 
as 40 to 50 cocrystals are reported.15, 19-27 Fifty cocrystals of piroxicam and about 40 for 
carbamazepine have been discovered.10, 22, 25-27 API cocrystals of different stoichiometries 
with the same components have also been reported and are usually discovered by 
different crystallization processes or solvents.19, 28 A key question is what factors dictate 




Efforts to enhance the success and efficiency of cocrystal screening methods have 
received considerable attention.9, 10, 12, 29 However, relatively less is known about the 
factors affecting cocrystal formation and thermodynamic stability.30, 31 Understanding the 
mechanisms and kinetics of cocrystallization, as well as the factors affecting cocrystal 
stability, is essential to control synthesis and phase transformations.32-35 This contribution 
aims to identify the factors that affect the solution-mediated formation of cocrystals with 
different stoichiometry by examining the role of cocrystal and solution chemistry on 
crystallization and phase stability.  
Carbamazepine−4-aminobenzoic acid (CBZ−4ABA) was studied as a model 
system. A 2:1 cocrystal has been reported.27 Herein, we report the discovery of a 1:1 
CBZ−4ABA cocrystal.  Both cocrystals can be prepared by reaction crystallization 
method (RCM) by varying solution concentration of reactants.  The relative 
thermodynamic stability and solubility of the two cocrystals and the crystalline drug are 
examined as a function of ligand (4ABA) solution concentration.  Previous studies with 
carbamazepine-nicotinamide and carbamazepine-succinic acid cocrystals have shown 
that cocrystal solubility and stability are described by mathematical models based on 
solution complexation and solubility product behavior.10, 30 In the current study this 
approach has been extended to: (i) develop models that describe the solubilities of 
cocrystals with different stoichiometry, (ii) generate phase diagrams that show 
crystallization and stability domains of various phases, and (iii) identify key parameters 
to determine the stability domains of cocrystals.  Results from these studies are applicable 




to anticipate conditions under which process-induced transformation can lead to cocrystal 




 Anhydrous monoclinic form III carbamazepine (CBZ(III)) and α-form of 4-
aminobenzoic acid (4ABA) were obtained from Sigma-Aldrich and were used as 
received. Both compounds were characterized by X-ray powder diffraction (XRPD) and 
Raman spectroscopy before carrying out experiments. Ethanol, obtained from Fisher 




1:1 and 2:1 carbamazepine−4-aminobenzoic acid cocrystals were synthesized 
using the reaction crystallization method10, 31. X-ray quality single crystals of 1:1 
cocrystal were grown by slow evaporation of solvent. 
Single crystal of 1:1 CBZ−4ABA cocrystal: A mixture of 100 mg (0.0042 mol) of CBZ 
(III) and 581.5 mg (0.042 mol) of 4ABA was dissolved in 5 ml ethanol. Slow evaporation 
of ethanol at room temperature yielded single crystals of the 1:1 cocrystal. The crystals 
were characterized by Raman microscopy prior to solving the crystal structure. 
Reaction crystallization method for 2:1 and 1:1 cocrystal synthesis:  The 2:1 
cocrystal was prepared by suspending 200 mg of CBZ(III) in 3.25g of 0.6m 4ABA 




saturated 4ABA suspension. The suspensions were magnetically stirred at room 
temperature for 12 hours and the solid phases recovered after filtration was characterized 
by XRPD and Raman spectroscopy. XRPD patterns were compared with the simulated 
patterns of 2:1 and 1:1 cocrystal to confirm that the solid phases were pure cocrystals. 
Simulated XRPD pattern of 2:1 cocrystal was obtained from the crystal structure database 
(CSD Refcode: XAQRAJ) and that of the 1:1 cocrystal was obtained by solving the 
crystal structure.  
 
CBZ(III)and cocrystal stability studies 
CBZ(III) stability as a function of ligand concentration was studied by suspending 
200mg CBZ(III) in 2ml of 0.1m, 0.6m and saturated 4ABA solution with excess solid 
4ABA. All suspensions were magnetically stirred for 48-96 hours at 25 ºC and the solid 
phases were characterized by Raman spectroscopy and X-ray powder diffraction 
(XRPD). 
The stability of 2:1 and/or 1:1 cocrystals in methanol, ethanol, isopropyl alcohol, 
acetonitrile, chloroform and water was studied by suspending 200mg of cocrystal in 2-
3ml of organic solvent or water. The suspension was stirred magnetically at 25 °C for 2–
7 days and the solid phases were characterized by XRPD. Transformation and stability of 
cocrystals in ethanol was also monitored in real-time by Raman spectroscopy. 
 
Transition concentration measurement 
 Three transition concentrations or isothermal invariant points (c1, c2, and c3) were 




(c1) for CBZ(III) and 2:1 cocrystal was determined by measuring reactant concentrations 
(CBZ and 4ABA) in ethanol saturated with CBZ(III) and 2:1 cocrystal. Saturation with 
respect to the two crystalline phases was achieved by suspending CBZ(III) in 0.12m and 
0.5m 4ABA in ethanol. 2:1 cocrystal was added to the suspensions after 24 hours. The 
suspensions were allowed to reach equilibrium by magnetically stirring at 25°C. Solid 
phase and solution concentration were monitored. The equilibrium was considered to be 
achieved when solution concentrations reached a steady value while two solid phases 
coexist. The solid phases in suspension were characterized by Raman spectroscopy. 
Solutions were analyzed by HPLC for CBZ concentration and 4ABA concentration was 
determined by gravimetric method. The suspensions were filtered and the solid phases 
were characterized by XRPD. 
The transition concentration c2 was determined by saturating ethanol with 2:1 and 
1:1 cocrystals. This was achieved by adding excess 2:1 and 1:1 cocrystals to 1.1m 4ABA. 
c3 was determined by saturating ethanol with 1:1 cocrystal and 4ABA. The procedures 
for analysis of solid and liquid phases were similar to those described above. 
 
Solubility studies 
2:1 Carbamazepine−4-aminobenzoic acid cocrystal: Cocrystal solubility studies as a 
function of ligand (4ABA) concentration were performed by suspending excess 2:1 
cocrystal in solutions of ethanol with varying ligand concentrations. The suspensions 
were allowed to reach equilibrium while magnetically stirring at 25 °C. Aliquots of 
solutions were withdrawn after 48, 70 and 90 hours using a syringe fitted with a 0.45μ 




the equilibrium concentration of CBZ. All the samples attained equilibrium by 70 hours. 
The equilibrium concentration of 4ABA in solution was then determined by mass 
balance. The solid phases at equilibrium were characterized by XRPD. 
Carbamazepine (CBZ(III)): The solubility dependence of CBZ(III) on ligand (4ABA) 
concentration was determined by suspending excess drug in varying concentrations of the 
ligand in ethanol at 25˚C. The equilibrium concentration of the drug was determined 
using a procedure similar to that described for the 2:1 cocrystal. The solid phases at 
equilibrium were characterized by XRPD. 
4-Aminobenzoic acid (4ABA): The solubility of 4ABA was determined by suspending 
excess 4ABA in ethanol. The suspension was allowed to reach equilibrium while 
magnetically stirring at 25°C. The equilibrium concentration of 4ABA in the solution was 
then determined using a gravimetric approach. The solid phase at equilibrium was 
characterized by XRPD.  
 
Raman spectroscopy 
Raman spectra was collected using a RXN1 Raman spectrometer equipped with 
an immersion probe or a Raman microprobe from Kaiser Optical Systems Inc., Ann 
Arbor, MI. Spectra were collected using 10 exposures and 1-3 accumulations using the 
vendor supplied Holograms software.  
 
X-ray Diffraction  
Powder: A bench top Rigaku Miniflex X-ray powder Diffractometer (Danvers, MA) 




was used to collect XRPD patterns of solid phases. Data was collected from 2˚ to 40˚ at a 
continuous scan rate of 2.5 deg/min. 
Single crystal: Single crystal X-ray diffraction data for 1:1 cocrystal was collected on a 
Bruker SMART APEX CCD-based X-ray diffractometer (Mo Kα radiation, λ = 0.71073 
Å) equipped with a low temperature device. Empirical absorption corrections using 
SADABS36 were applied. Structure solution and refinement were performed with 
SHELXTL37. All non-hydrogen atoms were refined anisotropically with the hydrogen 
atoms placed in idealized positions except for those involved in hydrogen bonding which 
were allowed to refine isotropically.  
 
High Performance Liquid Chromatography (HPLC) 
A Waters system (Milford, MA) equipped with a 5μm C18 Atlantis column (4.6 x 
250mm; Waters, Milford, MA) and UV/Vis detector was used to measure CBZ 
concentrations. The concentrations were measured using an isocratic method. Mobile 
phase consisting of 55% methanol and 0.1% trifluoroacetic acid in water was flowed 
through the column at 1ml/min. 20μL of samples was injected into the column and the 
absorbance of CBZ was monitored at 284nm. Data collection and processing was 










Crystal structure of 1:1 CBZ−4ABA 
A 1:1 cocrystal of CBZ−4ABA was discovered by reaction crystallization method 
at high ligand concentrations in ethanol.  Crystal structure analysis reveals an unexpected 
hydrogen bond pattern with carboxylic acid···acid and amide···amide homosynthons of 
4ABA and CBZ (figure 2.1). The carboxamide dimer is not replaced by the frequently 
occurring amide-carboxylic acid dimer.27, 38-40  As shown in figure 2.1, cyclic 
homodimers are linked by N−H⋅⋅⋅O hydrogen bonds between amine N−H donor and 
amide carbonyl acceptor to form a one dimensional tape. The anti N−H of amide group is 
not involved in any strong hydrogen bonding. Table 2.1 summarizes the crystallographic 
properties of 1:1 cocrystal. Figure 2.2 compares the simulated and experimental XRPD 


























































































































































































   
   
   
   
   
   
























   
   


























Cocrystal formation and stability  
Transformation of crystalline drug (CBZ(III)) to cocrystal (1:1 or 2:1) is 
dependent on the ligand (4ABA) concentration. The transformation was examined by 
slurrying CBZ(III) at three levels of ligand concentrations - 0.1m 4ABA, 0.6m 4ABA and 
in 4ABA suspension (saturated 4ABA solution with excess 4ABA solid). Figure 2.3 
shows the XRPD patterns of solid phases recovered from these studies. The powder 
patterns indicate that CBZ(III) is stable in 0.1m 4ABA but transforms to 2:1 cocrystal in 




Figure 2.3: XRPD patterns showing ligand concentration dependent transformation of 
(A) CBZ(III) in (B) 0.1m 4ABA, (C) 0.6m 4ABA, and (D) 4ABA suspension; simulated 






Cocrystal stability studies in neat ethanol or water indicate that both cocrystals are 
unstable. In water, both cocrystals transform to 2:1 cocrystal hydrate indicating that 
cocrystal hydrate is less soluble than the anhydrous cocrystals (appendix A). In ethanol, 
the 2:1 cocrystal transforms to CBZ(III) while the 1:1 cocrystal transforms to 2:1 
cocrystal (Figure 2.4). Figure 2.5 shows the Raman spectra acquired at different times 
during 1:1 cocrystal transformation in ethanol. The 1:1 cocrystal transforms to CBZ(III) 
and then to 2:1 cocrystal suggesting that the 1:1 cocrystal is more soluble than CBZ(III) 
and 2:1 cocrystal in ethanol. Peaks corresponding to these transformations are observed 




Figure 2.4: XRPD patterns indicating cocrystal instability in ethanol; 2:1 cocrystal (A) 
before slurrying, and (B) after slurrying in ethanol; 1:1 cocrystal (C) before slurrying, and 








Figure 2.5: Raman spectra showing transformation of 1:1 cocrystal in ethanol (A) before 
slurrying, (B) after 1 minute showing transformation to CBZ(III), and (C) after 5 minutes 
indicating transformation to 2:1 cocrystal. 
 
 
The stability of the cocrystals was also examined in other organic solvents. Table 
2.2 summarizes the results from stability studies in various solvents. XRPD patterns of 
the solid phases from the stability studies are included in appendix A.  
 
Table 2.2: Cocrystal stability in various solvents. 
Solvent 2:1 cocrystal 1:1 cocrystal 
Water Unstable, transforms to cocrystal 
hydrate 





Unstable, transforms to CBZ(III)
 





Unstable, transforms to CBZ(III)
 
Unstable, transforms to 2:1 
cocrystal 
   










Unstable, transforms to 4ABA 
 
Unstable, transforms to 4ABA 




    Results from stability studies in ethanol show that cocrystal formation and 
stability depend on the ligand concentration. Previous studies with CBZ-nicotinamide 
cocrystal in organic solvents and CBZ−Succinic acid cocrystal in water have shown 
similar dependence of drug and cocrystal stability on ligand concentration.10, 30 The 
transformation of drug to cocrystal at high ligand concentrations is due to lower solubility 
of cocrystal relative to the crystalline drug, whereas the drug is least soluble and most 
stable phase at low ligand concentrations. This change in the relative order of solubility 
and stability of the crystalline phases with increasing ligand concentration gives rise to 
the transition concentration (Ctr), at which two solid phases are in equilibrium with the 
solution.10, 30, 31 Since there are three components (API, ligand and solvent) and three 
phases (2 solid phases and liquid) at a fixed temperature and pressure, phase rule dictates 
that Ctr is an invariant point. Thus, based on the results from CBZ(III) and CBZ−4ABA 
cocrystal stability studies in ethanol (figures 2.3, 2.4 and 2.5), there must be invariant 
points at which CBZ(III)/2:1 cocrystal and 2:1 cocrystal/1:1 cocrystal are in equilibrium 
with the solution.  
Phase diagrams representing the solution compositions in equilibrium with the 
drug or cocrystal phases indicate that the transition concentration is a useful parameter to 
identify cocrystal stability domains.10, 30, 31  The stability domains of the two CBZ−4ABA 









Table 2.3 summarizes the transition concentrations or invariant points and the 
solid phases that coexist in equilibrium with the solution. From the invariant points, the 
stability domains of the different crystalline phases can be determined. The 2:1 cocrystal 
is stable at reactant concentrations between c1 and c2, while the 1:1 cocrystal is stable 
between c2 and c3. CBZ(III) is the stable phase at reactant concentrations below c1, while 
4ABA is stable above c3.  
 
 
Table 2.3: Solid phases and reactant concentrations at the invariant points for 
CBZ−4ABA−Ethanol system at 25 ˚C 
 
Invariant point Solid phases at equilibrium [CBZ] (m)a  [4ABA] (m)a 
c1 CBZ(III), 2:1 cocrystal 0.150±0.005 0.168±0.004 
c2 2:1 cocrystal, 1:1 cocrystal 0.093±0.001 1.144±0.013 
c3 1:1 cocrystal, 4ABA 0.096±0.002 1.280±0.040 
a Concentrations are the mean ± standard deviation 
 
Reactant concentrations at the invariant points can also be used to identify trends 
in the solubility dependence of the crystalline phases on ligand concentration. 
Examination of the reactant concentration at the invariant points indicates that CBZ 
concentration at c1 is higher than CBZ(III) solubility in ethanol (0.125m). This suggests 
an increase in CBZ(III) solubility with 4ABA concentration possibly due to solution 
complexation. Further, CBZ concentration at c2 is less than that at c1 suggesting a 
decrease in 2:1 cocrystal solubility with increase in 4ABA concentration. Similar results 




Phase solubility and triangular phase diagrams  
The solubilities of the two CBZ−4ABA cocrystals and CBZ(III) crystal were 
measured as a function of 4ABA concentration. These results, along with the reactant 
concentrations at the invariant points, were used to generate phase solubility and 
triangular phase diagrams. The phase solubility diagram (PSD) shows the reactant 
concentrations in solution at equilibrium with the different solid phases-crystalline drug, 
cocrystal and ligand. The reactant concentrations are usually in molarity or molality. The 
PSD is useful for determining the solubility dependence of the phases on solution 
composition, and for studying solution complexation.30, 41  Unlike the PSD, the triangular 
phase diagram (TPD) shows the total composition of the system, including that in the 
solid and liquid phases.10, 42  
Figure 2.6 presents the PSD for the CBZ−4ABA−Ethanol system. The PSD 
shows the CBZ concentration dependence on 4ABA when CBZ(III), 2:1 cocrystal, 1:1 
cocrystal, or 4ABA are in equilibrium with the solution. The concentrations of the drug 
and ligand in solution are expressed as analytical or total concentrations measured at 
equilibrium, [CBZ]T and [4ABA]T. This concentration is the sum of the concentrations of 
unbound (free) and bound reactant in solution. Symbols in figure 2.6 represent 
experimental data from solubility studies of CBZ(III), 2:1 cocrystal and 1:1 cocrystal 
performed as a function of 4ABA concentration. The solid lines ac1, c1c2, and c2c3 are the 
predicted solubilities of CBZ(III), 2:1 cocrystal and 1:1 cocrystal, respectively. The 






From the PSD, it is evident that the solubility of the different crystalline phases is 
dependent on ligand concentration. The solubility of CBZ(III) increases while that of the 
cocrystals decreases with increasing 4ABA concentration. The solubility curves intersect 
at the invariant points (c1, c2, or c3) where two solid phases coexist in equilibrium with 
the solution. Thus the PSD shows the stability domains for the different phases and the 
solution concentrations. The solubility of the cocrystals in neat ethanol is given by the 
intersection of the cocrystal solubility curves with the stoichiometric lines, 1:1 or 2:1. It is 
evident that in neat ethanol, the 2:1 cocrystal will transform to CBZ(III) and the 1:1 
cocrystal will transform to 2:1 cocrystal. This is in agreement with results of cocrystal 
stability studies in ethanol (figures 2.4 and 2.5).  
The solubilities and stability domains of the different crystalline phases are also 
represented on a triangular phase diagram (TPD) as shown in figure 2.7. The solubility of 
CBZ(III), 2:1 cocrystal, 1:1 cocrystal and 4ABA, in mass fractions, are represented by 
the curves ac1, c1c2, c2c3, and c3b, respectively. The stability domain of CBZ(III), 2:1 
cocrystal, 1:1 cocrystal and 4ABA are represented by regions 1, 2, 3 and 4, respectively. 
Regions 5, 6, and 7 represent regions where two solid phases are in equilibrium with the 
solution - CBZ(III)/2:1 cocrystal in region 5; 2:1 cocrystal/1:1 cocrystal in region 6; and 
1:1 cocrystal/4ABA in region 7. The solution composition in regions 5, 6, and 7  





















































































































































































































































































































































































































































































































































































































Mathematical models predicting the solubility of cocrystals and drug 
The phase diagrams presented in the previous section show that the solubilities of 
CBZ(III), 2:1 cocrystal and 1:1 cocrystal are dependent on ligand concentration. In this 
section, mathematical models predicting this dependence for the drug and the cocrystals 
will be presented. The models enable estimation of cocrystal solubility in pure solvents 
which are otherwise experimentally inaccessible due to cocrystal instability and 
transformation. Further, the models allow for prediction of solubility dependence on 
ligand concentration with a minimum number of experiments as will be illustrated for 1:1 
CBA−4ABA cocrystal. 
 
Models predicting 2:1 cocrystal solubility 
For the 2:1 cocrystal, the solubility decreases with increase in ligand 
concentration between c1 and c2 (figure 2.6).  Previous studies from our lab with other 
cocrystalline systems have shown that this dependence can be explained by the solubility 
product principle10, 30. Thus for a 2:1 cocrystal D2L, where D is the drug and L is the 
ligand, the equilibrium reaction for cocrystal dissociation in solution is given as: 
 
D2L(solid)                 2D(soln) + L(soln)                      (1) 
 








K =  





If the activity of the solid D2L is equal to 1, the above relation yields the solubility 
product (Ksp) for the cocrystal: 
L
2
Dsp aaK =  
Under ideal conditions activities can be replaced with concentrations as follows: 
]L[]D[K 2sp =                                            (2) 
For practical purposes henceforth, concentrations are used instead of activities. 
If there is negligible solution complexation then the total or analytical reactant 
concentrations in solution are 
[D]T = [D] and [L]T = [L]                               (3) 





]D[ =                                 (4) 
Equation (4) predicts that the drug concentration ([D]T) decreases with increase in ligand 
concentration ([L]T) when the cocrystal is in equilibrium with the solution.  Further, 
according to equation (4), a plot of [D]T against 
T]L[
1  must yield a straight line through 
the origin. The Ksp of the cocrystal can then be evaluated from the slope of the line. Ksp 
of the 2:1 cocrystal estimated in this manner is 8.4 x 10-4 m3. This model however 
underpredicts the cocrystal solubility dependence on ligand concentration.  
 The cocrystal solubility model (equation 4) does not consider solution 
complexation which may explain why the model underpredicts cocrystal solubility. In 
fact, results from the current study show an increase in CBZ(III) solubility with 4ABA 




been shown to affect the solubility of crystal and cocrystal phases.30, 41, 43  Models that 
describe 2:1 cocrystal solubility dependence on ligand concentrations were therefore 
developed by considering 1:1 and 2:1 solution complexation equilibria. These models 
along with the equilibrium reactions are shown in table 2.4.  
  Equations (5) – (9) in table 3 predict non-linear dependence of drug 
concentration on ligand concentration for the 2:1 cocrystal. Therefore the thermodynamic 
constants (K11, K21, and Ksp) can be evaluated by non-linear fit of the equations to the 
experimental data. Detailed derivations of equations (5) – (9) for the models presented, as 
well as the procedure for evaluating the constants, are included in appendix B.  
Figure 2.8 shows the fit of models I, II and III to the experimental data. Models I 
and II give a better fit than model III. At low ligand concentrations model III 
overestimates the dependence, while at high ligand concentrations it underestimates the 
dependence. Table 2.5 summarizes the values of the thermodynamic constants, R2 and F-
values for models I − III. Based on the R2 and F-value as well as the p-values for the 
constants, we note that the best fit is obtained with model II, equation (7). Further, we 
observe that the constants evaluated using equations (5) and (7) are similar and suggest 
negligible 2:1 solution complexation. Thus the 2:1 cocrystal solubility dependence on 
ligand concentration is explained by 1:1 solution complexation and equation (5) or (7) 
can be used to describe 2:1 cocrystal solubility. In addition to evaluating complexation 
constants from cocrystal solubility studies, complexation constants were also evaluated  
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Figure 2.8: Phase solubility diagram showing the experimental and predicted dependence 
of [CBZ]T on [4ABA]T when the 2:1 cocrystal is in equilibrium with the solution. 
Symbols indicate experimental data. Solid line represents the predicted dependence 




          






Models predicting carbamazepine (CBZ(III)) solubility 
 The solubility of CBZ(III) increases linearly with ligand concentration (figure 
2.9) suggesting the formation of a first order complex with respect to the ligand i.e, DmL. 
Complexation constants from these studies were evaluated using previously developed 
mathematical models based on 1:1 and 2:1 solution complexation.41, 43, 44  These models 






Figure 2.9: CBZ(III) solubility as a function of 4ABA concentration in ethanol at 25˚C. 
Symbols represent experimental data and the line represents the predicted dependence 















































































































































































































































   
   
   
   
   
   
   


























































































































































































































































































Models IV – VI in table 2.6 predict a linear dependence of drug solubility on 
ligand concentration. Thus a plot of [D]T against [L]T for these models will yield a 
straight line and the complexation constants can be evaluated from the slope of the line. 
Model IV has two unknowns (K11 and K21) in the expression for the slope and therefore 
the constants can only be evaluated from cocrystal solubility studies.44  Since results from 
2:1 cocrystal solubility studies indicate negligible 2:1 solution complexation, we 
therefore assume K21= 0 in model IV, and evaluate K11 from the slope. Models IV and V 
are identical when K21 = 0 in model IV. 
The complexation constants (K11, K21, and K′21), R
2, and F-values obtained using 
models IV−VI are summarized in table 2.7. The R2 and F-values are equal for all the 
models. K11 from model IV, evaluated by assuming K21=0, and model V are in agreement 
with that evaluated for the 2:1 cocrystal using models I and II (equations 5 and 7). 
However, K′21 obtained from model VI for drug solubility is significantly different from 
that evaluated for 2:1 cocrystal using model III (table 2.5). These results suggest 1:1 
complexation with negligible 2:1 complex formation in solution. Similar analysis to 
evaluate thermodynamic constants and determine the nature of the complex in solution 
has been carried out for other complexes.43, 45       
 
Model predicting 1:1 cocrystal solubility 
The 1:1 cocrystal solubility is not experimentally accessible below the invariant 
point c2 because of fast conversion to the 2:1 cocrystal.  The 1:1 cocrystal is stable in the 
region between c2 and c3 and the solubility could be measured by equilibrium methods.  




range of 4ABA concentration in Table I.  Therefore the solubility dependence on ligand 







]D[S +==                        (13) 
 
The Ksp of 4.85x10-2 m2 was evaluated using the total drug and ligand concentration at c2 
(table 2.3). K11 was evaluated from 2:1 cocrystal and drug solubility studies. The 
predicted solubility of the 1:1 cocrystal as a function of ligand concentration is shown in 
figure 2.6. 
 Equation (13) can be used to evaluate the Ksp, and hence predict the cocrystal 
solubility dependence on ligand concentration, if the complexation constant and the 




This study reports the discovery of a 1:1 cocrystal of CBZ and 4ABA by the 
reaction crystallization method. The crystal structure shows amide···amide and acid···acid 
homosynthons. This is unusual as acid···amide heterosynthon is expected to form in 1:1 
stoichiometry based on hydrogen bond complementarity.27, 38-40  In fact, the crystal 
structure of the previously reported 2:1 CBZ−4ABA anhydrous cocrystal exhibits an 
acid···amide heterosynthon along with an amide···amide homosynthon.27  A CSD search 
for organic compounds with only primary amide and carboxylic acid groups without 




these compounds showed 28 structures with acid···amide heterosynthon indicating 85% 
probability for heterosynthon formation. The remaining structures show acid···acid 
homosynthon (3%), amide-amide homosynthon (6%) and acid···amide catamer (6%). 
None of the crystal structures in the CSD show both acid···acid and amide···amide 
homosynthons. To our knowledge, the 1:1 CBZ−4ABA cocrystal is the first example 
where both homosynthons are present in the crystal structure. 
The studies reported here show that the stability of cocrystals with  
different stoichiometry is dependent on ligand concentration. The cocrystal richer  
in ligand component is more stable at higher ligand solution concentrations. As shown for 
the CBZ−4ABA cocrystals, 1:1 cocrystal is more stable at higher 4ABA concentrations 
whereas the 2:1 cocrystal is more stable at lower 4ABA concentrations in ethanol. The 
ability to form and sustain both cocrystals in a given solvent will depend on the solubility 
of the reactants. 
The stability domains for the different crystalline phases can be identified using 
phase solubility and triangular phase diagrams. These diagrams indicate that the 
crystallization outcomes and phase stability are governed by the solution composition of 
the drug and ligand. This is illustrated by the transformation pathways E for evaporation, 






Figure 2.10: TPD showing how transformation pathways R1 and R2 in reaction 
crystallization and pathway E during evaporation lead to supersaturation with respect to 
cocrystal or to a region where cocrystal is the thermodynamically stable phase. 2:1 
cocrystal is obtained along paths E and R1. 1:1 cocrystal is obtained along R2. 
 
 
During solvent evaporation, the initial reactant concentrations in solution as well 
as the extent and rate of solvent evaporation determine the solution composition of 
reactants, and hence the phase with respect to which supersaturation is generated. For 
instance, the pathway E in figure 2.10 represents evaporation of solvent from a solution 
of reactants in 1:1 mol ratio. Solvent evaporation in this case leads into the region where 




CBZ−4BA cocrystal was obtained by solvent evaporation in an earlier study.27 Further 
solvent evaporation along pathway E can result in a mixed phase of 1:1 and 2:1 cocrystal 
depending on the rates of solvent evaporation and crystallization. If the ratio of reactant 
concentrations in solution is changed such that it lies between the invariant points c2 and 
c3, solvent evaporation will lead into the region where supersaturation with respect to 1:1 
cocrystal is achieved. It is important to note that the 1:1 cocrystal stability domain as 
shown in figure 2.10 is narrower than that of the 2:1 cocrystal and may require careful 
control of evaporation rates to form 1:1 cocrystal. 
In contrast to solvent evaporation, supersaturation with respect to the cocrystals in 
reaction crystallization method is generated by reactant dissolution. The solution 
concentration of reactants depends on the relative amounts of reactants added as indicated 
by the pathways R1 and R2 in figure 2.10. R1 represents the change in composition by the 
addition of drug to an undersaturated 4ABA solution. R2 shows the change in solution 
composition when the drug is added to a suspension of 4ABA saturated with 4ABA. At a 
given total drug composition, the equilibrium solution composition is different for the 
two pathways. Consequently, the crystallization outcomes due to drug addition along the 
two pathways are also different. As shown in figure 2.10, the 1:1 cocrystal is obtained 
along R2 but not along R1.  
From the phase diagrams, PSD (figure 2.6) and TPD (figures 2.7 and 2.10), the 
equilibrium composition of the reactants in solution varies along a-c1-c2-c3-b. ‘a’ and ‘b’ 
correspond to drug and ligand solubility in the pure solvent. c1, c2, and c3 are the invariant 
points. Therefore, the key parameters essential to identify the stability domains of the 




concentrations at the invariant points (c1, c2, and c3). The number of invariant points in a 
system depends on the number of crystalline phases. The CBZ−4ABA-ethanol system 
presented in this study has 4 crystalline phases (CBZ(III), 2:1 cocrystal, 1:1 cocrystal and 
4ABA) and three invariant points. Studies with other cocrystals and molecular complexes 
show three crystalline phases (A, B, AB) and two invariant points.10, 42, 46  
The equilibrium solution composition of the reactants for the different crystalline 
phases, as shown in the phase diagrams, can be determined from solubility studies of the 
crystalline phases as a function of ligand concentration. The solution concentrations of 
reactants in equilibrium with solid phases can also be predicted using mathematical 
models based on heterogenous and homogenous equilibria as illustrated for the 1:1 
CBZ−4ABA cocrystal. The models are also useful predicting cocrystal solubility which 
are otherwise experimentally inaccessible due to cocrystal instability.  
The solubility models developed in this study for the CBZ−4ABA cocrystals 
show that the solubility of 2:1 cocrystal is explained by 1:1 solution complexation. 
Calculation of the species distribution based on the K11 value indicates that the 
concentration of the 1:1 solution complex varies from 10% to 50% of the total drug 
concentration under equilibrium conditions between the invariant points c1 and c2 (figure 
2.11).  Thus, a significant fraction of the drug remains uncomplexed in solution. 
According to the classical theory of crystallization, nucleation is preceded by the 
formation and growth of molecular clusters.47 While there is 1:1 complexation at 
saturated conditions, the molecular assemblies at supersaturated conditions are not known 







Figure 2.11: Species distribution plot showing concentration dependence of total  




Previous studies show that solution complexation at saturation is not an indicator 
of cocrystal formation or its stoichiometry. For instance, while the stoichiometry of the 
solution complex of sacrosine anhydride with aminobenzoic acids and hydroxybenzoic 
acids correspond to the stoichiometry of the solid complexes,43 studies on molecular 
complexes of hydroxybenzoic acids with ethyl theobromine and N, N, N', N' - 
methylterephthalamide indicate that the stoichiometry of the solution complex is different 
from that of the solid complex.45, 48  In fact, significantly large values of complexation 
constants have been reported in systems where no cocrystal formation has been 




ethanol indicate negligible complex formation in solution, yet this cocrystal can be 
synthesized from ethanol.30  This is because the driving force for crystallization is 
supersaturation and not solution complexation.  
 
Conclusions 
Two different stoichiometric cocrystals of CBZ−4ABA (2:1 and 1:1) are 
synthesized using reaction crystallization method (RCM) by varying ligand 
concentration. Stability of these cocrystals is dependent on reactant solution composition.  
Identification of isothermal invariant points is essential to establish the regions of 
cocrystal stability. The solubilities of cocrystals and equilibrium solution composition of 
reactants to generate phase diagrams can be predicted using mathematical models. The 
findings from this study have potential applications for cocrystal screening and synthesis 
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The effects of moisture on drug stability are of central importance for the 
development of pharmaceutical products.  Water can cause chemical instability and solid 
phase transformations that will compromise product safety and bioavailability.  Relative 
humidity dependent phase transformations are well documented and include anhydrous to 
hydrate,1-6 polymorphic,7 and amorphous to crystalline transformations.8, 9  Recent studies 
from our laboratory demonstrated that amorphous regions mediate transformations of 
solid reactants to cocrystal and that moisture enhances reactivity.10, 11 These studies 
showed that the mechanism involves increased molecular mobility and is associated with 
the plasticizing effects of water.10, 12    
Moisture sorption by hygroscopic materials can also lead to deliquescence.13-15  
This process refers to the formation of an aqueous solution by the absorption of water 
vapor at a characteristic relative humidity or deliquescent relative humidity (DRH).16  
DRH is a function of the chemistry of a solid, solid phase composition, and 
temperature.14, 15, 17-21   It is well established that the presence of a second solid 
component decreases the DRH.   Materials used in pharmaceutical formulations that 
 
79 
exhibit deliquescence include sugars, organic and inorganic salts.19, 22-24  Deliquescence 
dependent phase transformations for hydrates4 and deliquescence mediated chemical 
degradation have also been published.24-26  Although cocrystals have been shown to 
prevent formation of hydrated API during storage at high RH,27-30  various cocrystals 
have shown RH dependent transformation to hydrated API.29, 30   Therefore, it appears 
that identifying the mechanisms for cocrystal formation and stability would be of 
practical importance if cocrystals are to be developed as pharmaceutical products. 
 The research reported here is based on the premise that deliquescence can lead to 
cocrystal nucleation and growth because cocrystal solubility and thermodynamic stability 
are dependent on solution chemistry.  Earlier reports from our laboratory have shown that 
cocrystal solubility is a function of the cocrystal components in solution and is described 
by solubility product and solution speciation.27, 31, 32   This means that cocrystal solubility 
decreases as the liquid becomes richer in one of the cocrystal components.  The important 
implication of this mechanism is that supersaturation with respect to cocrystal can be 
generated by dissolving nonequivalent amounts of its components.  Supersaturation is 
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Hence, if the required supersaturation for cocrystal nucleation is attained then cocrystals 
are formed.  Evidence has been presented to show increase in cocrystal transformation 




 The thermodynamic stability of a cocrystal relative to pure API crystal has been 
demonstrated to vary with the concentration of reactants in solution.31, 32  Moreover, in 
solvents where cocrystal is more soluble than pure API there is a reactant transition 
concentration (Ctr) at which the cocrystal solubility is equal to the solubility of pure API 
or API solvate. At this concentration, both crystalline forms are at equilibrium.  Above 
the Ctr, cocrystal solubility is below that of API, and therefore cocrystal is the 
thermodynamically stable form. Rapid transformation of API to API cocrystal has been 
shown in aqueous media for API that readily transforms to API hydrate in pure water 
e.g., carbamazepine (CBZ) to carbamazepine-nicotinamide (CBZ-NCT) cocrystal.32 
The present study is based on the hypothesis that cocrystals are produced when 
solid reactants are exposed to deliquescent conditions, since dissolution of cocrystal 
reactants in the sorbed moisture can generate the supersaturation necessary for nucleation 
and growth of cocrystals. Cocrystal systems were selected from previously reported 
pharmaceutical cocrystals with APIs that form hydrates.29, 30, 34  This initial report 
presents results of cocrystal formation at constant RH in (1) binary blends of cocrystal 
reactants (CBZ/NCT), and (2) ternary blends of cocrystal reactants with a deliquescent 
additive that is not consumed by the reaction (CBZ/NCT, CBZ/SAC, 
caffeine/dicarboxylic acids, theophylline/dicarboxylic acids with sucrose or fructose).  
The influence of deliquescent additive, solid blend composition, and RH on the 
transformation rate to cocrystal was studied by on-line Raman spectroscopy during 
deliquescence.  To our knowledge this is the first report on cocrystal formation induced 







All chemicals were obtained from Sigma Chemical Company (St. Louis, MO), 
and were of USP grade.  Chemicals were used as received without further purification.  
All chemicals were characterized prior to use by X-ray powder diffraction (XRPD) and 
infra-red spectroscopy. XRPD of carbamazepine and theophylline agreed with the 
Cambridge Structural Database (CSD) simulated XRPD pattern of form III monoclinic 
CBZ (CSD refcode: CBMZPN01) and anhydrous theophylline (CSD refcode: 
BAPLOT01). The pattern of caffeine agreed with form II anhydrous caffeine.5  
All samples were sieved to collect particle size fractions of 45-63μm and 106-
125μm.  Large crystals were hand ground prior to sieving. Samples were annealed and 
characterized again by XRPD and FTIR prior to using them in our studies. These 
fractions were used in preparing samples to study deliquescence by gravimetric sorption 
analysis and cocrystal formation in bulk samples at constant RH. The composition of the 
deliquescent additives is expressed on a weight percent basis unless otherwise specified. 
Within the scope of this paper we can define the materials used as APIs, cocrystal 
formers or ligands, and deliquescent additives as listed in table 3.1. The term reactant 
refers to cocrystal components, i.e. API and ligand.  The deliquescence behavior of some 























Gravimetric Vapor Sorption 
Vapor sorption studies were conducted to determine DRH or to monitor the 
progress of moisture sorption towards equilibrium under constant RH and temperature. 
Both types of gravimetric vapor sorption studies use samples of 5-10mg with particle size 
of all components between 45 and 63μm unless otherwise noted.  All studies were done 
on an SGA-100 symmetrical gravimetric analyzer from VTI Corp. (Hialeah, FL).  The 
instrument uses a microbalance (CI Electronics, Wiltshire, UK) to monitor sample weight 
and a chilled dew point analyzer (Edgetech, Milford, MA) to detect and control humidity 
in the sample chamber.  Temperature is controlled to within 0.01oC and the instrument 
RH resolution is ±1%. All experiments were conducted at 25oC.  
 




Carbamazepine Nicotinamide Fructose 
Theophylline Saccharin Sucrose 
Caffeine Oxalic acid  
Sulfadimidine Glutaric acid  
 Malonic acid  
 Maleic acid  
 Anthranilic acid  




Deliquescent RH Determinations 
The DRH for single components and binary blends was determined using a non-
equilibrium sorption method.  This is an isothermal method that ramps RH by 2% 
increments.  The relative humidity is increased incrementally when the sample changes 
weight by less than 0.036% in fifteen minutes or 240 minutes whichever comes first at 
constant RH. While the samples only adsorb small levels of moisture below the DRH a 
large weight increase from moisture absorption is observed once the DRH is reached.  
 
Moisture Sorption Kinetics 
The time course of moisture sorption, and desorption in some instances, at fixed 
temperature and humidity was also studied for a variety of sample compositions.  In these 
studies a constant RH and temperature was maintained over the course of several days 
until the sample reached an equilibrium moisture sorption level. 
 
Bulk Sample Studies in RH Chambers 
The effects of DRH, storage RH, particle size, and the amount of deliquescent 
materials on the rate of cocrystal formation was studied using ternary mixtures of CBZ 
(III), with NCT or saccharin (SAC), and a deliquescent additive (fructose, sucrose or 
citric acid). In these studies the cocrystal reactant ratio in the solid phases was held 
constant at equimolar concentrations and the composition of the deliquescent additive 
was varied.  Raman spectroscopy has been shown to be valuable for real-time monitoring 





Desired RH conditions during storage at 25oC were generated in glass desiccators 
with appropriate saturated salt solution: NaCl for 75%, KCl for 85%, and K2SO4 for 98%.  
An aluminum plate with holes was suspended above the solution to hold samples and a 
1/8th inch thick quartz glass lid was used to seal the chamber.  The relative humidity in 
the chambers was confirmed using a HydroClip SC05 RH probe from Rotronics 
(Huntington, NY).  Probe accuracy is ±1.5%RH / ±0.2oC. 
Solid blends were stored at 0%RH in a P2O5 desiccator and analyzed by XRPD 
and IR prior to introduction into RH chambers. Quartz cuvettes containing 30-60mg of 
45-63μm (unless otherwise specified) crystalline blends were introduced into the RH 
chambers. Phase transformation in the blends was monitored by Raman spectroscopy.  A 
non-contact fiber optic probe was used to collect Raman spectra through the quartz 
chamber lid.  Spectra were collected frequently over random areas of the sample for 
several days.  A time course of the change in spectral features was used to monitor 
cocrystal formation. HoloReact™ software, from Kaiser Optical Systems (Ann Arbor, 
MI), was used for multivariate curve resolution to plot the change in spectral features 
correlating to reactants and cocrystal. The analysis region for CBZ-NCT systems was 
924-1182cm-1 and CBZ-SAC was 225-300cm-1. Samples were promptly analyzed by 
XRPD and IR once removed from the chamber. The mass of the blends before and after 
storage were also noted to determine the amount of moisture sorbed. 
 
Slurry Studies 
Screening for cocrystals was carried out according to methods published earlier.31, 




reactant concentrations would favor cocrystal formation. The slurries were placed in a 
25oC recirculation water bath and stirred continuously.  No nucleating seeds were added 
to these samples. Once removed from the water bath the slurries were dried by vacuum 
filtration and promptly analyzed by XRPD.  
 
Moisture uptake and stability of cocrystals during storage 
Approximately 50 mg cocrystal of CBZ, caffeine and theophylline cocrystals with 
various ligands were stored at different relative humidities (85%, 91% and 98% RH) to 
investigate moisture uptake and stability. Moisture uptake of cocrystals was determined 
by noting the mass change during storage. Solid phase stability during storage was 
monitored by Raman spectroscopy using a non-contact fiber optic probe. Solid phases 
were also characterized by XRPD. 
 
Raman Spectroscopy 
Raman spectra of solid phases were collected with a Kaiser Optical Systems, Inc. 
(Ann Arbor, MI), RXN1 Raman spectrometer equipped with a 785 nm laser. 
Crystallization in bulk samples was monitored in-situ with a fiber optic non-contact 
probe. Crystallization was also monitored in micro-scale using a Leica DMLP (Wetzlar, 
Germany) Raman microscope. Acquisition conditions were optimized so that the spectra 
collected for bulk studies had maximum intensity around 30-40k counts. The spectra 






Attenuated Total Reflectance Fourier Transform Infrared (ATR-FTIR) 
Spectroscopy  
IR spectra of solid phases were collected on a Bruker Vertex 70 FT-IR (Billerica, 
MA) unit equipped with a DTGS detector. Samples were placed on a zinc selenide 
(ZnSe) attenuated total reflectance (ATR) crystal accessory, and 64 scans were collected 
for each sample at a resolution of 4 cm-1 over a wavenumber region of 4000-600 cm-1. 
 
X-ray Powder Diffraction (XRPD) 
XRPD was used to identify crystalline phases and phase transformations after 
exposure to various storage conditions. XRPD patterns of solid phases were recorded 
with a Rigaku MiniFlex X-ray diffractometer (Danvers, MA) using Cu Kα radiation (λ = 
1.54 Å), a tube voltage of 30 kV, and a tube current of 15 mA. The intensities were 
measured at 2θ values from 2° to 40° at a continuous scan rate of 2.5°/min. Samples, 
prior to and after RH storage experiments, were analyzed by XRPD. Results were 
compared to diffraction patterns reported in literature or calculated from crystal structures 
reported in the Cambridge Structural Database (CSD). 
 
Polarized Optical Light Microscopy Studies 
Particles of cocrystal reactants and deliquescent additives were placed in contact 
with each other on a slide and introduced into a variable relative humidity microscope 
stage from Surface Measurement Systems (VGI 2000M. Middlesex, UK). This stage 
provides temperature and humidity control capability during optical microscopy studies. 




situ with water to the appropriate extent as monitored by internal sensors. Water uptake, 
deliquescence, dissolution, and crystallization were visually monitored with a Leica 
DMPL polarizing optical microscope (Wetzlar, Germany). Images were collected with a 
Spot Insight FireWire 4 Megasample Color Mosaic camera controlled with Spot software 








Figure 3.1 shows optical microscopy images of deliquescence-induced cocrystal 
formation of an initially dry ternary system of cocrystal reactants and a sugar. CBZ, 
NCT, and sucrose crystals were arranged on the controlled RH microscope stage as 
shown in figure 3.1(A) and exposed to 95%RH.  These images illustrate the sequence of 
events that lead to cocrystal formation: moisture uptake, dissolution, and crystallization.   
The first stage in the formation of cocrystals is the formation of a liquid phase as 
moisture is sorbed and deliquescence proceeds as shown by the liquid domain in figure 
3.1(B).  This is followed by dissolution of sucrose and cocrystal reactants as indicated by 
the change in size and shape of particles.  NCT dissolves faster than CBZ as expected 
based on their different aqueous solubilities.  A new phase is observed to crystallize from 
solution (figure 3.1(D)) near the surface of CBZ crystals.  This new phase was 
determined to be CBZ-NCT cocrystal by Raman microscopy. 
 
Cocrystallization in bulk samples  
The microscopy results presented above suggest that cocrystal formation can 
occur in solid blends of cocrystal reactants exposed to deliquescence conditions. In this 
section we present results on the moisture uptake behavior of bulk samples, and the 
factors that determine cocrystal formation by monitoring solid phase changes by 
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DRH of single components and binary blends  
 
To determine the DRH of blends composed of cocrystal reactants and 
deliquescent additives, moisture sorption isotherms were obtained under non-equilibrium 
conditions while the RH was ramped (figure 3.2).  DRHs were determined for pure 
components and binary mixtures of a deliquescent additive (sucrose or fructose) with the 
most water soluble cocrystal reactant (nicotinamide or saccharin) and are shown in table 
3.2. The weight percent of deliquescent additive in all the binary mixtures listed would be 
50% if one molar equivalent of CBZ is added.  The weight ratios of SAC blends are 




       
 




      
 











Sucrose - - 86.1 
Fructose - - 62.0 
Nicotinamide - - 94.5 
NCT/Sucrose 1.0 : 2.9 1.0 : 1.1 80.0 
NCT/Fructose 1.0 : 2.9 1.0 : 2.0 55.3 




The DRH values of the pure components are in good agreement with those 
available in the literature. The reported DRH for fructose and sucrose is 62% and 85% 
respectively.19, 24  Slight differences between the reported DRH values and those 
observed in this study for sucrose may be due to instrument accuracy of 1%RH and the 
specific equilibrium conditions used for each RH step listed in the methods section. The 
DRH of a pure substance is decreased by the addition of a second deliquescent 
component. Similar deliquescence behavior has been observed in binary and ternary 
systems with inorganic and organic components,15, 17, 19, 20  and is explained by the effect 
of solute composition on the water activity of solutions.  While in this study we report the 
DRH of blends at only one composition for the purpose of investigating transformation to 
cocrystal, the dependence of DRH on composition is currently being investigated.  
The DRH of binary mixtures was determined to avoid rapid cocrystal formation 
associated with ternary mixtures containing CBZ since transformation to cocrystal can 




water means it should have negligible impact on the DRH and water activity of solutions 
with sugar and NCT or SAC. The DRH of ternary blends is not expected to change in the 
presence of CBZ. Indeed CBZ exhibits no deliquescence as anticipated from its low 
solubility.28, 37  Consequently, ternary blends of CBZ with cocrystal former in equimolar 
ratios and 50% deliquescent additive referenced in the next section can be assumed to 
have the same DRH as blends listed in table 3.2.  
 
Cocrystallization in ternary blends 
Figure 3.3(A) shows the changes in the Raman spectra as CBZ-NCT cocrystal 
formation proceeds in CBZ/NCT/50% sucrose. Peaks at 1026.5 and 1035.0 cm-1, 
characteristic of CBZ-NCT cocrystal, are observed as cocrystal formation occurs. This is 
accompanied by a decrease in the intensity of the peak characteristic of CBZ at 1041.5 
cm-1. Figure 3.3(B) shows the changes in Raman spectra as CBZ-SAC cocrystal 
formation occurs in CBZ/SAC/50% fructose blends at 85%RH.  A peak at 231.7cm-1, 
characteristic of CBZ-SAC cocrystal, is observed as cocrystal formation occurs. A 
decrease in peak intensity for peaks characteristic of SAC and CBZ at 246.0 cm-1 and 
272.5 cm-1 respectively is also observed with cocrystal formation. These changes in the 
spectra were used to measure cocrystal formation in ternary blends during storage as a 
function of ambient RH and deliquescent additive. 
The progress of cocrystal formation in CBZ/NCT/sugar (fructose or sucrose) 
blends at 75% and 85%RH was monitored over a two day period by Raman 




while the cocrystal reactant molar ratio (CBZ/NCT) was constant at 1:1. A control 
sample without sugar is included at 85% RH for reference. 
 
 
       
Figure 3.3: Raman spectra showing cocrystal formation and CBZ depletion in (A) 
CBZ/NCT/50% Sucrose and (B) CBZ/SAC/50% Fructose at 85%RH.  
 
 
It is evident from figure 3.4 that deliquescence generates cocrystals.  Significant 
cocrystal formation was observed in CBZ/NCT/sugar blends above their DRH, while no 
cocrystal formation was detected in mixtures below their DRH.  For instance, cocrystal 
formation occurred in ternary blends with sucrose or fructose at 85%RH.  In contrast, 




transformed to cocrystal during the course of the study because RH was below DRH.   
The DRH for NCT is greater than 85% and for NCT/sucrose is greater than 75% as 
shown in table 3.2. 
  The rate and extent of cocrystal formation appears to be dependent on the sugar, 
the percentage of sugar, and the ambient RH as shown in figure 3.4.  At 85%RH the 
fructose blends transformed faster than sucrose blends. Faster rate of cocrystal formation 
was also observed in fructose blends stored at 85%RH than those stored at 75%RH. It can 
be seen that the rate of transformation decreases with time. Time intervals at the 
beginning of the transformation have rapid cocrystal formation followed by a slow 
conversion period or plateau region.  Samples with less deliquescent additive (sugar) 
exhibit a more gradual conversion to cocrystal as shown by the 10% fructose at 75%RH.  
After the initial interval of rapid conversion producing a small fraction of cocrystal the 
progress of transformation is slow as indicated by the slope of the plateau region.  In 
contrast, higher sugar compositions experience faster and extensive transformation to 
cocrystal during the initial time interval.  This behavior is also observed with increasing 






















































































































































































































Lower rates of cocrystal formation at low sugar composition may be associated 
with small volumes of water uptake and small domains of supersaturation leading to 
isolated regions of cocrystal formation in the bulk of the sample.  In fact, the curves in 
figure 3.4 have jagged features corresponding to the non-uniform distribution of cocrystal 
nucleation and growth sites throughout the bulk of the sample. To resolve this spatial 
distribution of transformation sites, spectra were randomly collected from different 
regions of the samples. Together the spectra collected represent the average level of 
transformation in the bulk.  
 The data in figure 3.4 has been shown over a two day time frame to highlight the 
dependence of cocrystal formation rates as a function of blend composition and RH. 
Transformation was monitored over a longer period by Raman until full conversion to 
cocrystal was achieved at which point the samples were analyzed by XRPD. Figure 3.5 
compares the XRPD patterns of CBZ and NCT blends containing 20% sugar (fructose or 
sucrose) before and after storage at 85%RH with the CBZ-NCT cocrystal XRPD pattern 
calculated from CSD. XRPD pattern homology between the stored blends and the 
cocrystal indicate cocrystal formation during storage. XRPD patterns of blends 
containing 10% and 50% sugars similarly showed evidence for cocrystal formation  






Figure 3.5:  XRPD of CBZ/NCT/20% Sugar blends confirms cocrystal formation after 
storage at 85%RH: 20% fructose (a) before storage and (b) after storage; 20% sucrose (c) 
before storage and (d) after storage; (e) CBZ-NCT calculated from CSD. 
 
  
 The moisture sorption behavior of reactive blends was investigated since water 
uptake is an important factor affecting solution composition, supersaturation, and 
consequently cocrystal formation.   Figure 3.6 shows the moisture sorption behavior of 
CBZ and NCT blends containing 50% sucrose or fructose at 85%RH. An increase in 
weight due to water uptake through deliquescence is observed for both blends. Moisture 
sorption is faster in the fructose blend than the sucrose blend. Both curves are 
characterized by a maximum in the moisture sorption behavior followed by desorption 
and leveling off.  Desorption correlates with the depletion of NCT from solution as it is 
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consumed by cocrystal formation. Previous moisture uptake studies of pure CBZ-NCT 




Figure 3.6: Moisture sorption in CBZ/NCT/50% Sugar (fructose or sucrose) at 85% RH. 
Dashed horizontal lines indicate equilibrium moisture sorption level of pure sugars scaled 
to the percent in the blends. 
 
  
 Comparison with the progress of cocrystal formation in these blends (figure 3.4) 
indicates that moisture sorption and cocrystal formation begin quickly and occur 
simultaneously. Both systems shown in figure 3.6 achieved an equilibrium level of water 
sorption in about half a day indicating that phase transformation to cocrystal has reached 
a steady state or is mostly complete.  The timeframe within which this plateau is attained 
agrees with that shown in figure 3.4 for transformation in bulk samples with 50% sugar 




the ternary blends by XRPD and FTIR after exposure to 85%RH in the vapor sorption 
analyzer confirmed cocrystal formation.  
   The final water content in the ternary blend containing fructose is ~35% while 
that containing sucrose is ~25% (figure 3.6). The equilibrium water content at 85% RH 
for pure sugar scaled to the amount in each blend is shown by a horizontal dashed line in 
figure 3.6. Thus the final water content in the ternary blends is proportional to the amount 
of sugars in these blends and the equilibrium moisture content of the sugars at 85%RH.   
 The rates of moisture sorption and reactant dissolution depend on surface area and 
hence particle size of the components in the blend.  A decrease in cocrystal formation rate 
was observed in blends of larger particles (106-125μm).  
 
Cocrystallization in binary blends  
 The preceding section showed that deliquescence generates cocrystals in ternary 
blends containing a deliquescent additive (sugar) and cocrystal reactants. However, 
cocrystal formation can also occur in binary blends if one or both cocrystal reactants are 
deliquescent. Figure 3.7(A) shows the moisture sorption behavior for an equimolar 
CBZ/NCT blend at 98%RH. An increase in weight is observed due to deliquescence of 
NCT (DRH = 94.5%) until a maximum is achieved after which desorption dominates as 
CBZ-NCT cocrystal (non-hygroscopic) forms.  This behavior is similar to that of ternary 
blends with sugars shown in figure 3.6.  Beyond the maximum, the weight of the binary 
blend decreases continuously due to depletion of NCT (hygroscopic) from solution. 
XRPD after storage of the binary blend for 4 days at 98%RH confirmed cocrystal  




           (A) 
 
        (B) 
 
Figure 3.7:  (A) Moisture sorption behavior of equimolar CBZ/NCT blend at 98% RH.  
(B) XRPD confirms CBZ-NCT cocrystal formation in CBZ/NCT blend after storage at 
98%RH: CBZ/NCT blend (a) before storage (b) after storage and (c) CBZ-NCT cocrystal 




Effect of reactant properties on cocrystal formation 
 The effect of cocrystal reactant properties on moisture sorption and cocrystal 
formation was studied by replacing NCT with SAC as the cocrystal reactant. NCT is 
highly hygroscopic and water soluble while SAC is non-hygroscopic, ionizable (pKa 
=1.8),38  and has lower aqueous solubility than NCT. The DRH of the SAC/fructose 
blend shown in table 3.2 is similar to that of pure fructose. This is due to non-hygroscopic 
nature and low aqueous solubility of SAC.   
 Figure 3.8 compares CBZ-NCT and CBZ-SAC cocrystal formation rates at 
85%RH in ternary blends of CBZ/50% fructose and NCT or SAC. Clearly the rate of 
CBZ-SAC cocrystal formation is slower than that of CBZ-NCT. This may be a result of 
cocrystal solubilities, reactant dissolution rate, and ionization in the sorbed moisture.  
 
 




 Figure 3.9(A) shows CBZ-SAC cocrystal formation in ternary blends of 
CBZ/SAC with fructose at 85% RH.  Cocrystal formation is more extensive and faster in 
blends with higher sugar level.  Figure 3.9(B) compares cocrystal formation rates during 
storage of CBZ/SAC/50% fructose blends at 75% and 85%RH.  These results are similar 
to those of CBZ/NCT/sugar blends where cocrystal formation rate increases with storage 
RH and sugar composition.  
 
 
Figure 3.9: CBZ-SAC cocrystal formation rate dependence on (A) fructose composition 
in ternary blends exposed to 85%RH: control sample without sugar (___), 10% (- - -) and 
50% (____) fructose, and (B) storage RH in CBZ/SAC/ 50% Fructose blends at 75% RH  
(- - -) and 85% RH (___). 
 
  
 Figure 3.10 shows the CBZ-SAC cocrystal formation in ternary blends of 
CBZ/SAC with fructose or citric acid at 85% RH.  Cocrystal formation is faster in blends 
with citric acid and blends with higher level of additive.  The transformation dependence 






Figure 3.10: Effect of deliquescent additive (CA or fructose) composition on CBZ-SAC 




Cocrystal formation via deliquescence is broadly applicable to other compounds 
Based on the above findings, transformation to cocrystal induced by 
deliquescence was studied with caffeine and theophylline systems. These APIs have been 
reported to form cocrystals from organic solvents and by co-grinding.29, 30  Our studies 
show that the cocrystals in table 3.3 are generated both by slurrying the reactants in 
aqueous solutions and by storing ternary blends with 20% fructose above the DRH.  All 
cocrystals have equimolar composition except theophylline-maleic acid, theophylline-
oxalic acid, caffeine-malonic acid, and caffeine-oxalic acid, which have the cocrystal 
reactants in 2:1 (API:ligand) molar ratio. Cocrystal formation was confirmed by XRPD 
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analysis.  These results illustrate broad applicability of the concepts presented to other 
APIs with a variety of cocrystal components.  The kinetics of deliquescent mediated 
cocrystal formation in these systems is currently being investigated in our laboratory. 
 
Table 3.3: API and corresponding ligands that formed cocrystals by both slurrying in 








Caffeine Oxalic acid 
 Maleic acid 
 Glutaric acid 
 Malonic acid 
Theophylline Oxalic acid 
 Maleic acid 
 Glutaric acid 
 Malonic acid 
Sulfadimidine Salicylic acid 





Moisture uptake and stability of cocrystals 
 
Results in the preceding sections show that moisture sorption can induce cocrystal 
formation in reactant mixtures. However, moisture uptake by cocrystals can also induce 
cocrystal instability. Figures 3.11 and 3.12 show the XRPD patterns of theophylline and 
caffeine cocrystals stored at 98%RH. Significant moisture uptake leading to 






          Figure 3.11: XRPD patterns showing theophylline cocrystal instability during  
          storage at 98%RH. Theophylline-glutaric acid (A) before storage, and (B) after 
          storage;  theophylline-citric acid hydrate (C) before storage, and (D) after storage;  
          (E) theophylline monohydrate reference pattern. 
 
    
 
            Figure 3.12: XRPD patterns indicating caffeine-glutaric acid cocrystal instability  
            during storage at 98%RH. Caffeine-glutaric acid (A) before storage, and (B) after  
            storage; (C) caffeine hydrate reference pattern.
 
106 
 Table 3.4 summarizes the moisture uptake and stability of some carbamazepine, 
theophylline and caffeine cocrystals at 85%, 91% and 98% RH. Moisture uptake of 
cocrystals increases with increase in RH. While caffeine and theophylline cocrystals 
deliquesce and transform to corresponding API hydrates at 98%RH, CBZ cocrystals are 
stable even after 6 months of storage. Raman spectra showing the stability of some of the 




Table 3.4: Moisture uptake and stability of carbamazepine (CBZ), theophylline(THP) and 
caffeine(CAFF) cocrystals during storage.  
 





























































































*solid phase is theophylline hydrate.  















The results of this study indicate that cocrystals can form spontaneously when 
solid mixtures with cocrystal reactants deliquesce. The mechanism for deliquescence-
induced cocrystal formation involves three important processes as revealed by 
microscopy studies (figure 3.1) and illustrated in scheme 3.1: water uptake, dissolution of 
cocrystal reactants, and crystallization of molecular complex. Several factors that 
determine transformation kinetics are nucleation rate, growth rate, and the density and 
distribution of nucleation sites.  Cocrystal nucleation and growth rates will depend on 
supersaturation.  Supersaturation is determined by how fast cocrystal reactants dissolve 
and this in turn depends on the amount and rate of water uptake.  
How dissolution of cocrystal reactants leads to supersaturation with respect to 
cocrystal is illustrated in scheme 3.1(ii) and is explained by considering the solution and 
cocrystal chemistry.31, 32 As the reactants dissolve in the sorbed moisture, their 
concentrations increase in solution.  Unequal reactant dissolution rates, due to different 
solubilities and/or surface areas, result in non-stoichiometric concentrations of reactants 
in the sorbed moisture. As the deliquesced solution becomes rich in one of the cocrystal 
components, the cocrystal solubility decreases leading to ever increasing supersaturated 
conditions where cocrystal is the least soluble phase as shown in figure 3.13. Cocrystal 
formation will be initiated when the critical supersaturation for nucleation is achieved. 
The CBZ and NCT system is particularly interesting since their aqueous solubilities are 
very different.   Due to the higher dissolution rate of the more soluble reactant (NCT), 
cocrystal nucleation occurs on the surface or in the vicinity of the less soluble reactant  








Scheme 3.1: Illustration of the moisture uptake process leading to deliquescence, reactant 
dissolution and cocrystal formation. A and B are cocrystal reactants, Ds is solid 






Figure 3.13: Schematic showing the solubility of cocrystal AB (SAB) and pure component 
crystal A (SA) as a function of ligand concentration B, the ligand transition concentration 
(Ctr) and a hypothetical cocrystallization pathway. Supersaturation is generated by the 




Our results show that deliquescence leads to cocrystal formation even with certain 
APIs that readily form hydrates during storage or by slurry conversion in water.1-3, 5, 37, 39-
42  Carbamazepine, caffeine, and theophylline spontaneously transformed to cocrystal 
when mixtures of cocrystal reactants with deliquescent additive were stored above the 
DRH of the dry mixtures.  This indicates that cocrystal nucleation and growth rates were 
faster than the rate of hydrate formation under the conditions studied.   The stability of 
cocrystal is also confirmed by the lack of transformation to single components or 
hydrates thereof. 
Although deliquescence in mixtures reported here exhibited cocrystal formation 
and stability, a reversal can occur given the right conditions. This is shown for some 
theophylline and caffeine cocrystals at high relative humidity where moisture uptake 
leading to deliquescence and transformation of cocrystals to API hydrates occurred 
during storage. The transformation of cocrystals to API hydrates is indicative of higher 
cocrystal solubility relative to the hydrated reactant, and occurs since the reactant 
concentrations resulting from cocrystal dissolution in the sorbed moisture are below the 
transition concentration as indicated in the phase diagram (figure 3.13).31, 32  Previous 
studies from our laboratory have shown that although in pure water CBZ-NCT cocrystals 
transform to CBZ dihydrate within minutes, the transformation is reversed (CBZ to 
cocrystal) at high NCT solution concentrations.32, 33  CBZ cocrystals of NCT or SAC are 
not hygroscopic at 98%RH and have been shown to be stable.27, 28  CBZ cocrystal 
formation during deliquescence is thus explained by the relationship between solution 
composition and thermodynamic stability of reactant and cocrystal phases.
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Caffeine and theophylline cocrystals shown in table 3.3 formed during 
deliquescence of blends of API/ligand/fructose (as well as in highly concentrated aqueous 
solutions of ligand) even though some of these cocrystals transform to hydrated API 
when exposed to moisture.  Caffeine-maleic acid cocrystals and theophylline cocrystals 
with maleic acid, malonic acid, and glutaric acid have been reported to transform to 
hydrated API when exposed to 98%RH.29, 30  Caffeine-glutaric acid has been reported to 
transform to hydrated caffeine at 43%RH.29  These results clearly indicate that for the 
direction of transformation to be reversed by aqueous solution composition there must be 
a transition concentration above which solubility of cocrystal is less than pure API and 
cocrystal formation is favorable. Therefore deliquescence will generate conditions of 
cocrystal stability or instability depending on solution chemistry including ionization and 
complexation processes.  
 
Deliquescence and cocrystal formation 
Previous studies on deliquescence and crystallization have shown hydrate 
formation in solid mixtures.3, 4, 6  There are also reports of crystallization as a result of 
moisture loss and efflorescence due to changes in ambient RH or DRH as composition of 
solution changes.35, 43, 44  It is important to note that in the studies reported here there was 
no RH cycling and crystallization was a result of solution composition.  To our 
knowledge this is the first report of cocrystal formation induced by deliquescence.  This 
finding also makes apparent the opportunity for producing cocrystals by green chemistry 
methods. Aqueous media can generate cocrystals as illustrated for carbamazepine,  
caffeine, theophylline and sulfadimidine systems.
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The ability of a deliquescent material to generate cocrystals depends on its 
potency for moisture uptake and on its ability to modify the mode and rate of nucleation.   
Blends stored below their DRH did not result in cocrystal formation during the course of 
the study as shown by binary blends of CBZ/NCT at 85%RH and ternary blends of 
CBZ/NCT/sucrose at 75%RH. Transformation to cocrystal was however associated with 
moisture uptake and storage RH above DRH as indicated by binary blends of CBZ/NCT 
at 98%RH and ternary blends of CBZ/NCT/sucrose at 85%RH.   
The interplay between moisture uptake and dissolution determines the liquid 
phase composition, supersaturation and subsequent nucleation. This is shown by the rapid 
initial cocrystal formation rates of CBZ-NCT at both low and high sugar composition 
when stored at RH above DRH.  Moreover, low small levels of moisture (< 7%) are 
capable of producing the necessary cocrystal supersaturation to initiate nucleation as 
shown for the transformation to CBZ-NCT in blends with 10% sucrose or fructose at 
85% RH. Deliquescent additives can also influence nucleation by their effects on solution 
viscosity, molecular associations that precede nucleation, and to the extent that material 
surfaces serve as catalysts for nucleation.  
 Generally one expects the amount of moisture uptake to control the 
transformation rate based on its temporal and spatial distribution.  Low levels of 
deliquescent additive and low moisture uptake will have the effect of reducing the 
regions of deliquescence. Consequently, small domains of supersaturation can develop in 
a liquid phase that is not uniformly distributed throughout the sample leading to isolated 
regions of cocrystal formation.   In this case high supersaturations are initially achieved 
and transformation rate to cocrystal is initially fast, but the rate will slow or even level off 
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before extensive conversion.  This mechanism explains the transformation to CBZ-NCT 
cocrystal at the lower fructose composition (10%) and 75%RH.  
 High levels of moisture sorption allow for greater exposure of reactants to the 
crystallization medium and to larger extent of cocrystal formation during the initial time 
period, provided the kinetics and distribution of moisture sorption maintain adequate 
supersaturation for cocrystal formation. This behavior is observed with the 
CBZ/NCT/fructose at higher RH (85%) or higher fructose (20 and 50%) showing faster 
and more extensive conversion compared to the CBZ/NCT/fructose at 10% fructose and 
75%RH.  Similar behavior was observed with CBZ/SAC/fructose blends. These results 
clearly indicate that for low fructose composition at low RH, the transformation is 
occurring at relatively low moisture uptakes where solute transport tends to be limited to 
small domains of liquid phase.  Faster transformation rates with more deliquescent 
additive at RH above DRH were also observed for CBZ/NCT/sucrose, 
CBZ/SAC/fructose, and CBZ/SAC/citric acid. 
  Quite a different situation arises when high amounts of moisture uptake lead to 
low supersaturation, saturation, or undersaturation with respect to cocrystal and 
consequently slow, prevent, or reverse the transformation to cocrystal.   High moisture 
uptake levels are associated with the hygroscopic nature of the blend components, the 
amount of hygroscopic or deliquescent additive, and high RH values above DRH. A 
reversal in the transformation to cocrystal was observed at CBZ/NCT/50% fructose at 
98%RH.  CBZ dihydrate formed after initial formation of cocrystal (results not shown). 
Moisture sorption and deliquescence of solid mixtures are a complex function of 
phase composition, relative humidity, and temperature.17, 20, 21  The study presented here 
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has focused on identifying the mechanism by which deliquescence induces cocrystal 
formation. Deliquescence and phase diagrams of composition and water activity (i.e, 
relative humidity) for the systems reported here are currently being investigated in our 
laboratory.    
In this first report we have compared the transformation to cocrystal with the 
moisture uptake behavior and deliquescence under non-equilibrium conditions.  Our 
results show that moisture uptake behavior is an indicator of cocrystal formation as 
shown by binary blends with deliquescent reactant (NCT) in figure 3.7(A) and by ternary 
blends with deliquescent additive (sugars) in figure 3.6.   
 Cocrystal formation during deliquescence is also dependent on the properties of 
cocrystal reactants, cocrystals, and solution chemistry.  Reactant properties that increase 
solution concentrations in the sorbed moisture such as dissolution rate and solubility are 
expected to increase the rate of transformation to cocrystal as shown by the CBZ-NCT 
cocrystal formation rate relative to CBZ-SAC.  In addition, particle size and solid-state 
form of reactants (amorphous, polymorphs and solvated forms) will influence the 
transformation rate to cocrystal when dissolution is the rate-limiting step.  
CBZ-NCT cocrystal formation was faster than CBZ-SAC in blends of cocrystal 
reactants and fructose.  This behavior is explained by the dependence of supersaturation 
on cocrystal solubility (Ksp in equation 1), reactant solubility and ionization.27  Previous 
studies in our laboratory have shown that the aqueous solubility of CBZ-SAC cocrystal is 
slightly higher than that of CBZ-NCT.28  NCT has an aqueous solubility much higher 
than SAC, 8.19 M versus 0.011 M at 20oC.45  SAC is an acid (pKa of 1.8)38 and at 
solution pH higher than pKa (> 2pKa) it will be largely in the ionized form.  This 
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ionization can lower the transformation to cocrystal by decreasing the concentration of 
reactant available for cocrystal formation. This is applicable to cocrystals with neutral 
components.46 Deliquescent additives with acidic or basic properties will therefore 
regulate the rate of cocrystal formation by altering the pH of the sorbed moisture.  The 
pH of the deliquesced sugar blends will be closer to neutrality. Consequently SAC is 
largely in its ionized form. Citric acid solutions on the other hand can reach pH values as 
low as 0.547 and therefore a greater fraction of SAC is non-ionized. This may be the 
reason for the faster CBZ-SAC cocrystal formation in blends with citric acid compared to 
blends with fructose. The effect of deliquescent additive on moisture uptake however, 
needs to be determined to fully evaluate the effect of solution pH.  
The mechanisms for cocrystal formation reported here are valuable to design 
stable formulations and predict conditions that will preserve cocrystal.  The amount of 
deliquescent additive required to prevent or reverse the transformation to cocrystal can in 
principle be estimated if one knows the moisture sorption of the blend at a given 
composition, temperature and RH, and the Ctr in the sorbed moisture. For example, the 
Ctr in water at which the solubility of the CBZ-NCT cocrystal is equal to the solubility of 
CBZ dihydrate is around 1m.33   As a first approximation it is assumed that additives do 
not change Ctr. Consequently, levels of moisture sorption that lead to NCT concentrations 
above 1m will favor cocrystal formation at adequate CBZ solution concentration as 
shown in figure 3.13.  Based on the results for the CBZ/NCT/50% fructose at 85%RH the 
moisture sorbed is about 35% and corresponds to moisture retained by fructose (70% for 
pure fructose at 85%RH).  If one considers that NCT will fully dissolve in the sorbed 
moisture of the ternary blend then the mass of water required to dilute NCT to the Ctr can 
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be calculated. The percentage of fructose in the dry blend that will lead to the transition 
concentration at 85% RH was calculated to be 80%.  Therefore if CBZ-NCT cocrystal is 
to be preserved in such ternary blend, fructose compositions must be lower than 80% in 
the dry blend.   Our results of cocrystal formation and stability in fructose blends are in 
agreement with this estimate.   
 
Conclusions 
This work demonstrates that moisture can generate cocrystals when particulate 
systems with cocrystal reactants are exposed to deliquescent conditions. Cocrystals of 
carbamazepine, caffeine, and theophylline were formed during deliquescence even when 
these APIs can form hydrates. The mechanisms responsible for cocrystal formation 
involve moisture uptake, dissolution of cocrystal reactants, cocrystal nucleation and 
growth.   These mechanisms are important to design formulations and predict conditions 
that will preserve cocrystals.  Cocrystal solubility dependence on aqueous solution 
composition and chemistry are good predictors of cocrystal formation and stability during 
deliquescence. Our findings have important implications for a green chemistry based 





1.    Airaksinen, S.; Karjalainen, M.; Kivikero, N.; Westermarck, S.; Shevchenko, A.;  
       Rantanen, J.; Yliruusi, J. Excipient Selection can Significantly Affect Solid-State  
       Phase Transformation in Formulation During Wet Granulation. AAPS  
       PharmSciTech. 2005, 6, E311-E322. 
 
2.    Kaneniwa, N.; Yamaguchi, T.; Watari, N.; Otsuka, M. Hygroscopicity of  
       Carbamazepine Crystalline Powders. Yakugaku. Zasshi. 1984, 104, 184-190. 
 
3.    Kesavan, J. G.; Peck, G. E. Solid-State Stability of Theophylline Anhydrous in  
       Theophylline Anhydrous-Polyvinylpyrrolidone Physical Mixtures. Drug Dev. Ind.  
       Pharm. 1996, 22, 189-199. 
 
4.   Otsuka, M.; Matsuda, Y. The Effect of Humidity on Hydration Kinetics of Mixtures  
      of Nitrofurantoin Anhydride and Diluents. Chem. Pharm. Bull. 1994, 42, 156-159. 
 
5.   Pirttimaki, J.; Laine, E. The Transformation of Anhydrate and Hydrate Forms of  
      Caffeine at 100-percent RH and 0-percent RH. Eur. J. Pharm. Sci. 1994, 1, 203-208. 
 
6.   Salameh, A. K.; Taylor, L. S. Physical Stability of Crystal Hydrates and their  
      Anhydrates in the Presence of Excipients. J. Pharm. Sci. 2006, 95, 446-461. 
 
7.   Yoshinari, Y.; Forbes, R. T.; York, P.; Kawashima, Y. Moisture Induced  
      Polymorphic Transition of Mannitol and Its Morphological Transformation. Int. J.  
      Pharm. 2002, 247, 69-77. 
 
8.   Andronis, V.; Yoshioka, M.; Zografi, G. Effects of Sorbed Water on the  
      Crystallization of Indomethacin from the Amorphous State. J. Pharm. Sci. 1997, 86,  
      346-351. 
 
9.   Tong, P.; Zografi, G. Effects of Water Vapor Absorption on the Physical and  
      Chemical Stability of Amorphous Sodium Indomethacin. AAPS PharmSciTech. 2004,  
      5, Art. No. 26. 
 
10. Jayasankar, A.; Somwangthanaroj, A.; Shao, Z. J.; Rodríguez-Hornedo, N. Cocrystal  
      Formation During Cogrinding and Storage is Mediated by Amorphous Phase. Pharm.  
     Res. 2006, 23, 2381-2392. 
 
11. Seefeldt, K. J.; Miller, J.; Alvarez-Núñez, F.; Rodríguez-Hornedo, N. Crystallization  
      Pathways and Kinetics of Carbamazepine-Nicotinamide Cocrystals from the  
      Amorphous State by In-situ Thermomicroscopy, Spectroscopy and Calorimetry  
      studies. J. Pharm. Sci. 2007, 96, 1147-1158. 
 
12. Hancock, B. C.; Zografi, G. The Relationship Between the Glass-Transition  




      Res. 1994, 11, 471-477. 
 
13. Kontny, M. J.; Conners, J. J., Water Sorption of Drugs and Dosage Forms. In 
      Encyclopedia of Pharmaceutical Technology, 2nd ed; Swarbrick, J.; Boylan, J. C.;  
      Marcel Dekker, Inc.: New York, 2002; pp.2970-2986. 
 
14. Kontny, M. J.; Zografi, G. Moisture Sorption Kinetics for Water-Soluble Substances  
      IV: Studies with Mixtures of Solids. J. Pharm. Sci. 1985, 74, 124-127. 
 
15. Salameh, A. K.; Taylor, L. S. Deliquescence in Binary Mixtures. Pharm. Res. 2005,  
      22, 318-324. 
 
16. Campen, L. V.; Amidon, G. L.; Zografi, G. Moisture Sorption Kinetics for Water- 
      Soluble Substances I: Theoretical Considerations of Heat Transport Control. J.  
      Pharm. Sci. 1983, 72, 1381-1388. 
 
17. Brooks, S. D.; Wise, M. E.; Cushing, M.; Tolbert, M. A. Deliquescence Behavior of  
      Organic/Ammonium Sulfate Aerosol. Geophys. Res. Lett. 2002, 29, Art. No. 1917. 
 
18. Carroll, S.; Craig, L.; Wolery, T. J. Deliquescence of NaCl-NaNO3, KNO3-NaNO3,  
      and NaCl-KNO3 Salt Mixtures from 90 to 120 Degrees C. Geochem. Trans. 2002, 6,  
      19-30. 
 
19. Salameh, A. K.; Mauer, L. J.; Taylor, L. S. Deliquescence Lowering in Food  
      Ingredient Mixtures. J. Food. Sci. 2006, 71, E10-E16. 
 
20. Salcedo, D. Equilibrium Phase Diagrams of Aqueous Mixtures of Malonic Acid  
      and Sulfate/Ammonium Salts. J. Phys. Chem. A. 2006, 110, 12158-12165. 
 
21. Wexler, A. S. Second-Generation Inorganic Aerosol Model. Atmos. Environ. 1991,  
      25A, 2731-2748. 
 
22. Parsons, M. T.; Mak, J.; Lipetz, S. R.; Bertram, A. K. Deliquescence of Malonic,  
      Succinic, Glutaric and Adipic Acid Particles. J. Geophys. Res. 2004, 109, Art. No.  
      D06212. 
 
23. Salameh, A. K.; Taylor, L. S. Deliquescence-Induced Caking in Binary Powder  
      Blends. Pharm.. Dev. Technol. 2006, 11, 453-464. 
 
24. Salameh, A. K.; Taylor, L. S. Role of Deliquescence Lowering in Enhancing  
      Chemical Reactivity in Physical Mixtures. J. Phys. Chem. B. 2006, 110, 10190- 
      10196. 
 
 
25. Carstensen, J. T.; Attarchi, F.; Hou, X.-P. Decomposition of Aspirin in the Solid-State  





26. Teraoka, R.; Otsuka, M.; Matsuda, Y. Effects of Temperature and Relative-Humidity  
      on the Solid-State Chemical-Stability of Ranitidine Hydrochloride. J. Pharm. Sci.  
      1993, 82, 601-604. 
 
27. Rodríguez-Hornedo, N.; Nehm, S. J.; Jayasankar, A. Cocrystals: Design, Properties  
      and Formation Mechanisms. In Encyclopedia of Pharmaceutical Technology, 3rd ed.;  
      Swarbrick, J., Eds.; Informa Health Care: New York, 2006, pp.615-635. 
 
28. Rodríguez-Spong, B. Enhancing the Pharmaceutical Behavior of Poorly Soluble  
      Drugs Through the Formation of Cocrystals and Mesophases. Ph.D. Thesis,  
      University of Michigan, Ann Arbor, 2005. 
 
29. Trask, A. V.; Motherwell, W. D. S.; Jones, W. Pharmaceutical Cocrystallization:  
      Engineering a Remedy for Caffeine Hydration. Cryst. Growth Des. 2005, 5, 1013- 
      1021. 
 
30. Trask, A. V.; Motherwell, W. D. S.; Jones, W. Physical Stability Enhancement of  
      Theophylline via Cocrystallization. Int. J. Pharm. 2006, 320, 114-123. 
 
31. Nehm, S. J.; Rodríguez-Spong, B.; Rodríguez-Hornedo, N. Phase Solubility  
      Diagrams of Cocrystals are Explained by Solubility Product and Solution  
      Complexation. Cryst. Growth Des. 2006, 6, 592-600. 
 
32. Rodríguez-Hornedo, N.; Nehm, S. J.; Seefeldt, K. F.; Pagán-Torres, Y.; Falkiewicz,  
      C. J. Reaction Crystallization of Pharmaceutical Molecular Complexes. Mol. Pharm.  
      2006, 3, 362-367. 
 
33. Jayasankar, A.; Nehm, S. J.; Rodríguez-Hornedo, N. The Use of Raman Spectroscopy  
      for Real-Time Monitoring of Cocrystal Formation During Wet Granulation. AAPS J.  
      2006, 8, R6165. 
 
34. Fleischman, S. G.; Kuduva, S. S.; McMahon, J. A.; Moulton, B.; Walsh, R. D. B.;  
      Rodríguez-Hornedo, N.; Zaworotko, M. J. Crystal Engineering of the Composition of  
      Pharmaceutical Phases: Multiple-component Crystalline Solids Involving  
      Carbamazepine. Cryst. Growth Des. 2003, 3, 909-919. 
 
35. Parsons, M. T.; Riffell, J. L.; Bertram, A. K. Crystallization of Aqueous Inorganic- 
      Malonic Acid Particles: Nucleation Rates, Dependence on Size and Dependence on  
      the Ammonium-to-Sulfate Ratio. J. Phys. Chem. A. 2006, 110, 8108-8115. 
 
36. Rodríguez-Hornedo, N.; Nehm, S. J.; Jayasankar, A. Process Analytical Technologies  
      to Analyze and Control Cocrystallization. Am. Pharm. Rev. 2007 10, 46-55. 
 
37. Murphy, D.; Rodríguez-Cintrón, F.; Langevin, B.; Kelly, R. C.; Rodríguez-Hornedo,  




      Carbamazepine and the Effect of Lattice Disorder. Int. J. Pharm. 2002, 246, 121-134. 
 
38. Zubair, M. U.; Hassan, M. M. A., Saccharin. In Analytical Profiles of Drug  
      Substances; Florey, K., Eds.; Academic Press: Orlando, 1984, pp. 487-519. 
 
39. Rodríguez-Hornedo, N.; Lechuga-Ballesteros, D.; Wu, H. J. Phase-Transition and  
      Heterogenous Epitaxial Nucleation of Hydrated and Anhydrous Theophylline  
      Crystals. Int. J. Pharm. 1992, 85, 149-162. 
 
40. Rodríguez-Hornedo, N.; Murphy, D. Surfactant-Facilitated Crystallization of  
      Dihydrate Carbamazepine During Dissolution of Anhydrous Polymorph. J. Pharm.  
      Sci. 2004, 93, 449-460. 
 
41. Ticehurst, M. D.; Storey, R. A.; Watt, C. Application of Slurry Bridging Experiments  
      at Controlled Water Activities to Predict the Solid-State Conversion between  
      Anhydrous and Hydrated Forms Using Theophylline as a Model Drug. Int. J. Pharm.  
      2002, 247, 1-10. 
 
42. Zhu, H.; Yuen, C.; Grant, D. J. W. Influence of Water Activity in Organic Solvent +  
      Water Mixtures on the Nature of the Crystallizing Drug Phase . 1. Theophylline. Int.  
      J. Pharm. 1996, 135, 151-160. 
 
43. Braban, C. F.; Abbatt, J. P. D. A Study of the Phase Transition Behavior of Internally  
      Mixed Ammonium Sulfate-Malonic Acid Aerosols. Atmos. Chem. Phys. 2004, 4,  
      1451-1459. 
 
44. Zhang, Y. H.; Hu, Y. A.; Ding, F.; Zhao, L. J. FTIR-ATR Chamber for Observation  
      of Efflorescence and Deliquescence Processes of NaClO4 Aerosol Particles on ZnSe  
      Substrate. Chinese Sci. Bull. 2005, 50, 2149-2152. 
 
45. O'Neil, M. J., The Merck index. 13th Merck & Co., Inc: New Jersey, 2001. 
  
46. Bethune, S. J. Thermodynamic and Kinetic Parameters that Explain Solubility and  
      Crystallization of Pharmaceutical Cocrystals. Ph.D. thesis, University of Michigan,  
      Ann Arbor, 2008. 
 
47. Maffia, M. C.; Meirelles, A. J. A. Water Activity and pH in Aqueous Polycarboxylic  






FACTORS THAT AFFECT THE FORMATION AND THERMODYNAMIC 




 Water-solid interactions are frequently encountered during processing and storage 
of pharmaceutical solids. Such interactions often lead to phase transformations such as 
amorphous to crystalline conversions and polymorphic transformations.1-3 Water, when 
incorporated in the crystal lattice along with a drug molecule, results in the formation of 
hydrates.4 Hydrate formation during processing or storage can adversely affect 
pharmaceutical performance and processability.5-10  
 Recent studies have shown that pharmaceutical cocrystals or crystalline 
complexes, consisting of an API and coformer, provide greater stability against 
hydration.  Cocrystals of carbamazepine, caffeine and theophylline are shown to prevent 
API hydrate formation at relative humidities where the anhydrous APIs generally 
transform to hydrates.11-13  Cocrystals are also shown to prevent deliquescence as with 
carbamazepine-nicotinamide cocrystal.13  Cocrystal design based on crystal engineering 
strategies and principles further allows modulation of other API properties such as 
solubility, dissolution rates and bioavailability as well as mechanical properties.13-20  
Cocrystals are therefore pursued as potential solid forms in drug development, and 
screening strategies for API cocrystals have received considerable attention.21-27  
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While the majority of API cocrystals are anhydrous,11, 12, 28-30  few are also 
reported to exist as hydrates.24, 26, 31 In most cases, cocrystal hydrates were 
serendipitously identified using organic solvents,24, 31 and the conditions governing the 
formation of cocrystal hydrates are not known. This study therefore aims to identify the 
factors and conditions that govern their formation and stability. 
 Water activity is well known to affect the stability of pharmaceutical hydrates.32-34 
Since the water activity is dependent on solution compositions,35, 36  it can be altered by 
varying the solution composition. This is achieved by addition of solution additives or 
excipients to aqueous solution. Studies from our lab have shown that coformer aqueous 
concentration affects cocrystal stability. Thus, the addition of coformer to aqueous 
solutions can also alter the water activity. Further, water activity when expressed in 
percentage is equal to relative humidity (RH): RH = aw x 100%.37 Thus the stability of 
hydrates will also depend on RH.  The current study examines (1) the effect of coformer, 
excipient and cosolvent aqueous concentrations on cocrystal hydrate formation and 
stability, (2) the effect of relative humidity (RH) on cocrystal hydrate and anhydrous 
cocrystal formation during storage of reactant mixtures, and (3) the relative 
thermodynamic stabilities of anhydrous and hydrated cocrystals. Results presented here 
have significant implications for anticipating phase transformations and controlling phase 
stability during processing and storage. 
 The model cocrystals selected in the current study include theophylline-citric acid 
(THP-CTA) and carbamazepine-4-aminobenzoic acid (CBZ-4ABA) cocrystals since 
anhydrous and hydrated cocrystalline phases have been identified for both systems.24, 31 
The hydrated cocrystalline phases in both systems were serendipitously identified by 
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slow evaporation using organic solvents or by cogrinding reactants.24, 31  THP-CTA and 
CBZ-4ABA were further selected as models systems due to differences in properties of 
the coformers. Citric acid is highly water soluble, deliquescent coformer, and is known to 
decrease the water activity at high concentrations.38 4ABA, on the contrary, has low 
aqueous solubility.39 These differences in coformer properties enable the evaluation of 
coformer effects on cocrystal hydrate formation and stability. The effect of excipients and 
cosolvents on water activity and cocrystal hydrate stability was examined using fructose 
and acetonitrile, respectively. Addition of fructose or acetonitrile to aqueous solutions is 






Anhydrous theophylline (THP), anhydrous form (III) monoclinic carbamazepine 
(CBZ), and α-form 4-aminobenzoic acid (4ABA) used in the studies were purchased 
from Sigma Aldrich. Anhydrous citric acid (CTA) was purchased from Fisher Scientific. 
All chemicals were characterized by X-ray powder diffraction (XRPD) and Raman 
spectroscopy prior to use. Ethanol and 2-propanol, purchased from Sigma Aldrich, were 










Anhydrous and hydrated cocrystals of theophylline-citric acid (THP-CTA) and 
carbamazepine-4-aminobenzoic acid (CBZ-4ABA) were prepared by the reaction 
crystallization method.21, 43  
  
Carbamazepine-4aminobenzoic acid cocrystal (CBZ-4ABA): 2:1 anhydrous CBZ-4ABA 
was prepared by suspending 200 mg of CBZ(III) in 3g of 0.6m 4ABA ethanolic solution.  
2:1:1 CBZ-4ABA cocrystal hydrate was prepared by suspending 1.72g CBZ(III) in 0.5g 
4ABA aqueous solution. The suspensions were magnetically stirred at room temperature 
for 12 hours. The solid phases after filtration were characterized by XRPD and Raman 
spectroscopy. XRPD patterns of the solid phases from ethanol and aqueous suspensions 
were compared with the simulated pattern of the anhydrous and hydrated cocrystals from 
the crystal structure database (CSD) to confirm they were cocrystals. 
 
Theophylline-citric acid cocrystal (THP-CTA): Anhydrous THP-CTA cocrystal was 
prepared by suspending 200 mg anhydrous theophylline in 11.4g of 1.89m citric acid 
solution in ethanol. Cocrystal hydrate was prepared by suspending 1.5g anhydrous 
theophylline in 9.0g of 5m aqueous citric acid solution. The suspensions were stirred 
overnight and the solid phases were characterized by XRPD and Raman spectroscopy. 
XRPD patterns of the solid phases from ethanol and aqueous suspensions were compared 
with the simulated patterns of the anhydrous and hydrated cocrystals from CSD to 
confirm they were cocrystals. 
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Coformer, excipient and cosolvent effects on cocrystal hydrate stability  
Theophylline-citric acid cocrystal: Cocrystal hydrate stability dependence on coformer 
(citric acid) solution concentration was examined by suspending excess cocrystal hydrate 
in aqueous solutions with varying coformer concentrations. The suspensions were 
magnetically stirred in a water bath at 25°C for 24 - 48 hours prior to adding anhydrous 
cocrystal. The suspensions were then stirred for 2-3 weeks to reach equilibrium. Solution 
concentrations of theophylline and citric acid at equilibrium were measured using HPLC. 
Equilibrium was considered to be achieved when the solution concentrations reached 
steady values. Solid phases were characterized by Raman spectroscopy and XRPD. The 
water activities of the equilibrated suspensions were determined by measuring the RH 
above the suspensions using a Hydroclip RH probe from Rotronics (Huntington, NY).  
Excipient effect on water activity and cocrystal hydrate stability can be examined 
by selecting excipients that modulate the water activity of aqueous solutions. Sugars such 
as sucrose and fructose have been shown to decrease the water activity of water as well as 
citric acid aqueous solutions.44  The chemical stability of sugars in the presence of acid is 
also reported in the literature.  In this study fructose was selected as the excipient since it 
is reported to be stable in the presence of citric acid while sucrose undergoes acid 
catalyzed inversion.44, 45  
Excess THP-CTA hydrate was suspended in aqueous fructose-citric acid solutions 
with varying fructose concentration but constant citric acid concentration (6.05moles/kg 
water) at 25°C. The suspensions were allowed to reach equilibrium as described above. 
Solid phase stability in suspensions was periodically monitored using Raman 
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spectroscopy and XRPD. The water activity of the suspensions was determined by 
measuring the RH as described above. 
 
Carabamazepine-4-aminobenzoic acid cocrystal: Anhydrous and hydrated cocrystal 
stability in pure water, and cocrystal hydrate stability in saturated aqueous 4ABA 
solution was examined by suspending excess anhydrous or hydrated cocrystal in water or 
4ABA solution. The suspensions were magnetically stirred for 7 days at 25°C, and the 
solid phases were characterized by Raman spectroscopy and XRPD.  
 Cocrystal hydrate stability was also studied in aqueous solutions with varying 
amounts of cosolvent by suspending excess cocrystal hydrate in cosolvent-water mixtures 
with varying water activity. The suspensions were magnetically stirred for 48 hours at 
25°C prior to adding anhydrous cocrystal. The suspensions were then stirred for an 
additional two weeks. Solid phases were characterized by Raman spectroscopy and 
XRPD to monitor phase transformations. 
 The addition of a cosolvent such as methanol, ethanol, isopropyl alcohol (IPA) or 
acetonitrile (ACN) is known to decrease the water activity of aqueous solutions.33, 42, 46  
In the current study, acetonitrile was selected as the model cosolvent to examine the 
effect of cosolvent concentrations on cocrystal hydrate stability as well as to measure the 
critical water activity of cocrystal hydrate. Cosolvent selection was based on preliminary 
stability studies that showed transformation of anhydrous cocrystal to crystalline drug in 
neat alcohols and alcohol-water mixtures with low water activities, whereas the cocrystal 
was stable in neat ACN.  A key requirement for critical water activity measurement is the 
coexistence of anhydrous and hydrated crystalline phases in equilibrium with the solution 
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at the critical water activity. Since the anhydrous cocrystal was stable in ACN, ACN-
water mixtures were used to measure the critical water activity.  
 The water activity of ACN-water mixtures as a function of water composition has 
been reported in a previous study,42 and is estimated using the following equations:  
aw = xw.γw                (1) 
aw is the water activity, xw is mole fraction water and γw is the activity coefficient of 
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The values (λw,acn-λww) and (λw,acn-λacn,acn) were obtained from literature, and are 6745 and 
1379 J/mol, respectively.42 The values of υacn and υw are 52.86 and 13 ml/mol, 
respectively.42  The water activity dependence on solution composition for ACN-water 











Transition concentration measurements for THP-CTA cocrystals 
Three transition concentrations or eutectic points (c1, c2, and c3) were identified 
for the THP-CTA cocrystals in water at 25˚C. The transition concentration (c1) between 
theophylline hydrate and cocrystal hydrate was determined by measuring the reactant 
concentrations (theophylline and citric acid) in water saturated with theophylline hydrate 
and cocrystal hydrate. Saturation with respect to the two crystalline phases was achieved 
by suspending excess anhydrous theophylline in 1.8m citric acid aqueous solution. The 
suspensions were allowed to reach equilibrium by magnetically stirring at 25°C. Solid 
phase and solution concentration were monitored. Equilibrium was considered to be 
achieved when solution concentrations reached a steady value while two solid phases 
coexist. The solid phases in suspension were characterized by Raman spectroscopy. 
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Solutions were analyzed for theophylline and citric acid concentrations by HPLC. The 
suspensions were filtered and the solid phases were characterized by XRPD. 
 The transition concentration c2 was determined by saturating water with 
anhydrous and hydrated cocrystals. This was achieved by adding anhydrous and hydrated 
cocrystals to 7.2m citric acid. c3 was determined by saturating water with anhydrous 
cocrystal and citric acid hydrate. The procedures for analysis of solid and liquid phases 
were similar to those described above. The water activities corresponding to the transition 
concentrations were determined by measuring the RH above the equilibrated suspensions 
using the hydroclip RH probe. 
 
Stability and transformations during storage  
The role of deliquescence on cocrystal formation in solid mixtures of theophylline 
and anhydrous citric acid at 75%, 85% and 98%RH at 25°C was studied using the 
procedures described in an earlier study.47 Approximately 50mg mixtures were stored in 
glass desiccators equilibrated to the desired RH using appropriate saturated salt solutions: 
NaCl for 75%, KCl for 85% and K2SO4 for 98%RH.48  The particle size of the reactants 
used in the study was 45-63 microns. Transformation during storage was monitored using 
a non-contact fiber optic Raman probe. Solid phases were also characterized by XRPD.  
Moisture uptake and stability of THP-CTA cocrystal hydrate was also 
investigated at 75%, 85% and 98%RH at 25°C. Solid phase stability and transformation 






Raman spectra of solid phases were collected with a Kaiser Optical Systems, Inc. 
(Ann Arbor, MI), RXN1 Raman spectrometer equipped with a 785 nm laser. Solid phase 
transformations were monitored using an immersion or non-contact fiber optic probe. The 
immersion probe was used to collect the spectra of solid phases in aqueous suspensions 
and the non-contact probe was used to monitor transformations in solid mixtures during 
storage. The spectra were collected between 100 and 1800 cm-1 with a resolution of 4 cm-
1 using the vendor supplied Holograms software. 
 
X-ray Powder Diffraction  
A bench top Rigaku Miniflex X-ray powder Diffractometer (Danvers, MA) using Cu Kα 
radiation (λ = 1.54Ǻ), a tube voltage of 30kV, and a tube current of 15mA was used to 
collect XRPD patterns of solid phases. Data was collected from 2˚ to 40˚ at a continuous 
scan rate of 2.5 deg/min. 
 
High Performance Liquid Chromatography (HPLC) 
A Waters system (Milford, MA) equipped with a 5μm C18 Atlantis column (4.6 x 
250mm; Waters, Milford, MA) and UV/Vis detector was used to measure theophylline 
and citric acid concentrations with a gradient method. The mobile phase was flowed 
through the column at 1ml/min and the composition was varied from 40% methanol to 
5% methanol in water with 0.1% trifluoroacetic acid. 20μL of samples were injected into 




Theophylline and citric acid concentrations were also measured using an isocratic 
method and a HPLC system from Agilant Technologies. Mobile phase composition was 
0.2% trifluoroacetic acid and 30% methanol in water. Mobile phase flow rate was 
1ml/min and sample injection volumes were 25μL.  
 
Thermal analysis 
 Thermal analysis of samples was carried out using a TA 2590 DSC (TA 
instruments, New Castle, DE) which was calibrated for temperature and cell constants 
using indium and n-dodecane. Samples (3-5 mg), crimped in hermetic sealed pans with 
pinholes, were analyzed in the DSC from 15 to 200°C at a heating rate of 10 °C/min. 
Samples were continuously purged with nitrogen at 50 ml/min. Samples were also 
analyzed on a TA 2950 TGA (TA instruments, New Castle, DE) to determine the mass 
change in samples due to dehydration.  Samples were heated from 25°C to 170°C at a 
heating rate of 10°C/min. 
 
Results 
Effect of coformer concentration on cocrystal hydrate stability 
 Cocrystal hydrate stability in aqueous solutions is dependent on coformer 
concentration. XRPD patterns in figure 4.2 show that theophylline-citric acid (THP-CTA) 
cocrystal hydrate is stable at coformer concentrations between 2.39m and 6.80m. Above 
7.31m citric acid, cocrystal hydrate transforms to anhydrous cocrystal, while 
transformation to theophylline hydrate occurs below 1.62m citric acid.  Previous studies 
have shown coformer concentration dependent stability and transformation of anhydrous 
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cocrystal to crystalline drug.21, 26, 43, 49  To our knowledge, this is the first study showing 
coformer concentration dependent stability and transformation of a hydrated cocrystal to 
anhydrous cocrystal or crystalline drug hydrate.   
 
Figure 4.2: XRPD patterns showing transformation of (A) THP-CTA cocrystal hydrate 
in solutions of varying coformer concentrations (B) 0.19m, (C) 1.62m, (D) 2.39m, (E) 
6.68m, (F) 6.80m, (G) 7.31m, (H) 7.76m, and (I) 9.12m; reference XRPD of (J) 
anhydrous cocrystal, and (K) theophylline hydrate. 
 
 
Cocrystal stability domains  
Studies with other cocrystalline systems have shown that the key parameter to 
identify cocrystal stability domains in coformer solutions is the transition concentration 
(Ctr), an isothermal invariant point at which two solid phases are in equilibrium with the 
solution.21, 26, 43, 49  Results from stability studies of THP-CTA cocrystals suggest that 
 
 132
there are three transition concentrations (c1, c2 and c3). The solid phases in equilibrium 
with the solution at c1, c2 and c3 are API hydrate/cocrystal hydrate, cocrystal 
hydrate/anhydrous cocrystal, and anhydrous cocrystal/coformer hydrate, respectively. 
The reactant concentrations and solid phases at equilibrium at the transition 
concentrations are summarized in table 4.1.  
 
 
Table 4.1: Reactant concentrations and solid phases at equilibrium at the transition 
concentrations (Ctr) for THP-CTA cocrystals at 25°C. 
 




Solid phases at equilibrium 
c1 0.1225 ± 0.0003 1.62 ± 0.05 Theophylline hydrate, cocrystal hydrate 
c2 0.0313 ± 0.0030 7.31 ± 0.01 Cocrystal hydrate, anhydrous cocrystal 
c3 0.0278 ± 0.0004 9.44 ± 0.20 Anhydrous cocrystal, citric acid hydrate 
aconcentrations are mean ± standard deviation. 
 
 From the Ctr values, the stability domains of the different crystalline phases can 
be identified on a phase solubility diagram (PSD) as shown in figure 4.3. Lines and 
curves between experimentally measured values were drawn based on the behavior of the 
cocrystal solubility dependence on coformer for other systems.26, 43, 49 Cocrystal hydrate 
is the solid phase in equilibrium with solutions having reactant concentrations between c1 
and c2, while the anhydrous cocrystal is the equilibrium solid phase in solutions with 
reactant concentrations between c2 and c3. Theophylline hydrate is the equilibrium solid 
phase in solutions with reactant concentrations below c1, and citric acid hydrate is the 






Figure 4.3: Phase solubility diagram of theophylline-citric acid cocrystals showing the 
stability domains and solubility dependence on coformer concentrations for the different 
crystalline phases. c1, c2, and c3 represent transition concentrations. ‘a’ and ‘b’ represent 
the aqueous solubilities of theophylline hydrate and citric acid hydrate as obtained from 
literature.9, 50 Lines through a, c1, c2, c3, and b are drawn based on the behavior of the 
cocrystal solubility dependence on coformer for other cocrystal systems. The stability 
domains of crystalline phases are: ac1 - theophylline hydrate, c1c2 - cocrystal hydrate, c2c3 
- anhydrous cocrystal, bc3 - citric acid hydrate. 
 
 
Drug and cocrystal solubility dependence on coformer concentration can also be 
predicted from the Ctr values as shown in figure 4.3. Theophylline concentration at c1 is 
higher than theophylline hydrate solubility in pure water33 (point ‘a’ in PSD). This 
indicates that the drug solubility increases with coformer concentration from ‘a’ to c1, 
possibly due to solution interactions such as complexation,49, 51 hydrotropy,52 etc. 
Theophylline concentration at c2 is less than that at c1 suggesting a decrease in cocrystal 
hydrate solubility with increase in coformer concentrations. Studies with other 
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cocrystalline systems showing similar cocrystal solubility dependence on coformer 
concentration have indicated that cocrystal solubility is described by the solubility 
product principle.43, 49   
Conversion of cocrystal hydrate to anhydrous cocrystal at coformer 
concentrations beyond c2 is explained by the effect of coformer concentration on water 
activity, a factor well known to affect the stability of pharmaceutical hydrates.32, 33, 53  
The water activities of aqueous citric acid solutions are reported in literature,38, 54 and are 
slightly higher (~ 5%) than those measured in the current study (table 4.2). This may be 
due to differences in solution interactions in the presence of theophylline as well as 
differences in methods used to measure the water activity. The transformation of 
cocrystal hydrate to anhydrous cocrystal with increasing coformer concentration must be 
due to lowering of water activity by the coformer. The critical water activity above which 
cocrystal hydrate is stable is 0.80. 
 
 
Table 4.2: Water activity and cocrystal hydrate stability dependence on citric acid 
concentration at 25.0 ± 0.5 °C. 
 
 
Citric acid (m) Water activity (aw) Solid phase at equilibrium 
1.62a 0.95 Theophylline hydrate, cocrystal hydrate 
2.39 0.89 Cocrystal hydrate 
6.68 0.83 Cocrystal hydrate 
6.80 0.81 Cocrystal hydrate 
7.31b 0.80 Cocrystal hydrate, anhydrous cocrystal 
7.76 0.80 Anhydrous cocrystal 
9.12 0.78 Anhydrous cocrystal 
atransition concentration c1;  btransition concentration c2 
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Effect of excipients on cocrystal hydrate stability 
In addition to the coformer, excipients such as sugars used in pharmaceutical 
formulations can also lower the water activity of aqueous solutions. Fructose is reported 
to lower the water activity of aqueous solutions.40, 41  The water activity of saturated 
solution of fructose is 0.64.40, 41  Therefore, the addition of fructose to aqueous solutions 
is expected to alter cocrystal hydrate stability. Since cocrystal hydrate is unstable and 
transforms to crystalline drug hydrate in aqueous solution without citric acid, fructose 
effect on cocrystal hydrate stability was investigated by adding varying amounts of 
fructose to aqueous solutions with fixed coformer concentration (6.05 mol/kg water) in 
which cocrystal hydrate is the stable phase.  
Table 4.3 shows the effect of fructose addition on water activity and cocrystal 
hydrate stability in aqueous citric acid solutions. Addition of fructose decreases the water 
activity of aqueous citric acid solutions. XRPD patterns in figure 4.4 show that cocrystal 
hydrate is the stable phase in aqueous citric acid solution without fructose (aw = 0.84). As 
the water activity is lowered by fructose addition, cocrystal hydrate transforms to 
anhydrous cocrystal at aw = 0.79. Based on these results, the critical water activity above 
which the cocrystal hydrate is stable is above 0.79.  This is in agreement with the critical 









Table 4.3: Water activity of fructose-citric acid aqueous solutions at 25.0 ± 0.5 °C 
CTA (m) Fructose (m) aw Solid phases at 
equilibrium 
6.05 0.00 0.84 Cocrystal hydrate 
6.05 0.94 0.82 Cocrystal hydrate 






Figure 4.4: XRPD showing transformation of THP-CTA cocrystal hydrate as a function 
of water activity. Water activity was varied by addition of fructose to 6.05m aqueous 
CTA solutions. (A) aw = 0.84, (B) aw = 0.82, and (C) aw = 0.79. Reference patterns of (D) 






Effect of relative humidity on cocrystal formation and stability  
Results from the above studies show that the transformation of cocrystal hydrate 
to anhydrous cocrystal is governed by water activity. Water activity when expressed in 
percentage is equal to relative humidity (RH).37  RH dependent transformation of reactant 
mixtures to cocrystal during storage has been shown in a previous study.47 
Transformation in these mixtures occurred due to deliquescence of reactants during 
storage. Citric acid is a deliquescent material and its deliquescence RH (DRH) is 75%RH 
at 25°C44. Therefore, the effect of RH on cocrystal formation and stability was studied in 
mixtures of THP/CTA at 75%, 85% and 98% RH at 25°C.  
Figure 4.5 shows the XRPD patterns of theophylline/citric acid mixtures after 
storage at various RH. The powder pattern indicates anhydrous cocrystal formation after 
storage at 75%RH for 6 weeks. A mixed phase of anhydrous and hydrate cocrystal is 
observed at 85%RH after 4 weeks. Peaks characteristic of anhydrous cocrystal at 13.4° 
and 26.1° and that of cocrystal hydrate at 14.3° are observed. At 98%RH a mixed phase 
of theophylline hydrate (2Θ values at 11.6° and 14.8°) and cocrystal hydrate (2Θ = 14.3°, 





Figure 4.5: XRPD patterns of THP/CTA mixtures showing transformation after storage at 
85% and 98%RH. (A) mixture before storage, mixture after storage at (B) 75%RH, (C) 
85%RH, and (D) 98%RH. Reference patterns of (E) Anhydrous cocrystal, (F) Cocrystal 
hydrate and (G) Theophylline hydrate  
 
 
The transformation pathways in mixtures stored at 85% and 98% RH were 
identified using Raman spectroscopy. At 85% and 98% RH, the mixture transforms to 
anhydrous cocrystal and then to cocrystal hydrate. Further transformation of cocrystal 
hydrate to theophylline hydrate was observed only at 98%RH (figure 4.6). Cocrystal 




Figure 4.6: Raman spectra showing the transformation pathway in THP/CTA mixtures 
during storage at (A) 85% and (B) 98%RH. 
 
 
Moisture uptake and stability of THP-CTA hydrate cocrystal at 85% and 98%RH 
was also investigated by storing the hydrated cocrystal under these conditions. Figure 4.7 
shows the XRPD patterns after storage for 4.5 months. Cocrystal hydrate sorbs less than 
2% moisture and remains stable at 85%RH after 16 weeks of storage. At 98%RH, 
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cocrystal hydrate deliquesces by sorbing 74 % water and transforms to theophylline 
hydrate. A previous study has reported the cocrystal hydrate to be stable at 98%RH.24 
However, cocrystal stability in this study was examined only for a week. The current 






Figure 4.7: XRPD patterns of THP-CTA cocrystal hydrate: (A) before storage; after 








Stability of carbamazepine-4-aminobenzoic acid  (CBZ-4ABA) cocrystals in aqueous 
solutions 
 
The stability of 2:1 CBZ-4ABA anhydrous and hydrated cocrystals in aqueous 
solutions was also studied. XPRD patterns in figure 4.8 indicate that both anhydrous and 
hydrated cocrystals are unstable in pure water. Cocrystal hydrate transforms to CBZ(D), 
while the anhydrous cocrystal transforms to cocrystal hydrate. In a saturated aqueous 
solution of the coformer (4ABA), cocrystal hydrate is the stable phase. These results 
indicate that CBZ-4ABA hydrate stability in aqueous solutions is dependent on coformer 
concentration. Cocrystal hydrate stability in saturated aqueous coformer solutions further 
suggests that the coformer concentration does not govern transformation between the 
hydrate and anhydrous cocrystals as shown for THP-CTA cocrystals. The critical water 
activity was therefore measured by examining cocrystal stability in acetonitrile-water 






Figure 4.8: XRPD patterns showing the stability of CBZ-4ABA anhydrous and hydrated 
cocrystals after suspending for a week in aqueous solutions. CBZ-4ABA hydrate (A) 
reference pattern, and after suspending in (B) pure water, and (C) saturated 4ABA 
solution; Anhydrous cocrystal (D) reference pattern, and after suspending in (E) pure 
water; (F) reference pattern of CBZ(D).  
 
 
XRPD patterns in figure 4.9 shows the dependence of anhydrous and hydrated 
cocrystal stability on water activity. The anhydrous cocrystal is stable at aw ≤ 0.26. 
Characteristic peaks corresponding to the anhydrous cocrystal are observed at 9.8° and 
17.5°. Cocrystal hydrate is stable at aw ≥ 0.30. Thus the critical water activity above 







Figure 4.9: XRPD patterns showing transformation of CBZ-4ABA cocrystal hydrate as a 
function of water activity (aw). Water activity was varied by addition of acetonitrile to 
water. (A) aw = 0.0, (B) aw = 0.06, (C) aw = 0.11, (D) aw = 0.16, (E) aw = 0.21; (F) aw = 




Thermal Analysis of cocrystal hydrates 
 
 Figure 4.10 shows the thermal data for CBZ-4ABA and THP-CTA cocrystal 
hydrates. An endotherm corresponding to dehydration is observed at 91.1±1.1°C for 
CBZ-4ABA hydrate in the DSC. The dehydration is followed by an exotherm indicating 
crystallization. This suggests dehydration of cocrystal hydrate results in amorphous phase 
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formation. The exothermic event is followed by endothermic events at 130°C, 139°C, and 
153°C.  
 The DSC data of THP-CTA cocrystal hydrate shows an endotherm at 53.1±0.3°C 
followed by another endotherm at 88.6±1.1°C. Thermogravimetric analysis of the 
cocrystal hydrate shows a weight change between 50°C and 110°C corresponding to the 
two endothermic events observed in the DSC. This suggests that the dehydration of 
cocrystal hydrate proceeds in two steps. Cocrystal hydrate dehydration is followed by 





Figure 4.10: DSC and TGA traces of CBZ-4ABA and THP-CTA cocrystal hydrates. 
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 The dehydration of cocrystal hydrates occur at higher temperatures when 
compared to the corresponding API hydrates. Carbamazepine dihydrate (CBZ(D)) and 




 Results from our current study show that the coformer aqueous concentration 
affects the thermodynamic stability of cocrystal hydrates in aqueous solutions. 
Depending on the coformer concentration, cocrystal hydrate can transform to crystalline 
drug or anhydrous cocrystal. Transformation of cocrystal hydrate to anhydrous cocrystal 
in aqueous coformer solutions occurs when the coformer modulates the water activity 
significantly. This is demonstrated for THP-CTA cocrystal hydrate. Conversion of 
cocrystal hydrate to anhydrous cocrystal with increasing coformer concentrations did not 
occur for CBZ-4ABA. This is because 4ABA has low aqueous solubility and negligibly 
affects the water activity of aqueous solution. The aw of saturated aqueous 4ABA (aw 
=0.98) is significantly higher than the critical aw of CBZ-4ABA hydrate (aw = 0.26-0.30).  
 A key parameter to identify anhydrous and hydrated cocrystal stability domains is 
the transition concentration between the different crystalline phases. Using the transition 
concentrations, phase solubility diagrams (PSD) showing the reactant solution 
concentrations in molality or molarity at equilibrium with the different solid phases as 
well as the cocrystal stability domains can be plotted as shown in figure 4.3.26, 49 
Alternatively, the stability domains can also be represented on a triangular phase diagram 
(TPD) that shows the total composition of the system, including that in the solid and 
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liquid phase, in mole or mass fractions.26, 49  Figure 4.11 shows the TPD for a 
hypothetical ternary system where the coformer modulates the water activity similar to 
THP/CTA/water system. A hypothetical ternary system is considered since the drug and 
cocrystal solubility in THP/CTA/water system cannot be represented on the TPD due to 
extremely low mole fractions of THP (<10-2).  
In figure 4.11, the solubility of the crystalline drug hydrate, cocrystal hydrate, 
anhydrous cocrystal, and ligand hydrate are represented by the solubility curves ac1, c1c2, 
c2c3, and c3b, respectively. The stability domains of cocrystal hydrate and anhydrous 
cocrystal are represented by regions 2 and 3. The hydrated drug and ligand are stable in 
regions 1 and 4, respectively. Mixed phases of crystalline drug hydrate/cocrystal hydrate, 
cocrystal hydrate/anhydrous cocrystal, and anhydrous cocrystal/ hydrated ligand will be 
present in regions 5, 6, and 7, respectively.  Similar phase diagrams have been reported 
for cocrystals with different stoichiometry.49  In these studies, the stability domains of the 
cocrystal with different stoichiometry are governed by cocrystal and solution chemistry. 
The current study with the theophylline-citric acid cocrystals suggests that the stability 
domains of the anhydrous and hydrated cocrystals are governed by water activity and 






Figure 4.11: TPD showing the stability domains for anhydrous and hydrated cocrystals 
with coformers that modulate the water activity. Points ‘a’ and ‘b’ correspond to API 
hydrate and coformer hydrate aqueous solubility. c1, c2, and c3 represent the transition 
concentrations or eutectic points. Curves ac1, c1c2, c2c3, and c3b represent the solubilities 
of crystalline drug hydrate, cocrystal hydrate, anhydrous cocrystal, and hydrated 
coformer respectively. Stability regions for the crystalline phases are: 1- crystalline drug 
hydrate; 2- cocrystal hydrate; 3-anhydrous cocrystal; 4- cocrystal hydrate; 5- crystalline 
drug hydrate/cocrystal hydrate; 6- anhydrous/hydrated cocrystals; 7- anhydrous 
cocrystal/hydrated coformer. Pathway R represents the transformation occurring during 
reaction crystallization or deliquescence in solid mixtures in storage. 
 
 
From the phase diagrams, the transformation pathway and crystallization 
outcomes can be predicted as represented by the pathway ‘R’ for reaction crystallization 
or deliquescence in solid mixtures. The addition of drug to a saturated solution of the 
coformer during reaction crystallization generates supersaturation with respect to the 
anhydrous cocrystal as shown by the pathway. Further addition of drug generates 
supersaturation with respect to cocrystal hydrate.  
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During deliquescence in solid mixtures, supersaturation with respect to cocrystals 
is generated by non-equivalent reactant concentrations in the deliquesced solution. As 
deliquescence begins, the sorbed water is saturated with coformer.37 Under these 
conditions, the anhydrous cocrystal is the least soluble and most stable phase. The 
dissolution of drug in this solution therefore generates supersaturation with respect to 
anhydrous cocrystal. Further transformation of anhydrous cocrystal to cocrystal hydrate 
will occur when supersaturation with respect to cocrystal hydrate is generated. This is 
achieved when the coformer concentration falls below that corresponding to transition 
concentration c2.  
The concentration of the coformer in a deliquesced solution depends on the RH. 
At the deliquescence RH, the deliquesced solution remains saturated with the coformer. 
However, at higher RH (RH > DRH), increased levels of water uptake lead to coformer 
dilution in the deliquesced solution thereby affecting cocrystal stability. Coformer 
dilution at high RH explains the observed transformation pathway in THP/CTA mixtures 
at 85% and 98%RH.  
Cocrystal hydrate instability and transformation to theophylline hydrate due to 
cocrystal deliquescence at 98%RH is similarly explained by the effect of reactant solution 
concentrations on cocrystal stability. Cocrystal stability studies in aqueous coformer 
solution indicate that the cocrystal hydrate is more soluble and transforms to theophylline 
hydrate at coformer concentrations below 1.62m (c1). Thus during cocrystal 
deliquescence, stoichiometric dissolution of the cocrystal in the sorbed water generates 
supersaturation with respect to the drug resulting in its crystallization.  
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In addition to the coformer, excipients and cosolvent that alter the water activity 
of aqueous solutions also affect cocrystal hydrate stability and transformation to 
anhydrous cocrystal as shown for THP-CTA and CBZ-4ABA cocrystal hydrates. Thus 
when the coformer does not alter water activity, the critical water activity for cocrystal 
hydrate formation and stability can be measured using excipients or cosolvents. When 
using these approaches to determine the critical water activity for cocrystal hydrate, it is 
important to ensure that transformation of cocrystal to crystalline drug does not occur in 
aqueous solutions with cosolvent or excipient.  This is because the equilibrium solid 
phases at the critical water activity are the anhydrous and hydrated cocrystals. 
The critical water activity of CBZ-4ABA and THP-CTA hydrates is different 
from those of the corresponding API hydrates. The critical aw for carbamazepine and 
theophylline hydrates is 0.62-0.64.33, 34, 46   The critical water activity is an indicator of 
the tendency to form hydrates, with lower water activities implying greater tendency for 
hydration. CBZ-4ABA cocrystal, therefore, has a higher tendency to transform to a 
hydrate than anhydrous CBZ, while THP-CTA cocrystal has a lower tendency to hydrate 
when compared to anhydrous theophylline. Differences in the critical water activities of 
API and cocrystal hydrates may be due to differences in the crystal structure, hydrogen 
bond interactions between water, API and/or coformer, as well as differences in solubility 








Coformers, excipients and cosolvents that modulate the water activity of aqueous 
solutions can affect cocrystal hydrate stability and induce transformation to anhydrous 
cocrystal. This is shown for theophylline-citric acid and carbamazepine-4-aminobenzoic 
acid cocrystal hydrates. Cocrystal stability can be evaluated by (i) examining cocrystal 
stability in aqueous suspensions with varying coformer, excipient or cosolvent 
concentrations, and (ii) storing the cocrystals at various RH. Key parameters to identify 
anhydrous and hydrated cocrystal stability domains are transition concentrations and 
critical water activity. THP-CTA and CBZ-4ABA cocrystal hydrates are stable at water 
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COCRYSTAL FORMATION DURING COGRINDING AND STORAGE IS 




Hydrogen bonds are the basis of molecular recognition phenomena in biological 
and pharmaceutical systems.  They are also key elements in the design of molecular 
assemblies and supermolecules in the liquid and solid states.  In the crystalline state, 
hydrogen bonds are responsible for the generation of families of molecular networks with 
the same molecular components (single component crystals and their polymorphs) or 
with different molecular components (multiple component crystals or cocrystals).1-12   
 Cocrystals, also referred to as molecular complexes, include two or more different 
components and often rely on hydrogen bonded assemblies between neutral molecules. 
Cocrystals with the same active pharmaceutical ingredient (API) can have strikingly 
different pharmaceutical properties (melting point, solubility, dissolution, bioavailability, 
moisture uptake, chemical stability, etc.), depending on the nature of the second 
component.13-16  It is important to note that cocrystals are a homogeneous phase of 
stoichiometric composition and not a mixture of pure component crystalline phases.    
Cocrystallization is a result of competing molecular associations between similar 
molecules, or homomers, and different molecules or heteromers.6, 10   Most studies on 
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cocrystal formation focus on design and isolation for the purpose of crystal structure 
determination, and the factors that control cocrystallization have not been explicitly 
considered.2, 3, 6, 9, 16-19  Cocrystals have therefore been prepared largely on a trial and 
error basis by solution, solid-state, or melt processes.20  Key questions in the discovery of 
families of cocrystals are: (i) what are the criteria for cocrystal former selection, (ii) can 
cocrystal screening and cocrystallization methods be theoretically based, and (iii) can 
cocrystals form as a result of stresses encountered during pharmaceutical processes and 
storage? The objective of the current study is to address the latter question.    
Solution-based methods in search of cocrystals have suffered from the risk of 
crystallizing the single component phases and often a very large number of solvents and 
experimental conditions need to be tested.  Furthermore, transferability to large-scale 
crystallization processes has been limited.  The success of crystallizing the molecular 
complex is significantly improved using the reaction crystallization method where 
nucleation and growth of cocrystals are directed by the effect of cocrystal components on 
decreasing the solubility of the molecular complex to be crystallized.21, 22   
 One way to cope with the complexities of solution-based methods has been to 
screen for cocrystals by cogrinding solid reactants.4, 6, 8, 10, 18  Although examples of 
cocrystals formed by this process are abundant, the underlying mechanisms and the 
factors that determine cocrystallization by cogrinding are not known.  Disorder induced 
by grinding or milling is well documented in the pharmaceutical literature and its effects 
on solid-state changes and reactivity have been thoroughly studied.23-28  These include 
amorphous phase formation, polymorphic transformations, complexation, and chemical 
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reactivity.  Therefore, the concepts of solid-state reactivity in pharmaceutical materials 
can be applied to understand the formation of cocrystals by solid-state methods.   
 Since the basis for reactivity in the solid-state lies on molecular mobility and 
complementarity, process-induced cocrystal formation must be related to the propensity 
of API and other components to form disordered or amorphous phases.  That is, as long 
as the transformation does not occur through the melt caused by high local temperatures 
during a process.  Cogrinding under cryogenic conditions is necessary to ascertain that 
the reaction does not proceed through the melt.  Thus, if amorphous phases generate 
cocrystals, then cocrystals can form not only during the process that induced the disorder, 
but also during storage.  Furthermore, the presence of plasticizers, such as water or other 
solvents that lower the Tg and enhance molecular mobility23, 29, 30 will increase reactivity 
and cocrystallization rate in the solid state.   To challenge these hypotheses is the focus of 
our work.   
 The objectives of the present study are to (i) investigate the underlying 
mechanisms of cocrystal formation during cogrinding and storage, and (ii) establish the 
effects of water by cogrinding hydrated crystal forms of reactants and by varying RH 
conditions during storage.  The hydrogen bonded 1:1 carbamazepine-saccharin (CBZ-
SAC) and carbamazepine-nicotinamide (CBZ-NCT) cocrystals are chosen as model 
systems since the crystal structures are reported.31  Both cocrystals have functional 
groups that are commonly encountered in other pharmaceutical components and their 
crystal structures are known. Cocrystals of carbamazepine with saccharin or nicotinamide 
have been shown to improve dissolution, mechanical properties, moisture uptake 
behavior, and chemical stability relative to the pure carbamazepine crystal, anhydrous 
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monoclinic form III, (CBZ(III)).13  Crystal structures have been reported and cocrystals 
are prepared by solution and solid-state methods.13, 21  We have shown that 
carbamazepine-saccharin and carbamazepine-nicotinamide cocrystals can be formed 
from amorphous phases generated either by quenching the melt of components, or by 
grinding a blend of components.32-34   
  Findings from the current study have significant implications for anticipating the 
propensity of solid components to form cocrystals during storage as a result of disorder 
created during a pharmaceutical process such as grinding. Process induced 
transformations to cocrystal may thus be added to the list of transformations that can 
considerably affect product safety and performance in addition to transformations 




Anhydrous monoclinic form III carbamazepine (CBZ(III)), saccharin (SAC), and 
form I nicotinamide (NCT)35 were obtained from Sigma Aldrich and were used as 
received. The compounds were analyzed by infra-red spectroscopy (ATR-FTIR), X-ray 
powder diffraction (XRPD), and differential scanning calorimetry (DSC) before carrying 
out the experiments.  
CBZ-SAC and CBZ-NCT cocrystals and carbamazepine dihydrate (CBZ(D)) 
were prepared according to the methods described earlier.13, 24 Solid phases were 
analyzed by XRPD, ATR-FTIR, DSC and thermogravimetric analysis (TGA). 
Experimental XRPD of the cocrystal was in agreement with that calculated using the 
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Lorentz-polarisation correction by Mercury (ver.1.3) for the structure reported in the 




Cogrinding was carried out at room temperature in a ball mill and under liquid 
nitrogen using a cryogenic impact mill. 
 Room temperature cogrinding methodology 
Anhydrous CBZ(III) was coground with SAC or NCT in stoichiometric ratio (1:1) 
in a 5100 SPEX CertiPrep Mixer/Mill (Metuchen, NJ) using a 3114 stainless steel vial 
having a grinding load volume of 0.6ml (0.5 inch diameter x 1 inch length). Two stainless 
steel beads about 0.25 inches in diameter were used for cogrinding. CBZ(III) and SAC 
were also coground in non-stoichiometric ratios (1:2 and 2:1). Total mass of each blend 
consisting of CBZ(III) and SAC or NCT was 0.5 grams.  Cogrinding of the blends was 
carried out at room temperature for different time periods up to 30 minutes. The 
temperature of the grinding vial, determined by placing a thermometer to the outside of 
the vial, was 45°C after 30 minutes of cogrinding.  
Cogrinding the dihydrate form of carbamazepine, CBZ(D), with SAC or NCT in 
stoichiometric ratio (1:1) of reactants was carried out in the room temperature mill.  Due 
to the low bulk density of this blend, the total mass of the blend ground was 0.25 grams 
since the vial could not hold 0.5 grams of the blend.  For comparison of the rate of 
cocrystal formation between the dihydrate and anhydrous system, a blend of CBZ(III) 
and SAC or NCT weighing 0.25 grams was also ground. Samples were analyzed by 
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ATR-FTIR, XRPD, and DSC to examine changes in crystallinity and in polymorph, 
solvate, and cocrystal forms during cogrinding and during storage. 
 
Cryogenic cogrinding methodology 
Cogrinding of CBZ(III) and SAC or NCT in stoichiometric ratio (1:1) was carried 
out in a 6750 SPEX CertiPrep cryogenic mill (Metuchen, NJ) using a polycarbonate vial 
with 4 ml capacity. A stainless steel rod was used as an impactor for grinding. The total 
mass of the blend was 1 gram. The mill was programmed to an impact frequency of 10Hz 
and 15 cycles, each cycle consisting of 2 minutes grinding followed by 2 minutes cooling 
period. Thus, the total grinding time was 30 minutes. The vial containing the coground 
sample was later transferred to a dessicator containing phosphorous pentoxide as the 
desiccant to allow the sample to reach room temperature and to prevent condensation of 
moisture on the sample due to low temperature of the sample. Ground samples were 
analyzed by the methods indicated above.  
Cryogenic milling of CBZ-NCT cocrystal was also performed to investigate 
cocrystal stability during grinding. Approximately 1gram cocrystal was milled for 
different times, and the ground sample was characterized for changes in crystallinity and 
molecular interactions by XRPD and FTIR. 
 
Storage of Samples 
Ground CBZ(III)/SAC mixtures were stored in desiccators equilibrated at 0% and 
75% relative humidities using phosphorous pentoxide and saturated sodium chloride 
solution respectively at room temperature (22-25°C).36  XRPD and FTIR spectra of the 
 
 162
milled blends during storage were obtained to evaluate changes in crystallinity and to 
monitor cocrystal formation. 
 
Attenuated Total Reflection Fourier Transform Infra-red (ATR-FTIR) 
Spectroscopy  
ATR-FTIR was used to identify intermolecular interactions that reflect hydrogen 
bond directed molecular associations and to determine solid-state forms (polymorph, 
solvate, or cocrystal).  The samples were analyzed using a Vertex 77 spectrometer from 
Bruker Optics (Billerica, MA) and a Nicolet 6700 spectrometer from Thermo Electron 
(Madison, WI). Both spectrometers were equipped with a DTGS detector and a single 
bounce ATR accessory with ZnSe crystal. Spectra (64 scans at 4cm-1 resolution) were 
collected in the 4000-600 cm-1 range.  
Quantification of CBZ-SAC cocrystal formation during cogrinding and during 
storage was done according to IR quantitative methods reported for blends of 
polymorphs.37, 38  Calibration curves were obtained as described below.  
Calibration standards were prepared by blending CBZ(III) and SAC in 1:1 molar 
ratio with the required amount of CBZ-SAC cocrystal. Cocrystal used in the calibration 
was prepared by the solution method described previously.13, 21  The total mass of each 
standard was 0.5 grams. The standards prepared had 0, 20, 40, 60, 80 and 100 per cent 
(by weight) CBZ-SAC cocrystal. Samples containing 10, 50 and 90 per cent CBZ-SAC 
cocrystal were used as validation standards for the calibration curve. 
 The standards were prepared by grinding 0.5 grams of each component separately 
for 2 to 3 minutes in the room temperature mill. This was done to reduce particle size  
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differences between these components and to obtain a homogeneous blend for the 
standards. The three components were then weighed and blended in a stainless steel vial 
without the grinding beads in the SPEX 5100 mill. The samples after blending were 
analyzed in the Nicolet 6700 spectrometer equipped with the ATR accessory. Three 
samples were taken from each standard and analyzed. The spectra of the replicates 
collected for each standard were compared to ensure homogeneity in the standards. If the 
spectra of the replicates of a particular standard differed from one another, the standard 
was prepared again by blending for a longer time. This procedure was repeated until a 
homogeneous blend was obtained. The spectra collected in this manner for all the 
standards were then used for obtaining a calibration curve using the Partial Least Square 
method in the Quant software for OPUS. The calibration curve obtained was then 
validated using the validation standards. The R2 values for the calibration and validation 
were 0.99. 
 
X-ray powder diffraction (XRPD) 
 XRPD was used to identify crystalline phases and to qualitatively examine 
changes in crystallinity.  Measurements were done with a Scintag X1 diffractometer 
(Cupertino, CA) having a copper-target X-ray tube (CuKα radiation 1.54 Å). Data were 
collected at a scan rate of 2.5°/min over a 2θ range of 5° to 40°.  The accelerating voltage 
was 35kV and the current was 20 Amperes.  
XRPD was also done using a Rigaku miniflex diffractometer (The Woodlands, 
TX) having a copper target X-ray tube. Data were collected at a scan rate of 2.5°/min 
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over a 2θ range of 2.5° to 40°. The accelerating voltage was 30kV and the current was 15 
mA.  
 
Differential Scanning Calorimetry (DSC) 
 Thermal analysis of samples was carried out using a TA 2590 DSC (TA 
instruments, New Castle, DE) which was calibrated for temperature and cell constants 
using indium and n-dodecane. Samples (6-8 mg) crimped in aluminum pans were 
analyzed in the DSC from -20 to 200°C at a heating rate of 10 °C/min. Samples were 
continuously purged with nitrogen at 50 ml/min. Samples were also analyzed using 
modulated differential scanning calorimetry (MDSC) to determine the Tg of coground 




FTIR spectra of crystalline and cocrystalline phases 
Since cocrystal formation is a result of interactions between different molecular 
components that also exist in the single-component crystalline states, vibrational 
spectroscopy is an excellent technique to characterize and study cocrystallization.  
Differences in hydrogen bond interactions of CBZ-SAC and CBZ-NCT cocrystals as well 
as crystalline reactants (CBZ(III), CBZ(D), SAC and NCT) shown in figure 5.1, lead to 
significant changes in FTIR spectra as shown in figures 5.2 and 5.3.   
The crystal structures of CBZ(III), CBZ(D) and both cocrystals, CBZ-SAC and 
CBZ-NCT (figure 5.1), show the formation of the carboxamide homodimer of CBZ with 
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the CBZ carboxamide unit acting as both a hydrogen bond donor (syn-NH) and acceptor 
(C=O).  Compared to other primary amide crystals, CBZ(III) and all anhydrous CBZ 
polymorphs do not posses the conventional ribbons of carboxamide dimers because the 
azepine ring sterically blocks the exterior amide hydrogen bond donor (anti-NH) and 
acceptor.  This anti-NH is however involved in linking CBZ and water molecules by N-
H---O hydrogen bonds as shown for CBZ(D), while maintaining the carboxamide 
homodimer.  Similar molecular interactions are observed in the acetone and DMSO 
solvates of CBZ.31   
One of the strategies in designing CBZ cocrystals is to fulfill the donors and 
acceptors in the carboxamide dimers by linking the anti-NH hydrogen bond donor and 
acceptor (C=O) sites of CBZ that are not involved in the homodimer as shown in the 
cocrystals of CBZ with SAC or NCT (figure 5.1).31  In the CBZ-SAC cocrystal, saccharin 
forms an N-H---O=C with the carbamazepine carbonyl, and an S=O---N-H with the 
additional donor of the carbamazepine amide.  Compared to the crystal structure of pure 
saccharin, homomeric N-H---O=C dimers are replaced with heteromeric N-H---O=C 
dimers in the cocrystal, leaving the carbonyl group in SAC free.  In addition, the free SO2 
in pure SAC is engaged in weak S=O---N-H bonds with CBZ in the cocrystal and forms  
S=O---H-C bonds between SAC molecules.31  In the CBZ-NCT cocrystal, the anti-NH of 
CBZ hydrogen bonds with the carbonyl of NCT resulting in the heteromeric N-H---O=C 
dimer in the cocrystal.31  These differences in hydrogen bond interactions are reflected in 
the FTIR spectra of these materials as discussed below, and were used to study 
cocrystallization by cogrinding solid reactants and during storage. 
 
 166
The IR spectrum of CBZ(III) (figure 5.2) shows peaks at 3465 and 3157 cm-1 that 
correspond to the free anti-NH and hydrogen bonded syn-NH respectively in CBZ(III).39 
A peak corresponding to the carbonyl stretch is observed in the spectrum at 1676 cm-1. 40, 
41  Peaks corresponding to NH and carbonyl stretch of the amide are also observed in the 
spectrum of CBZ(D). A peak at 3432 cm-1 for NH stretch, lower than that observed at 
3465 cm-1 in CBZ(III), is observed in the spectrum of CBZ(D). The shift of the peak 
towards lower wavenumber is due to hydrogen bonding between the free NH of CBZ and 
the oxygen of water.40, 41  The peak corresponding to the carbonyl stretch in CBZ(D) is 
observed at 1677 cm-1 and is similar to that observed in CBZ(III).  These spectral 
differences reflect the hydrogen bond pattern differences between the anhydrous (III) and 
hydrated forms of CBZ as presented in figure 5.1. 
The spectrum of pure SAC also shows peaks corresponding to NH and CO stretch 
of the secondary amide at 3094 and 1719 cm-1. 42-44   In addition, peaks corresponding to 
asymmetric and symmetric stretching of –SO2 group in SAC are also observed at 1332 
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Figure 5.2: Infra-red spectra of (A) CBZ(III) (B) CBZ(D) (C) SAC and (D) CBZ-SAC 
cocrystal prepared from solution. 
 
 
Comparison of the spectrum of CBZ-SAC cocrystal with that of CBZ(III) and 
SAC (figure 5.2) shows peak shifts in the carbonyl, amide, and SO2 regions in the 
cocrystal spectrum that relate to hydrogen bond interactions in their crystal structures. 
Peaks corresponding to free carbonyl of SAC and hydrogen bonded carbonyl of CBZ are 
observed at 1726 and 1645 cm-1, respectively in the spectrum of the cocrystal.13, 40, 41  A 
peak shift is observed corresponding to NH stretch of the amide from 3465 cm-1 for 
CBZ(III) to 3498 cm-1  for the cocrystal. Comparison of the spectrum of SAC and CBZ-
SAC cocrystal shows a peak shift corresponding to the asymmetric stretch of –SO2 from 
1332 cm-1 in the spectrum of SAC to 1327 cm-1 in the spectrum of the cocrystal. Similar 
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peak shifts due to hydrogen bond differences are also observed in CBZ-NCT cocrystal 
spectrum (figure 5.3). CBZ-NCT cocrystal spectrum shows peaks at 3447 and 3389 cm-1 
corresponding to the amide NH.  Peaks corresponding to the carbonyl stretch are 
observed at 1682 and 1657cm-1.  
 
 
Figure 5.3: Infra-red spectra of (A) CBZ(III) (B) CBZ(D) (C) NCT and (D) CBZ-NCT 
cocrystal prepared from solution. 
 
 
Cocrystal formation by cogrinding anhydrous CBZ(III) and SAC 
XRPD patterns and FTIR spectra before and after cogrinding CBZ(III) and SAC 
equimolar blends for 30 minutes under ambient and cryogenic conditions are shown in 
figures 5.4 and 5.5. A decrease in XRPD peak intensities was observed, with the decrease 
being greater for the blend milled under cryogenic conditions (figure 5.4).  This indicates 
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a larger reduction in the crystallinity of reactant materials under cryogenic conditions, 
with a few low intensity peaks that are common to cocrystal or reactants. Ambient 
temperature cogrinding resulted in transformation to the cocrystalline phase as indicated 
by the diffraction peaks at 7.08° and 28.3° unique to the CBZ-SAC cocrystal.  A low 
intensity broad peak around 27.0° corresponding to CBZ and or SAC suggests the 




Figure 5.4: XRPD patterns showing cocrystal and amorphous phase formation after room 
temperature and cryogenic cogrinding of CBZ(III) and SAC. (A) before cogrinding,  (B) 
after 30 minutes room temperature cogrinding, (C) after 30 minutes cryogenic cogrinding 
and (D) CBZ-SAC cocrystal prepared from solution (symbols □, ○, and ■ indicate 






FTIR analysis provided information regarding the intermolecular interactions and 
phase transformations occurring in these processes (figure 5.5).  Infrared spectra show 
stronger peaks corresponding to CBZ-SAC cocrystal at 3498, 1726 and 1645 cm-1 after 
ambient temperature cogrinding.  These observations are consistent with the XRPD 
analysis and suggest that hydrogen bond heteromeric associations between CBZ and 
SAC, similar to those in the cocrystal, occur at a faster rate during cogrinding at ambient 
temperature than under cryogenic conditions. Peaks characteristic of CBZ(III) and SAC 
are also observed, indicating some unreacted components. 
Spectral shifts after cryogenic cogrinding also reflect changes in intermolecular 
interactions between CBZ and SAC in the XRPD disordered phase.  A broad shoulder 
between 3475 and 3520 cm-1, corresponding to  –NH2 stretch in the amide group, and 
spectral changes in the carbonyl stretching region that reflect changes in hydrogen bond 
interactions preceding complex formation are observed.   Further studies of spectral shifts 
and chemical interpretations are currently under investigation in our laboratory. 
To confirm the presence of a disordered or an amorphous phase, DSC analysis 
was carried out.  Figure 5.6 shows the presence of an amorphous phase in the 
cryogenically coground sample with a Tg around 41°C, followed by a crystallization 
event (exotherm) around 69°C before an endotherm at 174°C that agrees with the melt of 
the CBZ-SAC cocrystalline phase at 176°C. XRPD analysis of the sample after the 
exothermic crystallization event and before the melt, shows peaks corresponding to 
cocrystal and a few peaks with weak intensities due to unreacted components (appendix 
D).   The presence of unreacted components would cause a decrease in the melting point 
and may be the reason for the slightly lower melting points measured.  Cogrinding under 
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ambient conditions showed a single endothermic event at 174°C.  Pure CBZ(III) has been 
reported to exhibit an endothermic transition to CBZ(I) at 174°C followed by the melt of 
form I at 189°C.46  The melting point of pure SAC was determined to be 228°C.  Due to 





Figure 5.5: Infra-red spectra showing interactions between CBZ and SAC after 30 
minutes room temperature and cryogenic cogrinding of CBZ(III) and SAC. (A) before 
cogrinding, (B) after room temperature cogrinding, (C) after cryogenic cogrinding and 








Figure 5.6: DSC analysis of CBZ(III) and SAC blends after cogrinding for 30 minutes 
under the following conditions: (A) room temperature, (B) cryogenic condition,  (C) 
CBZ-SAC cocrystal prepared from solution, and (D) inset showing the Tg determined 
using MDSC after  cryogenic cogrinding. 
 
 
The glass transition temperature of amorphous materials is an important property 
that determines molecular mobility and reactivity,47 and is thus considered in examining 
the results from cogrinding under ambient and cryogenic conditions. The Tg values, 
measured by melt-quenching the reactants in the DSC, are 52°C for anhydrous CBZ24 
and 85°C for SAC. Since the temperature in the cryogenic mill is below the glass 
transition temperature of the blend and individual components by at least 200°C, 
molecular mobility decreases under these conditions and the amorphous state generated 
by cogrinding is maintained.23, 48  This explains the high degree of disorder observed in 
the XRPD pattern of the equimolar blend of CBZ(III) and SAC after 30 min cogrinding 
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under cryogenic conditions. In contrast, the temperature in the room temperature mill 
after 30 minutes cogrinding was observed to rise to 45°C which is close to the glass 
transition temperatures of CBZ and the equimolar blend. Under these conditions, 
molecular mobility increases in the amorphous phases leading to faster crystallization, 
and in this case cocrystallization of CBZ-SAC. 
The extent of cocrystallization during cogrinding at room temperature is shown in 
figure 5.7.  Quantification was done by FTIR analysis as described in the methods 
section. These results indicate the quick formation of the CBZ-SAC cocrystal with a 
faster rate of cocrystallization in the early stages of the process and approximately 85% 








Cocrystal formation during storage 
Cocrystallization during solid state cogrinding under ambient temperatures has 
been reported for a number of systems.4, 6, 9, 10, 49  However the formation of cocrystals 
during storage, to our knowledge, has not been reported. Based on the current 
understanding of amorphization induced by grinding, and considering the factors that 
affect the stability of amorphous phases and crystallization of single component crystals 
from the amorphous state, we studied cocrystal formation during storage after cogrinding 
solid reactants. Coground equimolar blends of CBZ(III) and SAC were stored at room 
temperature (22 to 25°C) under 0% and 75% RH.  Cocrystallization was monitored by 
XRPD and FTIR. 
Figure 5.8 shows that cocrystallization occurs at 0% and 75% RH after cryogenic 
cogrinding.  Based on these findings we studied the extent of cocrystallization after 5 
minute ambient temperature cogrinding.  Results show that cocrystal formation initiated 
during cogrinding proceeds during storage (figure 5.9) and that the rate of 
cocrystallization increases with RH.   
Cocrystal formation during storage after mechanical activation of the solid and 
the rate dependence on RH suggests an amorphous phase mediated transformation. 
Water, a potent plasticizer, has a Tg of -138°C and has been shown to decrease the glass 
transition temperature of amorphous solids.29, 30  Therefore, moisture sorption will 
increase the molecular mobility and the rate of crystallization of amorphous phases. 
Higher rate of cocrystal formation during storage at high RH may therefore be due to a 
decrease in Tg and a consequent increase in molecular mobility in the disordered regions 




Figure 5.8: XRPD patterns showing cocrystal formation during storage after cryogenic  
cogrinding of CBZ(III) and SAC for 30 minutes. (A) freshly ground blend (day 0)  






Figure 5.9: Cocrystal formation during storage under 0%RH and 75%RH at room  
temperature after cogrinding CBZ(III) and SAC for 5 minutes at room temperature.  




Cocrystal formation by cogrinding carbamazepine dihydrate and saccharin 
Since our results indicate that cocrystal formation proceeds through amorphous 
phases induced by grinding and that the rate of cocrystallization during storage increases 
on exposure to high relative humidities, one would anticipate that the use of crystalline 
solvates in cogrinding would increase the rate of cocrystallization.  In this case, the 
solvent in the crystal structure serves as a potent plasticizer.  Cogrinding with the 
dihydrate form of CBZ was therefore carried out to test this hypothesis. 
XRPD and FTIR analysis confirm our hypothesis.  XRPD patterns (figure 5.10) 
shows transformation to cocrystal during cogrinding under ambient conditions for 10 
minutes, since the pattern of the coground reactants is in agreement with the pattern of 
the cocrystal prepared from solution. Peaks characteristic of CBZ(D), CBZ anhydrous 
polymorphs or SAC were absent after cogrinding. 
To compare the rate of cocrystallization between CBZ(D) and CBZ(III) systems, 
the same cogrinding protocol was used with CBZ(III) and SAC. The XRPD pattern after 
cogrinding for 10 minutes (figure 5.11) shows evidence for cocrystal formation and 
unreacted components.  
The FTIR spectra (figure 5.12) provided further evidence for cocrystallization. 
The spectrum of cocrystal prepared by cogrinding the dihydrate is very similar to that of 
the cocrystal prepared from solution. Peaks corresponding to unreacted components were 
not detected. The spectrum of the coground anhydrous CBZ (III) shows peaks 
characteristic of cocrystal as well as those corresponding to unreacted CBZ and SAC. 
These results suggest that the rate of cocrystallization is increased by cogrinding with the 




Figure 5.10: XRPD pattern showing cocrystal formation after cogrinding CBZ(D) and  
SAC at room temperature for 10 minutes. (A) before cogrinding, (B) after cogrinding  
and (C) CBZ-SAC cocrystal prepared from solution. (Symbols □ and ○ indicate CBZ(D) 
and SAC respectively) 
 
 
Figure 5.11: XRPD pattern of CBZ(III) and SAC showing cocrystal formation after 10 
minutes cogrinding at room temperature. (A)  before cogrinding, (B) after cogrinding 
and (C) CBZ-SAC cocrystal prepared from solution. (Symbols □ and ○ indicate CBZ(III) 






Figure 5.12: FTIR spectra showing interactions between CBZ and SAC after 10 minutes 
room temperature cogrinding of SAC with either CBZ(D) or CBZ(III).  
CBZ(D)/SAC mixture (A) before cogrinding, and (B) after cogrinding; CBZ(III)/SAC 




Faster rate of cocrystallization by cogrinding with CBZ(D) may be due to the 
potent plasticizing action of water from the hydrate in reducing the Tg of the amorphous 
phase.   CBZ(D) has 13.5% water and upon dehydration there is 7.9% water in the blend.  
This leads to significant plasticizing effects since solvents at low concentrations have the 




Cocrystal formation in non-stoichiometric anhydrous CBZ(III) blends 
Cocrystal formation was observed by cogrinding CBZ(III) and SAC in 1:2 and 
2:1 ratios at ambient temperature for 30 minutes. The results also suggested the presence 
of unreacted CBZ and unreacted SAC in the 2:1 and 1:2 blends respectively after 
cogrinding. 
 
Cocrystal formation by cogrinding CBZ(III) and NCT  
 Cocrystal formation during cogrinding was also studied in CBZ(III)/NCT 
mixtures. Figure 5.13 shows the XRPD patterns of CBZ(III)/NCT mixture after 
cogrinding at ambient and cryogenic conditions. Cogrinding CBZ(III) and NCT at 
ambient condition results in cocrystal formation. Peaks characteristic of the cocrystal are 
observed in the XRPD pattern at 2 theta values of 6.4°, 8.7° and 9.9° after cogrinding the 
mixture. The pattern also shows evidence for unreacted CBZ and NCT (2 theta = 14.7 
and 15.8). However, cogrinding CBZ(III) and NCT at cryogenic conditions does not 
result in cocrystal formation. The XRPD pattern after cryogenic grinding resembles the 






Figure 5.13: XRPD of CBZ(III)/NCT mixture after 30 minutes grinding at ambient and 
cryogenic conditions showing cocrystal formation and disorder. CBZ(III)/NCT mixture 
(A) before grinding; after grinding at (B) ambient, and (C) cryogenic conditions; (D) 
reference pattern of CBZ-NCT cocrystal 
  
 
FTIR spectrum of CBZ(III)/NCT mixture after grinding is shown in figure 5.14. 
The spectrum of the mixture after grinding at ambient conditions shows peaks at 3446, 
3389, 1683 and 1658cm-1 indicating cocrystal formation. Shifts in the IR spectrum are 
also observed after cryogenic grinding. Peaks at 3448 and 1658cm-1 suggest interactions 
between the reactants similar to those observed in the cocrystal. In addition, the spectrum 
also shows evidence for unreacted components as indicated by the peaks at 3464 and 
1677cm-1, consistent with results from XRPD patterns. Since the XRPD pattern does not 
show evidence for cocrystal after cryogenic grinding, it is possible that interactions 
between CBZ and NCT in the cryogenic ground mixture occur in the disordered regions 




Figure 5.14: Infra-red spectra showing interactions between CBZ and NCT after room 
temperature and cryogenic grinding of CBZ(III)/NCT mixture. CBZ(III)/NCT mixture 
(A) before grinding; after grinding at (B) ambient conditions, and (C) cryogenic 
conditions; (D) reference pattern of CBZ-NCT cocrystal. 
 
 
Thermal analysis of cryogenic ground mixture shows an exotherm with onset at 
99.1°C and an endotherm with onset at 119.1°C, followed by another endotherm at 
157.7°C that corresponds to cocrystal melting point of 158.7°C (figure 5.15). These 
events are different from those observed in CBZ or NCT. NCT exhibits an endotherm 
corresponding to melting with an onset at 126-128°C.35  Analysis of the mixture ground 
under ambient conditions shows an endotherm corresponding to cocrystal melting at 
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157.5°C. Lower melting points of the cocrystal in the ground mixtures may be due to the 




Figure 5.15: Thermal analysis of CBZ(III)/NCT mixture after 30 minutes grinding at (A) 
ambient condition, and (B) cryogenic condition; (C) CBZ-NCT cocrystal. 
 
 
Results from the above study show that cocrystal formation by cogrinding 
reactants is dependent on temperature. Since cryogenic cogrinding of reactants did not 
result in cocrystal formation, cryogenic grinding of CBZ-NCT cocrystal was performed 






CBZ-NCT stability during cryogenic grinding 
Figure 5.16 shows the XRPD pattern of CBZ-NCT cocrystal after 5, 10, 30, and 
60 minutes cryogenic grinding. Conversion of cocrystal to CBZ(III) and NCT after 5 
minutes grinding indicates cocrystal instability. Reduction in peak intensities with longer 
grinding times indicates amorphous phase formation due to grinding. Cocrystal stability 
under cryogenic conditions was also investigated without any mechanical activation. In 
this case, cocrystal was stable even after 60 minutes of storage under cryogenic 
conditions. This suggests that mechanical activation is necessary to induce cocrystal 
instability under cryogenic conditions.  
 
 
Figure 5.16: XRPD showing CBZ-NCT cocrystal instability after cryogenic grinding for 
different times. CBZ-NCT cocrystal (A) before grinding, and after grinding for (B) 5 






Cocrystal formation by cogrinding CBZ(D) and NCT 
Water present in hydrated reactants has been shown to affect cocrystal formation 
during cogrinding in a preceding section. Cogrinding of CBZ(D) and NCT was therefore 
performed at cryogenic and ambient conditions to study the effect of hydrated reactants 
on crystallization outcomes during cogrinding. Unlike CBZ(III)/NCT mixture, cryogenic 
grinding of CBZ(D)/NCT mixture results in cocrystal formation (figure 5.17). Cogrinding 
CBZ(D) and NCT at ambient conditions similarly facilitates cocrystal formation and 
enhances the rate of cocrystallization. Figure 5.18 shows the XRPD patterns of 
CBZ(III)/NCT and CBZ(D)/NCT mixtures after 5 minute grinding under ambient 
conditions. The patterns indicate complete conversion of CBZ(D)/NCT mixture to 
cocrystal. In contrast, the pattern of CBZ(III)/NCT mixture after 5 minutes cogrinding 
shows evidence for unreacted components in addition to cocrystal formation. Results 
from FTIR spectral analysis of the ground mixtures are in agreement with the above 
findings. Faster rates of cocrystal formation with hydrated reactants may be due to 







Figure 5.17: XRPD pattern showing cocrystal formation after 12 minutes cryogenic 
grinding of CBZ(D)/NCT mixture. CBZ(D)/NCT mixture (A) before grinding, and  




Figure 5.18: XRPD pattern showing the effect of anhydrous and hydrated reactant (CBZ) 
on CBZ-NCT cocrystal formation during cogrinding at ambient conditions for 5 min. 
CBZ(D)/NCT mixture (A) before grinding, and (B) after grinding; CBZ(III)/NCT 




Our results demonstrate that cocrystal formation during storage is mediated by the 
formation of disordered regions or amorphous phases induced by cogrinding reactants.  
The rate of cocrystal formation during cogrinding of solid reactants depends on the 
grinding temperature and on the solid-state form of the reactants. Cogrinding CBZ(III) 
and SAC under cryogenic conditions results in amorphous phase formation. This is 
possibly due to reduced molecular mobility under cryogenic conditions, and hence 
reduced rate of cocrystal formation.  Amorphization by low temperature grinding (4°C 
and cryogenic conditions) has been demonstrated for indomethacin (Tg of 43°C),23  while 
grinding in the proximity of the Tg yielded partially amorphous materials.23, 27   In the 
case of CBZ(III) and NCT, cryogenic cogrinding shows evidence for disorder and 
crystalline reactants.  
Studies on the solid-state complexation of coground mixtures of cholic acid with 
either methyl p-hydroxybenzoate or ibuprofen demonstrated the formation of crystalline 
inclusion complexes during room temperature grinding and the formation of an 
amorphous phase under cryogenic conditions.26   The amorphous phase transformed to 
the crystalline complex after 1 hour of heat treatment at 60°C.  Crystalline complex 
formation was suggested to be a result of two factors: (i) amorphous phase formation by 
mechanical force and (ii) crystallization of complex by thermal activation.  This behavior 
is similar to that observed in our studies with CBZ and SAC, however, we observed 
crystallization of the complex at room temperature.   
Studies on cogrinding of ursodeoxycholic acid (UDCA) with anthrone and/or 
phenanhrene exhibited different behavior. Crystalline complex formation between UDCA 
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and phenanthrene or anthrone occurred during cogrinding at ambient temperature, while 
cogrinding the reactant mixture at low temperatures (0°C, -55°C and -70°C) resulted in 
amorphous UDCA and crystalline phenanthrene or anthrone.25 Cogrinding the crystalline 
complex of UDCA and phenanthrene or anthrone at low temperature also resulted in 
amorphous UDCA and crystalline second component. Heating the mixture of amorphous 
UDCA and crystalline anthrone and/or crystalline phenanthrene at 75°C for 40 minutes 
formed a mixture of the single component crystalline phases.25  This behavior is similar 
to that observed with CBZ and NCT. However, in our studies crystalline components 
were observed after cryogenic cogrinding for short times. Longer grinding times resulted 
in amorphization.  
In-situ studies with binary amorphous phases of CBZ and NCT have shown that 
crystallization outcome form amorphous phase is dependent on heating rates. Low 
heating rates resulted in cocrystal formation from amorphous phase, while high heating 
rates resulted in cocrystallization.33, 34  Cocrystallization may thus be a result of 
molecular mobility in the amorphous state coupled with favorable interactions between 
heteromeric molecular complexes, so that crystallization of the pure phases is prevented. 
The conversion of CBZ-NCT cocrystal to crystalline CBZ and NCT during cryogenic 
cogrinding may be preceded by the generation of amorphous phase. A rapid change in 
temperature from cryogenic to ambient conditions after cryogenic grinding of cocrystal 
or reactant mixture may have induced the transformation of amorphous phase to 
crystalline reactants.  
The rate of cocrystal formation during cogrinding, besides depending on the 
grinding temperature, also depends on the solvated crystal form of reactants.  Faster rate 
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of cocrystal formation by cogrinding CBZ(D) and SAC or NCT suggests that water in the 
crystal lattice of CBZ(D) acts as a plasticizer. Matsuda et al. have shown that CBZ(D) 
forms an amorphous phase upon dehydration before conversion to the anhydrous 
CBZ(III) during grinding at room temperature.28 Water from CBZ(D) may thus be 
present in the amorphous phase formed during cogrinding and serves as a plasticizer to 
reduce the Tg. The predicted Tg of the amorphous phases of CBZ/SAC and CBZ/NCT in 
the presence of this water is at least 20°C below room temperature. The Tg was calculated 
from the modified Gordon Taylor equation and the Simha-Boyer rule50 using the 
following values: Tg of amorphous CBZ/SAC of 29°C, Tg of amorphous CBZ/NCT 
21°C, Tg of water -138°C and K value of 0.25 generally found for small molecules.30  
Similar behavior has been reported for crystallization of indomethacin polymorphs during 
grinding of its solvates.23   
Cocrystal formation during storage and its dependence on relative humidity 
demonstrates that moisture facilitates cocrystallization in blends ground under ambient 
and cryogenic conditions.   This behavior is explained by the effect of water on molecular 
mobility and is consistent with the increased transformation to cocrystal during 
cogrinding the hydrated form of CBZ as discussed above.  
The formation of cocrystal during cogrinding or during storage of mechanically 
activated blends in preference to the formation of crystalline CBZ and SAC or NCT 
raises an interesting question regarding competition between the kinetics of cocrystal 
formation and crystallization of the individual components from the disordered state. At 
the molecular level this may be regarded as a competition between heteromeric and 
homomeric interactions. The formation of CBZ-SAC cocrystal from the amorphous 
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phase suggests that under the conditions in which the experiments were performed 
heteromeric interactions are favored over homomeric interactions. Similar mechanisms 
are used in the stabilization of amorphous phases of drugs.  Hydrogen bond directed 
stabilization of amorphous phases with drugs has been demonstrated for amorphous 
molecular dispersions with polymers51-53 and from amorphous dispersions with granules 
of adsorbent.54  In these cases, crystallization of the homomeric drug crystals is prevented 
by heteromeric interactions with the polymers or the adsorbents.  
Comparison of the FTIR spectra after cogrinding under ambient and cryogenic 
conditions shows that heteromeric aggregation occurs in the disordered state and at low 
temperatures, although at a slower rate than that at ambient temperature conditions. 
Similarly, the formation of cocrystal by cogrinding CBZ(D) and SAC or NCT suggests 
that molecular associations between CBZ and coformer resulting in cocrystal are more 
favored than those observed between CBZ and water in carbamazepine dihydrate.  
The thermodynamic stability of the cocrystal with respect to the individual 
component crystal phases needs to be considered. The free energies of cocrystal 
formation for CBZ-SAC and CBZ-NCT, estimated from cocrystal and reactant 
solubilities at 25°C, are -5.9 and -4.8 KJ/mol respectively.55 The negative free energies 














The results of this study show that amorphous phases generated during cogrinding 
can lead to cocrystal formation during storage.  Water has a significant effect and 
increases the rate of cocrystallization during (i) cogrinding hydrated form of reactants, 
and (ii) storage of co-ground reactants at high RH. This study demonstrates that 
amorphous phases can lead to cocrystal formation under conditions where there is 
increased molecular mobility, and when hydrogen bond associations between different 
components are more favorable than those between similar components.  Perhaps the 
most relevant implication of these findings is that cocrystals can be formed during 
pharmaceutical unit operations and during storage.  Therefore, transformations to 
cocrystal may be added to the list of process-induced transformations to consider besides 
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CONCLUSIONS AND FUTURE WORK 
 
 
This dissertation has focused on investigating the mechanisms, thermodynamics, 
and kinetics of cocrystallization. The specific goals of the study were to (i) identify the 
factors and conditions governing the formation and stability of cocrystals with different 
stoichiometry, (ii) examine the propensity and underlying mechanisms of cocrystal 
formation in solid mixtures due to moisture sorption, (iii) examine the effect of coformer, 
excipients and cosolvent concentration in aqueous solutions on the formation and 
thermodynamic stability of cocrystal hydrates, and (iv) identify the mechanisms by which 
mechanical activation of reactant mixtures induces cocrystal formation. 
 The formation, stability, and solubility of cocrystals with different stoichiometry 
are dependent on coformer solution concentration. 1:1 and 2:1 carbamazepine-4-
aminobenzoic acid (CBZ-4ABA) cocrystals were synthesized by varying the coformer 
concentration using the reaction crystallization method. Cocrystal stability studies 
indicate that the cocrystal richer in ligand (1:1 cocrystal) is more stable at higher ligand 
concentrations. The stability domains of the cocrystals can be identified by measuring the 
transition concentration between the different crystalline phases (drug/2:1 cocrystal, 2:1 
cocrystal/1:1 cocrystal, 1:1 cocrystal/ligand). Cocrystal and drug solubilities as well as 
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the equilibrium solution composition of reactants to generate phase diagrams can be 
predicted using mathematical models based on cocrystal and solution chemistry.  
 The solubility models developed in this study for CBZ-4ABA cocrystals indicate 
1:1 complex formation in solutions equilibrated with the 2:1 cocrystal. Thus, the 
stoichiometry of the complex in solution at equilibrium does not correspond to cocrystal 
stoichiometry. Crystallization occurs under supersaturated conditions, and is governed by 
molecular recognition, thermodynamics and kinetics. The current study identifies the 
nature of complex in solution at equilibrium with cocrystal, while the molecular 
interactions and nature of complex leading to cocrystal formation under supersaturated 
conditions are not known. Studies evaluating the nature of these interactions and 
complexes, as well as the effect of complexation on cocrystal nucleation rates, will 
provide valuable insights regarding the mechanistic aspects of cocrystallization from 
solutions. Further, solvent effects on complex formation, cocrystal solubility, and 
stability also needs to be explored. 
Water is commonly encountered during processing and storage of pharmaceutical 
materials. Water-solid interactions can induce phase transformations such as hydrate 
formation, polymorphic conversions, or amorphous to crystalline conversions. In this 
study, moisture sorption and deliquescence of solid mixtures of cocrystal reactants is 
shown to induce cocrystal formation. Cocrystals of carbamazepine-nicotinamide (CBZ-
NCT) and carbamazepine-saccharin (CBZ-SAC), caffeine and theophylline with 
carboxylic acid ligands such as oxalic acid, maleic acid, malonic acid, glutaric acid and 
citric acid were formed during deliquescence even at conditions when the APIs are 
reported to form hydrates. The mechanisms responsible for cocrystal formation involve 
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moisture uptake, dissolution of cocrystal reactants, cocrystal nucleation and growth. 
Cocrystal formation rates in reactant mixtures depends on RH, amount of moisture 
sorbed, surface area of reactant particles, reactant hygroscopicity, solubilities and 
dissolution rates. This is demonstrated for cocrystals of carbamazepine with nicotinamide 
and saccharin. Mixtures of CBZ/NCT transformed to cocrystal faster than CBZ/SAC 
mixtures. Higher reactivity in CBZ/NCT mixtures is due to the deliquescent nature and 
high aqueous solubility of NCT relative to SAC.  
The propensity for cocrystal formation in reactant mixtures is altered by the 
presence of hygroscopic additives in reactant mixtures. Small amounts of deliquescent 
additives such as fructose, sucrose and citric acid in the reactant mixtures are shown to 
induce cocrystal formation even at conditions when the cocrystal reactants do not 
deliquesce. The transformation rate in this case depends on the nature of deliquescent 
additive and solid composition. Hygroscopic polymers such as PVP that are non-
deliquescent and exhibit different moisture uptake behavior are well known to affect solid 
phase stability and induce phase transformations. Future studies need to examine the 
effect of moisture uptake by hygroscopic polymers on cocrystal formation in reactant 
mixtures. 
While moisture uptake and deliquescence in reactant mixtures induces 
transformation of drug to cocrystal, a reversal in transformation can occur due to 
cocrystal deliquescence. This is shown for cocrystals of theophylline with glutaric acid 
and citric acid, and caffeine-glutaric acid cocrystal. Cocrystals of carbamazepine with 
maleic and glutaric acid however did not deliquesce under similar storage conditions. 
Further studies examining the underlying cause for differences in the moisture uptake 
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behavior and stability of these cocrystals during storage can provide valuable insights for 
designing cocrystals with the desired hygroscopicity and stability.  
Cocrystal solubility dependence on aqueous solution composition and chemistry 
are good predictors of cocrystal formation and stability during deliquescence. The 
transformation of a drug to cocrystal in a saturated aqueous solution of coformer is an 
indicator for cocrystal formation due to deliquescence in solid reactant mixtures. This is 
shown for cocrystals of carbamazepine, caffeine and theophylline with various 
coformers. Similarly, cocrystal transformation to crystalline drug in pure water is 
indicative of the propensity for cocrystal instability due to moisture uptake and 
deliquescence. 
 Most cocrystals identified to date are anhydrous, and a few have been 
serendipitously identified to exist as hydrates. The formation and stability of 
pharmaceutical hydrates is well known to depend on water activity (aw). In this 
dissertation, coformers that modulate the water activity of aqueous solutions are shown to 
affect cocrystal hydrate formation and stability. Increasing the coformer concentration is 
shown to decrease the water activity resulting in transformation of theophylline-citric 
acid (THP-CTA) cocrystal hydrate to anhydrous cocrystal. Increasing the coformer 
concentration however did not result in the conversion of CBZ-4ABA cocrystal hydrate 
to anhydrous cocrystal. This is because 4ABA has low aqueous solubility and negligible 
decreases the water activity to 0.98, while the critical water activity of cocrystal hydrate 
is 0.26-0.30.  
In addition to the coformer, excipients and cosolvent addition to aqueous 
solutions can also affect aw and cocrystal hydrate stability. Fructose addition to aqueous 
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citric acid solutions is shown to decrease the aw resulting in transformation of THP-CTA 
cocrystal hydrate to anhydrous cocrystal. The addition of acetonitrile to water similarly 
decreased the aw resulting in conversion of CBZ-4ABA cocrystal hydrate to anhydrous 
cocrystal.  
Anhydrous and hydrate cocrystals can also form in reactant solid mixtures due to 
deliquescence. The formation of these cocrystalline phases and their stability in this case 
is dependent on the coformer concentration in the deliquesced solution which in turn is 
dependent on the level of water uptake. THP/CTA mixture transforms to anhydrous 
cocrystal at 75%RH. At 85% and 98%RH, the mixture transforms to anhydrous cocrystal 
and then to cocrystal hydrate. Transformation of anhydrous to hydrated cocrystal is 
explained by the effect of water uptake on coformer concentration that affects the 
stability of cocrysalline phases. 
In the solid-state, cocrystal formation due to mechanical activation of reactants is 
shown to be amorphous phase mediated. Enhanced molecular mobility in the amorphous 
phase generates cocrystals as long as heteromeric associations are favored over 
homomeric associations. This is shown for cocrystals of carbamazepine (CBZ) with 
saccharin (SAC) and nicotinamide (NCT). Cogrinding carbamazepine and saccharin at 
ambient conditions forms CBZ-SAC cocrystals, while cogrinding under cryogenic 
conditions results in amorphous phase formation due to low molecular mobility at low 
temperature. Cocrystals of CBZ and NCT also form by cogrinding at ambient conditions. 
However, mechanical activation of CBZ-NCT cocrystal under cryogenic conditions 
results in mixture of crystalline reactants.  
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Cocrystal formation from amorphous phases depends on the glass transition 
temperature (Tg) of cocrystal reactants and the presence of additives. Water present in the 
crystal lattice or in the vapor phase facilitates cocrystallization from amorphous phases 
by serving as a plasticizer.  Amorphous phases of CBZ and SAC, generated by 
cogrinding, transform to cocrystal during storage at high RH. Cogrinding CBZ(D) with 
SAC or NCT enhances cocrystal formation rates during cogrinding.  
The current study demonstrates the influence of molecular recognition and 
kinetics on cocrystallization. However, the thermodynamics of cocrystal formation also 
needs to be considered. Cocrystal formation during storage, and free energies of cocrystal 
formation evaluated from cocrystal and reactant solubilities suggest that CBZ-SAC and 
CBZ-NCT cocrystals are the thermodynamically stable phase at room temperature. 
Future studies should therefore explore the propensity for spontaneous cocrystal 
formation without mechanical activation of cocrystal reactants.  
Stresses encountered during processing and storage can induce phase 
transformations such as amorphous to crystalline conversion, hydrate formation, and 
polymorphic conversions. The conversion of crystalline drug to cocrystals can be added 
to the existing list of possible phase transformations. This dissertation has identified the 
mechanisms and kinetics of cocrystallization, and factors affecting cocrystal stability. 
Results presented herein have potential implications for anticipating cocrystal formation, 









































Figure A-1: XRPD showing 2:1 CBZ-4ABA cocrystal stability in various solvents.  
(A) 2:1 CBZ-4ABA anhydrous cocrystal reference; Cocrystal stability in (B) methanol, 
(C) isopropyl alcohol, (D) acetonitrile, (E) water, (F) chloroform, (G) CBZ(III), and (H) 









Figure A-2: XRPD showing 1:1 CBZ-4ABA cocrystal stability in various solvents. 
(A) 1:1 CBZ-4ABA anhydrous cocrystal reference; Cocrystal stability in (B) methanol, 






Mathematical models based on cocrystal and solution chemistry to predict cocrystal 
2:1 cocrystal solubility 
 
In this section, detailed derivations of mathematical models predicting the 
solubility of a 2:1 cocrystal (D2L) as a function of ligand concentration are presented. 
The models presented consider the effect of 1:1 and 2:1 solution complexation on 
cocrystal solubility. 
 
Model I – 1:1+ 2:1 solution complexation 
The equilibrium reactions for cocrystal dissociation in solution and solution complexation 
can be written as shown below. 
  
D2L(solid)    2D(soln) + L(soln)                                           (1)  
 
D(soln) + L(soln)              DL(soln)               (2)  
DL(soln) + D(soln)              D2L(soln)                                  (3) 
Ksp is the solubility product constant and is given as Ksp = [D]2[L]                      (4) 
 
K11 and K21 are the complexation constants for the reactions and are given as: 
 
]L][D[
]DL[K11 =                             (5) 
 
]D][DL[
]LD[K 221 =                            (6) 
Rearranging equation (5) and substituting for [D] from equation (4) gives the following 






]L[KK]DL[ sp11=                            (7) 
 
Rearranging equation (6) and substituting for [D] and [DL] from equations (4) and (7) 
yields: 
sp21112 KKK]LD[ =                           (8) 
 
Mass balance for the concentration of the drug and ligand in solution can be written as 
shown below: 
[D]T = [D] + [DL] + 2[D2L]                         (9) 
[L]T = [L] + [DL] + [D2L]             (10) 





]D[ ++=                      (11) 
 
sp2111sp11T KKK]L[KK]L[]L[ ++=                       (12) 
 
              
Re-arranging equation (12): 
 
]L[KK]L[KKK]L[ sp11sp2111T =−−                       (13) 
 
Squaring both sides of equation (13) and re-arranging gives the following quadratic 
equation in [L]: 
 
( )( ) ( ) 0KKK]L[KKKKK]L[2]L[]L[ 2sp2111Tsp211sp2111T2 =−++−−                   (14) 
 
Let c = [L]T - K11K21Ksp                                (15) 
 
Therefore, ( ) 0cKKc2]L[]L[ 2sp2112 =++−                       (16) 
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Equation (16) is a quadratic equation and can be solved to obtain an expression for [L] as 













11 +±+=                      (17) 
 



















=         (18) 
 




11 KKK4 << Tsp
2









=                     (19) 
 
Equation (19) gives an expression for the free ligand concentration ([L]) as a function of 
the thermodynamic constants (Ksp, K11, K21) and [L]T. There are two solutions for [L] and 
these two solutions differ in the sign of the term Tsp11 ]L[KK2 . Substituting the above 
expressions for [L] in equation (9) yields the following two expressions relating [D]T to 






































Equations (20) and (21) predict a non-linear dependence of [D]T on [L]T when the 
2:1 cocrystal is in equilibrium with the solution. The thermodynamic constants K11, K21 
and Ksp can be evaluated by non-linear regression. The initial estimates for the constants 
were obtained assuming no solution complexation. Hence, the initial values for K11 and 
K21 were 0. The slope of the line obtained by plotting [D]T against 2/1T]L[
− yielded the 
initial value of Ksp. All the constants were allowed to vary during the regression 
procedure. The values of the constants for subsequent iterations were determined using 
the Levenberg-Marquadt algorithm subject to the constraint that the constants are all 








i,T ]D[]D[ , where  
pred
T]D[  
and expT]D[ are the predicted and experimental total drug concentrations, respectively.  
 
 
Model II – 1:1 solution complexation 
 
The equilibrium reactions for cocrystal dissociation in solution and solution complexation 
can be written as shown below.  
D2L(solid)    2D(soln) + L(soln)                                         (22) 
      
 
D(soln) + L(soln)              DL(soln)                        (23)                
 
Ksp and K11 are cocrystal solubility product and complexation constants and are given by  
equations (4) and (5). 
 
Mass balance for the concentration of the drug and ligand in solution gives: 





[L]T = [L] + [DL]                          (25) 






T +=                                                          (26) 
 
]L[KK]L[]L[ sp11T +=                                                           (27) 
 
              
Re-arranging equation (27): 
 
]L[KK]L[]L[ sp11T =−                                               (28) 
 
Squaring both sides of equation (28) and re-arranging yields the following quadratic  
 
equation in [L]. 
 
( ) 0]L[]L[2KK]L[]L[ 2TTsp2112 =++−  
 













=                                  (29) 
 







=                                   (30) 
 
Equation (30) expresses the free ligand concentration ([L]) as a function of the 
thermodynamic constants and [L]T. There are two solutions for [L] and these two 
solutions differ in the sign of the term Tsp11 ]L[KK2 . Substituting the above 
expressions for [L] in equation (26) gives the following two expressions relating [D]T to 




































Equations (31) and (32) predict a non-linear dependence of [D]T on [L]T when the 2:1 
cocrystal is in equilibrium with the solution. The thermodynamic constants K11 and Ksp 
can be evaluated by non-linear regression as described earlier. 
 
 
Model III – 2:1 solution complexation 
 
The equilibrium reactions for cocrystal dissociation and 2:1 complex formation in 
solution are as follows: 
D2L(solid)    2D(soln) + L(soln)                                                                   (33) 
2D(soln) + L(soln)                    D2L(soln)                       (34) 
Ksp is the cocrystal solubility product and is given by Ksp = [D]2[L]                              (35)           





21 =                    (36) 
From equations (35) and (36), [D2L] = K′21Ksp                     (37) 
Mass balance on drug and ligand concentration is written as: 
[D]T = [D] + 2[D2L]                         (38) 
[L]T = [L] + [D2L]                                    (39) 











]D[ +=                         (40) 
[L] = [L]T – K′21Ksp                                  (41) 
         















=                                     (42) 
 
 
Equation (42) predicts non-linear dependence of [D]T on [L]T for the 2:1 cocrystal. 
Therefore, the constants can be evaluated by non-linear regression. Initial estimates for 
the constants were obtained assuming no complexation. Thus, K′21 = 0 and Ksp was 
estimated from the slope of the line obtained by plotting [D]T against 2/1T]L[
− . The values 
of the constants in subsequent iterations were evaluated using the Levenberg-Marquadt 








i,T ]D[]D[ , where  
pred
T]D[  and 
exp
T]D[ are the predicted and experimental total drug concentrations, respectively. 
Alternatively, the constants can be evaluated by linear regression as described below. 
 









]D[ +=              (43) 
 
The values of the constants Ksp and K′21 in equation (43) are evaluated from the slope and 
intercept of the line obtained by plotting [D]T against 2/1T]L[ − . These values of the 
constants are then used to evaluate ( ) 2/1sp'21T KK]L[ −− in equation (42). New values of 
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Ksp and K′21 are then obtained by plotting [D]T against ( ) 2/1sp'21T KK]L[ −− . The 








Effect of RH on the stability of carbamazepine, theophylline and caffeine  








     Figure C-1: Raman spectra showing the stability of (A) carbamazepine-glutaric acid  






       
       Figure C-2: Raman spectra showing the stability of (A) carbamazepine-maleic acid  





























        
       Figure C-3: Raman spectra showing the stability of (A) theophylline-glutaric acid  
       cocrystal after storage at (B) 91%RH for 4.5 months; (C) Theophylline hydrate  









       Figure C-4: Raman spectra showing the stability of (A) anhydrous theophylline- 
       citric acid cocrystal after storage at (B) 85%RH, (C) 91%RH, and (D) 98%RH for  









            Figure C-5: Raman spectra showing the stability of (A) theophylline-citric acid  
            hydrate cocrystal after storage at (B) 85%RH, and (C) 91%RH for 4.5 months;  






























            Figure C-6: Raman spectra showing the stability of (A) caffeine-glutaric acid  

















               
              Figure D-1: XRPD showing disorder induced in CBZ-SAC cocrystal after 30  
              minutes cryogenic grinding. CBZ-SAC cocrystal (A) before grinding, and (B)  







Figure D-2: XRPD pattern showing CBZ-SAC formation after heating the amorphous 
phase generated by 30 minute cryogenic cogrinding of CBZ(III) and SAC. (A) 
CBZ(III)/SAC mixture after 30 min cryogenic cogrinding, and (B) coground mixture 
after heating in DSC to 115°C; (C) CBZ-SAC cocrystal (reference) 
